Genfit (GNFT) 20-F 27 May 20 2019 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2019shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Registrant Name	GENFIT S.A.
Entity Central Index Key	0001757064
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding	38,858,617
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Title of 12(b) Security	American Depositary Shares, each representing one ordinary share, nominal value €0.25 per share
Trading Symbol	GNFT
Security Exchange Name	NASDAQ
Entity File Number	001-38844
Entity Incorporation, State or Country Code	I0
Entity Address, Address Line One	Parc Eurasanté
Entity Address, Address Line Two	885, avenue Eugène Avinée
Entity Address, City or Town	Loos
Entity Address, Country	FR
Entity Address, Postal Zip Code	59120
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Registration Statement	false
Document Accounting Standard	International Financial Reporting Standards
Business Contact
Document Information [Line Items]
Entity Address, Address Line One	Parc Eurasanté
Entity Address, Address Line Two	885, avenue Eugène Avinée
Entity Address, City or Town	Loos
Entity Address, Country	FR
Entity Address, Postal Zip Code	59120
Contact Personnel Name	Pascal Prigent
Country Region	33
City Area Code	3 20
Local Phone Number	16 4000
Contact Personnel Fax Number	33 (0)2 2016 4001

Consolidated Statements of Fina

Consolidated Statements of Financial Position - EUR (€) € in Thousands		Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017
Current assets
Cash and cash equivalents		€ 276,748	€ 207,240	[1]	€ 273,820	[1]
Current trade and others receivables		12,033	8,794	[1]	7,955	[1]
Other current financial assets	[1]				31
Other current assets		1,968	2,078	[1]	1,761	[1]
Inventories		4	4	[1]	4	[1]
Total - Current assets		290,753	218,116	[1]	283,572	[1]
Non-current assets
Intangible assets		920	796	[1]	636	[1]
Property, plant and equipment		16,453	7,764	[1]	6,324	[1]
Non-current trade and other receivables	[1]		1,489		1,921
Other non-current financial assets		1,727	1,313	[1]	729	[1]
Deferred tax assets				[1]		[1]
Total - Non-current assets		19,099	11,362	[1]	9,611	[1]
Total - Assets		309,853	229,478	[1]	293,183	[1]
Current liabilities
Current convertible loans		1,312	1,312	[1]	1,329	[1]
Other current loans and borrowings		3,226	1,848	[1]	1,834	[1]
Current trade and other payables		36,917	35,974	[1]	23,580	[1]
Current deferred income and revenue		139	1	[1]	1	[1]
Current provisions		2,061	112	[1]	361	[1]
Total - Current liabilities		43,657	39,248	[1]	27,106	[1]
Non-current liabilities
Non-current convertible loans		164,142	159,176	[1]	154,539	[1]
Other non-current loans and borrowings		14,939	7,255	[1]	6,978	[1]
Non-current trade and other payables		450
Non-current deferred income and revenue	[1]		1		2
Non-current employee benefits		1,408	1,085	[1]	936	[1]
Deferred tax liabilities		1,193	1,773	[1]	2,165	[1]
Total - Non-current liabilities		182,132	169,291	[1]	164,620	[1]
Shareholders' equity
Share capital		9,715	7,796	[1]	7,792	[1]
Share premium		377,821	251,554	[1]	251,932	[1]
Retained earnings (accumulated deficit)		(238,340)	(158,897)	[1]	(102,531)	[1]
Currency translation adjustment		14	6	[1]	(8)	[1]
Net profit (loss)		(65,144)	(79,521)	[1]	(55,728)	[1]
Total shareholders' equity - Group share		84,065	20,939	[1]	101,457	[1]
Total - Shareholders' equity		84,065	20,939	[1]	101,457	[1]
Total - Shareholders' equity & liabilities		€ 309,853	€ 229,478	[1]	€ 293,183	[1]
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Consolidated Statements of Oper

Consolidated Statements of Operations - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	[1]	Dec. 31, 2017	[1]
Revenues and other income
Revenue	€ 30,839	€ 69		€ 118
Other income	10,122	7,425		6,737
Revenues and other income	40,961	7,494		6,856
Operating expenses and other operating income (expenses)
Research and development expenses	(66,170)	(67,024)		(54,189)
General and administrative expenses	(17,265)	(9,076)		(9,421)
Marketing and market access expenses	(13,708)	(717)
Other operating income (expenses)	(1,649)	(162)		60
Operating income (loss)	(57,832)	(69,484)		(56,695)
Financial income	5,221	728	[2]	642	[2]
Financial expenses	(13,110)	(11,118)	[2]	(3,096)	[2]
Financial profit (loss)	(7,889)	(10,391)	[2]	(2,453)	[2]
Net profit (loss) before tax	(65,721)	(79,875)		(59,148)
Income tax benefit (expense)	576	354		3,420
Net profit (loss)	(65,144)	(79,521)	[3]	(55,728)	[3]
Attributable to owners of the Company	€ (65,144)	€ (79,521)		€ (55,728)
Basic and diluted earnings (loss) per share
Basic and diluted earnings (loss) per share (€/share)	€ (1.76)	€ (2.55)		€ (1.79)
[1]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method and therefore, the comparative information for 2017 and 2018 has not been restated . The impact of this application is presented in note 4.7
[2]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.
[3]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of the application is presented in note 4.7

Consolidated Statements of Othe

Consolidated Statements of Other Comprehensive Loss - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	[2]	Dec. 31, 2017	[2]
Statement Of Comprehensive Income [Abstract]
Net profit (loss)	€ (65,144)	€ (79,521)	[1]	€ (55,728)	[1]
Actuarial gains and losses net of tax	(168)	(31)		(210)
Other comprehensive income (loss) that will never be reclassified to profit or loss	(168)	(31)		(210)
Exchange differences on translation of foreign operations	8	14		(29)
Other comprehensive income (loss) that are or may be reclassified to profit or loss	8	14		(29)
Total other comprehensive income (loss)	(65,304)	(79,537)		(55,967)
Attributable to owners of the Company	€ (65,304)	€ (79,537)		€ (55,967)
[1]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method and therefore, the comparative information for 2017 and 2018 has not been restated . The impact of this application is presented in note 4.7
[2]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of the application is presented in note 4.7

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - EUR (€) € in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017
Cash flows from operating activities
Net profit (loss)		€ (65,144)	€ (79,521)	[1],[2]	€ (55,728)	[1],[2]
Adjustments for:
+ Depreciation and amortization on tangible and intangible assets		3,263	1,819
+ Impairment and provision for litigation		357	(208)
+ Expenses related to share-based compensation		1,657	787
- Gain on disposal of property, plant and equipment		(19)	(2)
+ Net finance expenses (revenue)		11,437	10,971
+ Income tax expense (benefit)		(576)	(354)
+ Other non-cash items including Research Tax Credit litigation		1,702	0
Operating cash flows before change in working capital		(47,324)	(66,507)
Change in:
Decrease (increase) in trade receivables and other assets		(1,640)	(724)
(Decrease) increase in trade payables and other liabilities		1,284	11,056
Change in working capital		(356)	10,332
Income tax paid			93
Net cash flows used in operating activities		(47,680)	(56,081)
Cash flows from investing activities
- Acquisition of property, plant and equipment		(2,030)	(2,938)
+ Proceeds / reimbursement from disposal of property, plant and equipment		2,517	3
- Acquisition of financial instruments		(160)	(1,050)
Net cash flows provided by (used in ) investment activities		327	(3,986)
Cash flows from financing activities
+ Proceeds from issue of share capital (net)		126,486
+ Proceeds from subscription / exercise of share warrants		43	37
+ Proceeds from new loans and borrowings net of issue costs			1,800
- Repayments of loans and borrowings		(1,884)	(2,000)
- Financial interests paid (including finance lease)		(7,785)	(6,351)
Net cash flows provided by (used in ) financing activities		116,860	(6,514)
Increase (decrease) in cash and cash equivalents		69,508	(66,580)
Cash and cash equivalents at the beginning of the period	[3]	207,240	273,820
Cash and cash equivalents at the end of the period		€ 276,748	207,240	[3]	273,820	[3]
Previously stated
Cash flows from operating activities
Net profit (loss)					(55,728)
Adjustments for:
+ Depreciation and amortization on tangible and intangible assets					1,226
+ Impairment and provision for litigation					186
+ Expenses related to share-based compensation					278
- Gain on disposal of property, plant and equipment					8
+ Net finance expenses (revenue)					2,296
+ Income tax expense (benefit)					(3,420)
+ Other non-cash items including Research Tax Credit litigation					17
Operating cash flows before change in working capital					(55,137)
Change in:
Decrease (increase) in inventories					10
Decrease (increase) in trade receivables and other assets					(2,106)
(Decrease) increase in trade payables and other liabilities					7,364
Change in working capital					5,268
Income tax paid					13
Net cash flows used in operating activities					(49,856)
Cash flows from investing activities
- Acquisition of property, plant and equipment					(2,800)
+ Proceeds / reimbursement from disposal of property, plant and equipment					15
- Acquisition of financial instruments					(163)
Net cash flows provided by (used in ) investment activities					(2,948)
Cash flows from financing activities
+ Proceeds from subscription / exercise of share warrants					37
+ Proceeds from new loans and borrowings net of issue costs					177,338
- Repayments of loans and borrowings					(1,655)
- Financial interests paid (including finance lease)					(1,372)
Net cash flows provided by (used in ) financing activities					174,348
Increase (decrease) in cash and cash equivalents					121,544
Cash and cash equivalents at the beginning of the period			€ 273,820		152,277
Cash and cash equivalents at the end of the period					€ 273,820
[1]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method and therefore, the comparative information for 2017 and 2018 has not been restated . The impact of this application is presented in note 4.7
[2]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of the application is presented in note 4.7
[3]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - EUR (€) € in Thousands	Total		Share Capital	Share Premium	Treasury Shares	Retained Earnings (Accumulated Deficit)	Currency Translation Adjustment	Net Profit (Loss)	Total Shareholders' Equity Group Share
Balance at Dec. 31, 2016	€ 142,797		€ 7,792	€ 237,305	€ (127)	€ (68,527)	€ 21	€ (33,667)	€ 142,797
Balance, shares at Dec. 31, 2016			31,166,437
Net profit (loss)	(55,728)	[1],[2]						(55,728)	(55,728)
Other comprehensive income (loss)	(239)					(210)	(29)		(239)
Total other comprehensive income (loss)	(55,967)	[2]				(210)	(29)	(55,728)	(55,967)
Allocation of prior period profit (loss)						(33,667)		33,667
Equity component of OCEANE net of deferred taxes	14,312			14,312					14,312
Share-based compensation	278			278					278
Other movements	37			37					37
Balance at Dec. 31, 2017	101,457	[3]	€ 7,792	251,932	(127)	(102,404)	(8)	(55,728)	101,457
Balance, shares at Dec. 31, 2017			31,166,437
Net profit (loss)	(79,521)	[1],[2]						(79,521)	(79,521)
Other comprehensive income (loss)	(17)					(31)	14		(17)
Total other comprehensive income (loss)	(79,537)	[2]				(31)	14	(79,521)	(79,537)
Allocation of prior period profit (loss)						(55,728)		55,728
Capital increase	(1,201)		€ 4	(1,201)		(4)			(1,201)
Capital increase, shares			17,484
Share-based compensation	787			787					787
Treasury shares	(603)				(603)				(603)
Other movements	37			37					37
Balance at Dec. 31, 2018	20,939	[3]	€ 7,796	251,554	(730)	(158,167)	6	(79,521)	20,939
Balance, shares at Dec. 31, 2018			31,183,921
Net profit (loss)	(65,144)							(65,144)	(65,144)
Other comprehensive income (loss)	(160)					(168)	8		(160)
Total other comprehensive income (loss)	(65,304)					(168)	8	(65,144)	(65,304)
Allocation of prior period profit (loss)						(79,521)		79,521
Capital increase	126,479		€ 1,919	124,567		(7)			126,479
Capital increase, shares			7,674,696
Share-based compensation	1,657			1,657					1,657
Treasury shares	252				252				252
Other movements	43			43					43
Balance at Dec. 31, 2019	€ 84,065		€ 9,715	€ 377,821	€ (478)	€ (237,862)	€ 14	€ (65,144)	€ 84,065
Balance, shares at Dec. 31, 2019	38,858,617		38,858,617
[1]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method and therefore, the comparative information for 2017 and 2018 has not been restated . The impact of this application is presented in note 4.7
[2]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of the application is presented in note 4.7
[3]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

The Company

The Company	12 Months Ended
	Dec. 31, 2019
Company Information [Abstract]
The Company	1. THE COMPANY Founded in 1999 under the laws of France, GENFIT S.A. (the "Company") is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative drugs and diagnostic tools in therapeutic areas of high unmet need due in particular to the lack of effective treatments or diagnostic solutions and/or the increase in patients worldwide. The Company concentrates its research and development (R&D) efforts in the potential marketing of therapeutic and diagnostic solutions to combat certain metabolic, inflammatory, autoimmune and fibrotic diseases affecting in particular the liver (such as non-steatohepatitis alcoholic - NASH) and more generally gastroenterological diseases. The consolidated financial statements of the Company include the financial statements of GENFIT S.A. and those of its wholly-owned subsidiaries: GENFIT CORP (U.S. subsidiary) and GENFIT PHARMACEUTICALS SAS (French subsidiary) (together referred to in these notes to the consolidated financial statements as "GENFIT" or the "Group").

Major Events In The Period

Major Events In The Period	12 Months Ended
	Dec. 31, 2019
Disclosure Of Major Events In Period [Abstract]
Major Events In The Period	2. MAJOR EVENTS IN THE PERIOD 2.1 Initial Public Offering on the Nasdaq Global Select Market On March 29, 2019, Genfit completed a capital increase to a specified categories of investors, without preferential subscription rights, of an aggregate of • 7,147,500 ordinary shares in the form of American Depositary Shares, each representing one ordinary share (“ADSs”), at a public offering price of $20.32 per ADS (the “ADS Offering”), and • 500,000 ordinary shares in Europe (including France) and countries outside of the United States at the corresponding offering price of €18.00 per ordinary share (the “European Private Placement,” and together with the ADS Offering, the “Global Offering”). The number of shares issued in the ADS Offering includes an additional 997,500 ADSs issued upon the full exercise by the underwriters for the Global Offering (the “Underwriters”) of their option to purchase additional ADSs (the “Underwriters’ Option”). Aggregate gross proceeds of the Global Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, were approximately US $155.4 million (or €137.6 million based on the March 26, 2019 exchange rate of 0.88566 dollars to 1 euro). All of the ADSs and ordinary shares in the Global Offering were offered by GENFIT (see the consolidated statements of changes in equity.) The ADSs have been listed for trading on Nasdaq since March 27, 2019. The expenses incurred and deducted from the issue premium are broken down as follows: Expenses related to the global offering (in € thousands) Registration, filling, listing fees (290 ) Underwriting (9,634 ) Legal fees and expenses (1,225 ) Accounting fees and expenses (1,045 ) Printing expenses (160 ) TOTAL (12,354 ) A total of €12.3 million of expenses were incurred, of which € 1.2 million were incurred and recorded at December 31, 2018. 2.2. Licensing Agreements LabCorp Agreement On January 2, 2019, the Company signed a licensing agreement with Covance, LabCorp’s drug development business. The licensing agreement will expand access to NIS4, a non-invasive IVD technology developed by Genfit to identify and monitor NASH patients, in the clinical research space. The primary focus of the licensing agreement will be to deploy NIS4 in the clinical research space through Covance’s central laboratories to further validate the test’s use for better identification and characterization of patients. Following commercial launch of NIS4 through Covance’s central laboratories, the Company expects to recognize revenues under this agreement during the course of 2020. Terns Pharmaceuticals Agreement On June 24, 2019, the Company signed a of a licensing and collaboration agreement with Terns Pharmaceuticals, an international company based in the United States and China, dedicated to the development of new therapies for the treatment of liver diseases. Pursuant to the agreement, Terns Pharmaceuticals obtained the exclusive rights to develop and market elafibranor in mainland China, Hong Kong, Macau and Taiwan (“Greater China”) for both NASH and PBC. The main terms of the agreement include: • An exclusive license with the right to sublicense to develop, manufacture, distribute and market elafibranor for the treatment of patients suffering from NASH and PBC in Greater China; • The Company’s undertaking to transfer to Terns Pharmaceuticals its know-how and data regarding elafibranor; • The Company’s undertaking to provide, or have provided to Terns Pharmaceuticals the drug product it requires for its clinical trials. As part of the deal, GENFIT and Terns Pharmaceuticals will also undertake joint R&D projects in liver disease, including the development of elafibranor in combination with Terns Pharmaceuticals’ proprietary compounds. Under the terms of the licensing agreement, GENFIT has received or may receive: • A $35 million upfront payment upon the signature of the agreement, received on July 3, 2019; • Clinical and regulatory milestone payments; • Commercial milestone payments; • Mid-teen percentage royalties based on sales in the territory. The potential clinical, regulatory and commercial milestone payments represent up to USD$193 million. 2.3. Extension of corporate headquarters In May 2018, Genfit signed an agreement with the lessor of its corporate headquarters to extend in 2019 the current lease, that was at the time set to expire in 2022, for another ten years and to lease for ten years a new building to be built on the same premises. The new lease agreement is non-cancellable for a nine year period beginning in 2019. Pursuant to the agreement, Genfit acted as agent of the lessor for the construction of the new building and was responsible for the cost of its construction. The agreement provides that the lessor must reimburse Genfit for costs of construction up to €2.5 million. All costs incurred above €2.5 million will be assumed by Genfit.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2019
Disclosure Of Basis Of Presentation [Abstract]
Basis of Presentation	3 . BASIS OF PRESENTATION The Consolidated Financial Statements of GENFIT have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”), and as adopted by the European Union at December 31, 2019. The consolidated financial statements have been prepared using the historical cost measurement basis except for certain assets and liabilities that are measured at fair value in accordance with IFRS. These consolidated financial statements for the year ended December 31, 2019 were prepared under the responsibility of the Board of Directors that approved such statements on May 20, 2020. The term IFRS includes International Financial Reporting Standards ("IFRS"), International Accounting Standards (the "IAS"), as well as the Interpretations issued by the Standards Interpretation Committee (the "SIC"), and the International Financial Reporting Interpretations Committee ("IFRIC"). The principal accounting methods used to prepare the condensed Consolidated Financial Statements are described below. All financial information (unless indicated otherwise) is presented in thousands of euros (€). 3 .1 . Changes in accounting policies and new standards or amendments The Group adopted IFRS 16 Leases on January 1, 2019. The new IFRIC 23 standard “Uncertainty over Tax Treatment”, came into effect on January 1, 2019, but they had no significant effect on Group financial statements. Other required standards and interpretations, applicable from January 1, 2019, do not have any significant effect on the Group’s financial statements for the year ended December 31, 2019. They concern, principally: • Amendment to IFRS9: “Prepayment features with negative compensation” • Amendment to IAS 28: “Long-term interests in Associates and Joint Ventures” • Amendment to IAS 19 “Plan Amendment, Curtailment or Settlement” New or amended policies or standards Effective date Potential impact on consolidated financial statements IFRS 16 Leases IFRS 16 aligns the accounting for operating leases with that of finance leases Applicable for all reporting periods from January 1, 2019 The group adopted IFRS 16 using the modified retrospective method and elected to apply it to contracts that were previously identified as leases under IAS 17 and IFRIC 4. The Group used the exemptions provided for leases whose term is less than 12 months from the date of 1st application and those relating to assets of low value. See note 4.7 to the consolidated financial statement 3 .2. Standards, interpretations and amendments issued but not yet effective The Group has not identified any standards or amendments issued but not yet effective as of January 1, 2020 that may have a significant impact on the Group's consolidated financial statements. However, following publication of the final decision of IFRS IC on December 16, 2019 relating to the duration of leases and its interaction with the amortization period for non-removable fixtures, the Group is in the process of identifying those agreements which may be impacted, collecting the necessary information and performing analyses in order to estimate the possible impacts of this decision. These analyses mainly relate to the identification of agreements that may be impacted, the collection of relevant information, in particular among existing fixtures, the determination of estimates to define the execution period and the rental period. As of December 31, 2019, the Group’s analysis of the impact of the IFRS IC decision requires sufficient time and is still ongoing. Its implementation could result in an extension of the rental period initially assumed and lead to a revision of the lease debt and the right of use asset relating to the relevant leases. However, the Group should not be significantly impacted given the absence of contracts with an automatic renewal / extension of rental period or contracts that may be terminated for an indefinite period, and for which the lease period is likely to be modified following completion of the analyses.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Disclosure Of Voluntary Change In Accounting Policy [Abstract]
Summary of Significant Accounting Policies	4 . SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 4 .1. Use of estimates and judgments In preparing these consolidated financial statements, management makes judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, incomes and expenses. Actual amounts may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. The estimates and underlying assumptions mainly relate to research tax credits (see Note 4.19.2, "Research tax credit", employee benefits (see Note 4.18, "Employee benefits"), share-based payments (see Note 20, "Share-based compensation"), accruals related to clinical trials (see Note 19, "Operating expenses") and convertible loans (see Note 12, "Loans and Borrowings"). 4 .2. Consolidation The Group controls an entity when it is exposed to variable returns from its involvement with the entity, and it has the ability to affect those returns through its power over the entity. The Group controls all the entities included in the scope of consolidation. 4 .3. Foreign currency 4 .3.1. Foreign currency transactions Transactions in foreign currencies are translated into the respective functional currencies of the entities of the Group at the exchange rates applicable at the transaction dates. Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the reporting date. The resulting exchange gains or losses are recognized in the statements of operations. 4 .3.2. Translation of foreign subsidiary financial statements The assets and liabilities of foreign operations having a functional currency different from the euro are translated into euros at the closing exchange rate. The income and expenses of foreign operations are translated into euros at the exchange rates effective at the transaction dates or using the average exchange rate for the reporting period, unless this method cannot be applied due to significant exchange rate fluctuations. Gains and losses arising from foreign operations are recognized in the statement of other comprehensive loss. When a foreign operation is partly or fully divested, the associated share of gains and losses recognized in the currency translation reserve is transferred to the statements of operations. The Group’s presentation currency is the euro, which is also the functional currency of GENFIT S.A. The functional currency of GENFIT CORP is the U.S. dollar. The applicable exchange rates used to translate the financial statements of this entity for each of the periods are as follows: Year ended Year ended Year ended Ratio : 1 US dollars (USD) = x euros (EUR) 2017/12/31 2018/12/31 2019/12/31 Exchange rate at period end 0.83382 0.87336 0.89015 Average exchange rate for the period 0.88704 0.84758 0.89341 4.4 Revenues from ongoing activities under client agreements The Group signed an agreement with Terns Pharmaceuticals on June 24, 2019. The Group’s accounting policies associated with revenue are as follows: 4.4.1. IFRS 15 Under IFRS 15, revenue is recognized when the Company fulfills a performance obligation by providing separate goods or services to a customer, i.e., when the customer obtains control of those goods or services. An asset is transferred when the customer obtains control of that asset or service. Under this standard, each contract must be analyzed, on a case-by-case basis, in order to verify whether it contains performance obligations towards third parties, and, if applicable, to identify their nature in order to determine the appropriate accounting of amounts that the Company has received or is entitled to receive from third parties, for example: • The transfer of control over the intellectual property, via a license granted by the Company, as it exists at the time of the sale, the date of which will determine that of the revenue recognition; • If the license is considered as a right of access to the intellectual property of the Company over the life of the license, the revenue would be recognized over this lifetime; • The supply of products whose revenues would be recognized at the time of transfer of control of the delivered products, • Potential revenue from milestones, or from royalties or royalties based on sales, would not be recognized until the achievement of the milestone or completion of the sale. 4.4.2 Application to the Terns Pharmaceuticals license agreement The Company identified three performance obligations under the license agreement with Terns: • An exclusive license, with the right to sub-license, to develop, manufacture, distribute and promote elafibranor in NASH and PBC in Greater China; • A transfer to Terns Pharmaceuticals of the Company’s Licensed Know-How and data regarding elafibranor and related support until the Marketing Authorization Application by Terns Pharmaceuticals; and • Supply by the Company to Terns Pharmaceuticals of drug product to carry out its clinical trials in Greater China. The supply of drug product following the market authorization would be subject to a separate agreement if applicable. Under the terms of the licensing agreement, the Company has received or could potentially receive: • A $35 million non-refundable Upfront Payment payable within 10 business days from June 24, 2019 upon the transfer of the existing Company’s Licensed Know-How. This Upfront Payment was received on July 3, 2019; • Development Milestone Payments upon the achievement of the development milestones for the licensed product; • Commercial Milestone Payments upon the achievement of commercial milestones depending on reaching certain aggregate thresholds; • Mid-teen percentage Royalties based on sales by Terns Pharmaceuticals in Greater China; and • Compensation for the supply of drug product for the clinical trials on a cost-plus basis. The potential Development and Commercial Milestone payments may represent up to $193 million. Under IFRS 15, the allocation and recognition of revenue was determined as follows based on the fair value of each of the performance obligations: • The $35 million upfront payment was allocated to the license and the transfer of the existing know-how and related support to Terns Pharmaceuticals based on an estimate of the latter measured as the maximum estimated value to be incurred by the Company’s employees and management for the support given to Terns Pharmaceuticals. On this basis, $34.9 million was recognized as revenue in 2019 and $0.1 million was deferred to future periods. • Development and Commercial Milestones Payments whose payment depends on the achievement of certain scientific, regulatory or commercial objectives, as provided in the contract, are variable compensation that will be recognized as revenue when the milestones are met. No amounts were recognized in 2019. • Royalties on commercial sales by Terns Pharmaceuticals will be recognized as revenue pursuant to information given to the Company by Terns Pharmaceuticals, under the terms and timeframes set out in the agreement. No amounts were recognized in 2019. • Revenue on Supply for drug product will be recognized based on the delivery of drug product to Terns Pharmaceuticals. No amounts were recognized in 2019. As part of this agreement, Genfit and Terns Pharmaceuticals will also undertake joint research and development projects in liver disease, including the development of elafibranor in combination with Terns Pharmaceuticals’ proprietary compounds. This collaboration agreement is only potential at the date of signing the license agreement and does not yet constitute a reciprocal commitment at December 31, 2019. It therefore has no accounting impact at this time. This contract contains several delivery obligations. As a result, the Company has ensured, as required by IFRS 15, that the revenue allocation of the transaction corresponds to the fair value of each obligation. 4.5 . Intangible assets Intangible assets mainly consist of software and operating licenses acquired by the Group. They are recognized at cost less accumulated amortization and impairment. Amortization expense is recorded on a straight-line basis over the estimated useful lives of the intangible assets. The estimated useful lives of both software and license agreements are between 1 and 8 years. 4.6 . Property, plant and equipment Property, plant and equipment are initially recognized at cost. Cost includes expenditures that are directly attributable to the acquisition of the asset. Routine maintenance costs are expensed as incurred. Subsequently, depreciation expense is recognized on a straight-line basis over the estimated useful lives of the assets. If components of property, plant and equipment have different useful lives, they are accounted for separately. Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted, if appropriate. Estimated useful lives are as follows: Building on non-freehold land 10 years Fittings and fixtures Between 9 and 25 years Scientific equipment Between 2 and 12 years Computer equipment Between 2 and 5 years Furniture Between 4 and 10 years Vehicles Between 4 and 6 years Any gain or loss on disposal of an item of property, plant and equipment is determined by comparing the proceeds from disposal with the carrying amount of the item. The net amount is recognized in the consolidated statements of operations under the line item "Other operating income (expenses)." 4.7 . Leases 4.7.1 IFRS 16 and IAS 17 The Group has applied IFRS 16 in accordance with the modified retrospective method, under which the cumulative effect of the adoption of IFRS 16 is recorded as an adjustment to the balance of accumulated deficit as at January 1, 2019. As a result, comparative information presented for 2018 has not been restated and is therefore presented, as before, in accordance with the principles of IAS 17 and its interpretations. The resulting changes in accounting policies are explained in detail below. Significant accounting policies of IAS 17 Finance leases When substantially all of the risks and rewards of ownership are transferred from the lessor to the lessee, the leases are classified as finance leases, resulting in the initial recognition of an asset equal to the fair value of the relevant property or the present value of the minimum future payments due under the contract, whichever is lower. They are subsequently amortized or depreciated, as the case may be. The resulting financial liabilities are recorded in current and non current “other loans and borrowings”. Operating leases A lease agreement is qualified as an operating lease when substantially all of the risks and rewards of ownership are not transferred to the lessee. Payments under operating leases are recognized as an expense on a straight-line basis over the term of the lease. Benefits received from the lessor such as rent suspensions or variable payments are allocated on a straight-line basis over the term of the lease. Significant accounting policies under IFRS 16 IFRS 16 introduces for the lessee a single model of accounting on the balance sheet for leases. The lessee recognizes a "right of use" asset which represents its right to use the underlying asset, and a lease liability for its obligation to pay the rent. The Group recognizes a "right of use" asset and a lease liability at the start of the lease term. The "right of use" asset is initially measured at cost and then at cost less any amortization and accumulated impairment losses. The amount can be adjusted based on certain revaluations of the lease liability. The lease liability is initially measured at the discounted value of the rents owed and not yet paid at the start date of the contract. The discount rate used is the implicit interest rate of the contract or, if it cannot be easily determined, the Company’s incremental borrowing rate. The Group generally uses the latter as the discount rate. The lease liability is then adjusted by the interest expense minus the amounts of rent paid. It is revalued in the event of a change in future rents following a change in the index or rate, a new estimate of the amount to be paid under a residual value guarantee or, where applicable, a revaluation of the exercise of an option to purchase or to extend, or the non-exercise of an option to terminate (which then becomes reasonably certain). The Group has exercised its judgment in determining the term of the lease agreements that provide for extension options. The fact that the Group has determined that it is reasonably certain to exercise such options has an impact on the lease term used and has a significant impact on the amount of lease debt and the "right of use" asset in the accounts. 4.7.2 Application of the new IFRS 16 standard IFRS 16 “Leases”, adopted by the European Union on October 31, 2017, is mandatorily applicable for the reporting periods starting on or after January 1, 2019. It replaces IAS 17 “Leases” and its interpretations. This new standard removes the concepts of finance lease and operating lease for the lessee and requires all leases to be recognized on the lessee's balance sheet in the form of a "right of use" asset with the corresponding entry for a financial debt. The Group's leases, formerly classified as operating leases in accordance with IAS 17, concern real estate assets, including the Group's corporate headquarters. Contracts formerly classified as finance leases include, in particular, scientific equipment. As part of the transition, the Group adopted the "modified retrospective" method and chose to apply some of the practical expedients offered by IFRS 16, namely: • The exclusion of contracts of less than 12 months duration; • Exclusion of low value contracts; • Carryforward of contracts previously accounted for as finance lease contracts under IAS 17 "Leases". The new standard is implemented as follows: • The lease term for a contract corresponds to its non-cancellable period, extended, as the case may be, based on the Group's assessment of the reasonably certain nature of the exercise of contractual renewal or cancellation options; • The discount rate applied is the incremental borrowing rate corresponding to the duration of the contract, in the absence of an implicit rate in the contract. To determine the incremental borrowing rate, the Group determined the remaining term of the contracts as from January 1, 2019. The weighted average incremental borrowing rate at January 1, 2019 was 1.26%. Duration is the average life of financial flows weighted by their discounted value. "Right of use" assets and lease liabilities were recognized in the Group's balance sheet as at January 1, 2019 for € 9,227 and € 8,947, respectively. In accordance with IFRS 16, the Group has chosen to present the “right of use” assets in the same line item as property, plant and equipment as the assets of the same type. As of December 31, 2018, the differences between the commitments related to operating leases presented in application of IAS 17 and the lease liability estimated in accordance with IFRS 16 can be explained as follows: In € thousands 12/31/2018 Operating lease commitments as a lessee, as of 12/31/2018 as published 4,791 Differences related to extension options for which the exercise is reasonably certain 5,264 Differences in the amounts retained for the calculation of commitments and lease liability (396) Expenses not included in the lease liability but included in the commitments (190) Undiscounted lease liability estimated under IFRS 16 at 1/1/2019 9,469 Impact of discount (522) Lease liability estimated under IFRS 16 at 1/1/2019 8,947 The impact of the duration is entirely attributable to the Group's headquarters, where an agreement to extend the building led to a revision of the commitment period for Genfit and the lessor under this lease. The lease expense that would have been recognized in 2019 if IAS 17 had applied would have amounted to € 1,480. Under IFRS 16, expenses recognized in 2019 amounted to € 1,241 in depreciation for right of use assets and € 128 in interest expense. 4.8 . Impairment of tangible assets, intangible assets and goodwill If indicators of impairment are identified, amortizable intangible assets and depreciable tangible assets are subject to an impairment test under the provisions of IAS 36, Impairment of Assets The Company does not have any goodwill. 4.9. IFRS 9 “Financial Instruments” replaces IAS39 “ Financial Instruments: Recognition and Measurement” starting from the 2018 financial year and takes into account three aspects of booking financial instruments: • Classification and measurement; • Impairment; • Hedge accounting. As was the case in the previous periods, application of IFRS 9 does not have an impact on the Group’s financial statements. Loans and borrowings are initially measured at fair value and subsequently recorded at amortized cost. 4.10 . Inventories The Company recognizes inventories of laboratory consumables in connection with its former co-research agreements. These inventories are measured at the lower of cost and net realizable value. Cost is determined using the weighted average cost method. 4.11 . Trade and other receivables Trade and other receivables are recognized at fair value, which is the nominal value of invoices unless payment terms require a material adjustment for the time value discounting effect at market interest rates. Trade receivables are subsequently measured at amortized cost. A valuation allowance for trade receivables is recognized if their recoverable amount is less than their carrying amount. Receivables are classified as current assets, except for those with a maturity exceeding 12 months after the reporting date. 4 .12 . Other financial assets Loans and receivables are financial assets with fixed or determinable payments that are not listed on an active market and are valued using the amortized cost method. A gain or loss arising from a change in the fair value of an available-for-sale financial asset is recognized in other comprehensive income (loss) except for impairment losses and foreign exchange gains and losses, until the financial asset is derecognized. At that time the cumulative gain or loss previously recognized in other comprehensive income (loss) is reclassified from equity to profit or loss as a reclassification adjustment. 4.13 . Cash and cash equivalents Cash and cash equivalents comprise cash on hand, bank accounts and term deposits, together with short-term deposits and highly liquid investments. They are readily convertible to a known amount of cash and thus present a negligible risk of a change in value. They also include Undertakings for Collective Investments in Transferable Securities (UCITs) whose characteristics allow them to be classified as cash and cash equivalents. Initially recognized at their purchase cost at the transaction date, investments are subsequently measured at fair value. Changes in fair value are recognized in net financial income (expenses). 4.14 . Equity Share capital comprises ordinary shares and ordinary shares with double voting rights classified in equity. Costs directly attributable to the issue of ordinary shares or share options are recognized as a reduction in the share premium. The liquidity agreement consists of a share buyback program contracted to an investment service provider. Purchases and sales of the Company's shares carried out under the contract are recognized directly in shareholders’ equity under treasury shares. See note 10 “Other financial income”. 4.15 . Loans and borrowings Financial liabilities are initially recognized at fair value, net of directly attributable transaction costs, and are subsequently measured at amortized cost using the effective interest rate method. The Group derecognizes financial liabilities when the contractual obligations are discharged, cancelled or expire. The bonds convertible or exchangeable into new or existing shares (OCEANE—see Section 12.1, "Breakdown of convertible loan") are recognized as follows: in accordance with IAS 32, Financial Instruments—Presentation The liability component is measured, at the date of issuance, at its fair value on the basis of future contractual cash flows discounted at market rates (taking into consideration the issuer's credit risk) of a debt having similar characteristics but without having the conversion option. The value of the conversion option is measured by the difference between the bond's issue price and the fair value of the liability component. After deduction of the pro rata portion of expenses related to the transaction, this amount is recognized in the line item "Share premium" under shareholders' equity and is subject to a calculation of deferred tax according to IAS 12.28. The liability component (after deduction of the portion of the expenses related to the transaction pro rata portion to the respective parts attributed to liability and the conversion option) is measured at amortized cost. A non-monetary interest expense, recorded in net loss is calculated using an effective interest rate to progressively bring the debt component up to the amount which will be repaid (or converted) at maturity. A deferred tax liability is calculated on the basis of this amount. The shareholders' equity component is not remeasured. 4.16 . Trade and other payables Trade and other payables are initially recognized at the fair value of the amount due. This value is usually the nominal value, due to the relatively short period of time between the recognition of the instrument and its repayment. 4.17 . Provisions Provisions are recognized when the Group has a present obligation (legal, regulatory, contractual or constructive) as a result of a past event, for which it is probable that an outflow of resources will be required to settle the obligation, and of which the amount can be estimated reliably. The amount recognized as a provision is the best estimate at the reporting date of the expenditure required to settle the present obligation. Provisions are discounted when the time value effect is material. 4.18 . Employee benefits The Group's pension schemes and other post-employment benefits consist of defined benefit plans and defined contribution plans. 4.18 .1. Defined benefit plans Defined benefit plans relate to French retirement benefit plans under which the Group is committed to guaranteeing a specific amount or level of contractually defined benefits. The obligation arising from these plans is measured on an actuarial basis using the projected unit credit method. The method consists of measuring the obligation based on a projected end-of-career salary and vested rights at the measurement date, according to the provisions of the collective bargaining agreement, corporate agreements and applicable law. Actuarial assumptions are used to determine the benefit obligations. The amount of future payments is determined on the basis of demographic and financial assumptions such as mortality, staff turnover, pay increases and age at retirement, and then discounted to their present value. The discount rate used is the yield at the reporting date on AA credit-rated bonds with maturity dates that approximate the expected payments for the Group's obligations. Re-measurements of the net defined benefit liability which comprise actuarial gains and losses are recognized in the statements of other comprehensive loss. The Group determines the net interest expense on the net defined benefit liability for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability, taking into account any changes in the net defined benefit liability during the period as a result of contributions and benefit payments. 4.18 .2. Defined contribution plans Under defined contribution plans, the management of plans is performed by an external organization, to which the Group pays regular contributions. Payments made by the Group in respect of these plans are recognized as an expense for the period in the statements of operations. 4.18 .3. Short-term employee benefits A liability is recognized for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Group has a present legal or constructive obligation to pay the amount as a result of past service provided by the employee, and the obligation can be estimated reliably. 4 .19. Other income 4 .19.1. Government grants The Group received until 2016 various forms of government grants. This government aid is provided for and managed by French state-owned entities, and specifically "BPI France" (" Banque Publique d'Investissement Subsidies received are non-refundable. Conditional advances received are interest-free or are subject to low interest rates depending on contractual provisions. Grants related to assets Grants related to assets are intended to finance the purchase of long-term assets. They are presented in the statements of financial position as deferred income and recognized in the line item "Other income" in the statements of operations on a systematic basis over the useful life of the related asset. Grants related to income Grants related to income are intended to finance research programs. They are presented in the statements of financial position as deferred income and recognized in the line item "Other income" in the statements of operations as and when costs related to the research programs are incurred. Conditional advances related to research programs Conditional advances that are interest-free or subject to low interest rates are intended to finance research program’s needs. In accordance with IAS 20, Accounting for Government Grants and Disclosure of Government Assistance The grant portion of conditional advances is treated as a grant related to income. For advances granted by BPI France, repayment is required in the event of commercial success. In addition, if the Group decides to stop the research program, the conditional advance may be required to be repaid. If a program is unsuccessful, a pre-determined amount may be repayable. If a program is unsuccessful, a predetermined amount may be repayable The remaining amount, if any, is then considered as a grant and written off in the line item "Other income" in the statements of operations. 4 .19.2. Research tax credit The Research Tax Credit (" Crédit d'Impôt Recherche The Group applies for CIR for research expenditures incurred in each fiscal year and recognizes the amount claimed in the line item "Other income" in the statements of operations in the same fiscal year. In the notes to the financial statements, the amount claimed is recognized under the heading "Research tax credit" (see Note 9, "Trade and other receivables" and Note 18, "Revenue and other income"). The CIR for fiscal years 2010, 2011, 2012 and 2014 was under audit by the tax authorities and a provision was made in the accounts. (see Note 24, "Litigation and contingent liabilities"). 4 .20. Research and development expenses Research expenses are recorded in the financial statements as expenses (see Note 19, "Operating expense"). In accordance with IAS 38, Intangible Assets • Technical feasibility necessary for the completion of the development project; • Intention on the Group's part to complete the project and to utilize it; • Capacity to utilize the intangible asset; • Proof of the probability of future economic benefits associated with the asset; • Availability of the technical, financial, and other resources for completing the project; and • Reliable evaluation of the expenses attributed to the intangible asset during its development. 4 .21. Classification of operating expenses Research and development expenses include: • employee-related costs; • costs related to external employees seconded to the Company (such as clinical development, biometrics and IT…); • lab supplies and facility costs; • donations to The NASH Epidemiology Institute endowment fund, in particular to fund the creation of patient registry; • fees paid to scientific advisers and contracted research and development activities conducted by third parties; • intellectual property fees corresponding to the filing of the Group's patents and, • provision in relation to the Research Tax Credit dispute (see note 24 to our financial consolidated statements ) Contracted research and development activities conducted by third parties include services subcontracted to research partners for technical and/or regulatory reasons. In particular, this includes the production of active ingredients and therapeutic units, all or a part of clinical trials and pre-clinical trials that are necessary to the development of GENFIT's drug candidates and biomarker candidates. General and administrative expenses include: • employee-related costs for executive, business development, intellectual property, finance, legal and human resources and communications functions; • facility-related costs; • marketing, legal, audit and accounting fees; • press relations and communications firm fees; • the cost of external employees seconded to the Company (such as security, reception, and accounting..); • other service costs (recruitment, etc.); • grants to the endowment fund, The NASH Epidemiology Institute TM • intellectual property fees corresponding to the maintenance of the Group's patents. Marketing and market access expenses include: • employee-related costs for marketing and business development, functions; • facility-related costs; • marketing, and market access firm fees; • the cost of external employees seconded to the Company (market access..) and • other service costs (recruitment, etc); 4 .22. Share-based compensation The fair value of equity-settled share-based compensation granted to employees, officers, board members and consultants as determined on the grant date is recognized as a compensation expense with a corresponding increase in equity, over the vesting period. The amount recognized as an expense is adjusted to reflect the actual number of awards for which the related service and non-market performance conditions are expected to be met. The fair values of equity-settled share-based compensation granted to employees are measured using the Black-Scholes model with respect to the share warrants (BSA) and redeemable share warrants (BSAAR) and using the Monte Carlo model for the stock options (SO) and free shares (AGA). Measurement inputs include share price on the measurement date, the exercise price of the instrument, expected volatility, expected maturity of the instruments, expected dividends, and the risk-free interest rate (based on government bonds). With respect to the redeemable share warrants, service and non-market performance conditions attached to the transactions are not taken into consideration in determining fair value but are taken into consideration related to recognition of expense. Regarding the stock options and free shares, market conditions are taken into account in the determination of the fair value of the plans award. For share-based compensation awards with non-vesting conditions, the grant date fair value of the share-based compensation is measured to reflect such conditions and there is no adjustment for differences between expected and actual outcomes. GENFIT may also grant equity-settled share-based compensation in exchange for services to consultants who are not considered employees. In such cases, the value of the services is measured when they are rendered by the consultants and the share-based compensation exchanged for the services is measured at an equal amount. If the value of the services cannot be measured reliably, then such value is measured with reference to the fair value of the equity instruments granted. Share-based compensation granted to consultants consists of share warrants, some of which may be redeemed at GENFIT's discretion. Share-based compensation granted to employees consists of redeemable share warrants, stock options and free shares 4 .23. Income tax Income tax expense (or benefit) comprises current tax expense (or benefit) and deferred tax expense (or benefit), as applicable. Deferred taxes are recognized for all the temporary differences arising from the difference between the tax basis and the accounting basis of assets and liabilities. Deferred tax assets are recognized for unused tax losses, unused tax credits and te

Financial Risks Management

Financial Risks Management	12 Months Ended
	Dec. 31, 2019
Foreign Exchange Rates [Abstract]
Financial Risks Management	5 . FINANCIAL RISKS MANAGEMENT The Group may be exposed to the following risks arising from financial instruments: foreign exchange risk, interest rate risk, liquidity risk and credit risk. 5 .1. Foreign exchange risk The nature and exposure of the Group to currency risk has evolved due to a growing portion of its operations being denominated in US dollars, and because the Group decided not to convert into euros the US dollar denominated cash it raised in March 2019 IPO. The Company expects to use cash held in US dollars to meet expenses denominated in this currency over the next few years. In the future, and in particular with respect to its clinical trials and pre-marketing activities, the Group will manage an increasing number of transactions denominated in foreign currencies or indirectly exposed to currency risk. The increase in the overall exposure of the Company to this risk will depend, in particular, on: • the currencies in which the Group receives its revenues; • the currencies chosen when agreements are entered into, such as licensing agreements, or co-marketing or co-development agreements; • the location of clinical trials on drug or biomarker candidates; • the ability, for its co-contracting parties to indirectly transfer foreign exchange risk to the Company; and • the Group’s foreign exchange risk policy. During the 2017 fiscal year, the Group used specific hedging arrangements (e.g., purchase of U.S. dollars and of UCITS in U.S. dollars, as well as currency forwards in U.S. dollars). In 2018, the Group considered the implementation of appropriate certain hedging arrangements without ultimately using any such arrangements. During 2019, the Company did not use any specific hedging arrangements in light of the Company’s decision to leave a significant part of its cash and cash equivalents in US dollars. 5. FINANCIAL RISKS MANAGEMENT (Continued) The following table shows the sensitivity of the Group's cash and cash equivalent and expenses in U.S. dollars to a variation of 10% of the U.S. dollar against the euro in 2017, 2018 and 2019: Sensitivity of the Group's cash and cash equivalents to a variation of +/- 10% of the US dollar against the euro As of (in € thousands or in US dollar thousands, as applicable) 2017/12/31 2018/12/31 2019/12/31 Cash and cash equivalents denominated in US dollars 3,611 1,188 153,438 Equivalent in euros, on the basis of the exchange rate described below 3,011 1,038 136,582 Equivalent in euros, in the event of an increase of 10% of US dollar vs euro 3,345 1,153 151,758 Equivalent in euros, in the event of a decrease of 10% of US dollar vs euro 2,737 944 124,166 Sensitivity of the Group's expenses to a variation of +/- 10% of the US dollar against the euro Year ended (in € thousands or in US dollar thousands, as applicable) 2017/12/31 2018/12/31 2019/12/31 Expenses denominated in US dollars 5,993 9,613 40,355 Equivalent in euros, on the basis of the exchange rate described below 4,997 8,396 35,922 Equivalent in euros, in the event of an increase of 10% of US dollar vs euro 5,552 9,328 39,914 Equivalent in euros, in the event of a decrease of 10% of US dollar vs euro 4,543 7,632 32,657 2019/12/31 : Equivalent in euros, on the basis of a 1 euro = 1.1234 US dollar ratio 2018/12/31 : Equivalent in euros, on the basis of a 1 euro = 1.145 US dollar ratio 2017/12/31 : Equivalent in euros, on the basis of a 1 euro = 1.1993 US dollar ratio Cash, cash equivalents and financial assets As of (in € thousands or in US dollar thousands, as applicable) 2017/12/31 2018/12/31 2019/12/31 At origin, denominated in EUR Cash and cash equivalents 270,210 206,199 139,863 Current and non current financial assets 729 1,303 1,614 Total 270,939 207,502 141,477 At origin, denominated in USD Cash and cash equivalents 3,611 1,041 136,884 Current and non current financial assets 31 10 113 Total 3,642 1,051 136,997 Total, in EUR Cash and cash equivalents 273,820 207,240 276,748 Current and non current financial assets 760 1,313 1,727 Total 274,581 208,553 278,474 5. FINANCIAL RISKS MANAGEMENT (Continued) 5 .2. Interest rate risk As of December 31, 2019, the Group was only liable for governmental advances or conditional advances with no interest or interest at a fixed rate, generally below market rate, and for fixed-rate bank loans (the only variable-rate loan was repaid in 2017). As of December 31, 2017, 2018, and 2019 the Group's financial liabilities totaled €164,680, €169,593 (net of the equity component of the convertible loan and debt issue costs), and €183,617 respectively. Current borrowings are at a fixed rate. The Group's exposure to interest rate risk through its financial assets is also insignificant due to low market rates and since these assets are mainly euro-denominated Undertakings for the Collective Investment of Transferable Securities (UCITs), medium-term negotiable notes or term deposits with progressive rates denominated in euros or US dollars.. 5 .3. Liquidity risk The Group's loans and borrowings mainly consist of bonds convertible or exchangeable into new or existing shares (OCEANE), government advances for research projects and bank loans. For conditional advances, reimbursement of the principal is subject to the commercial success of the related research project. The Company has conducted a specific review of its liquidity risk and considers that it is able to meet its future maturities. On December 31, 2017, 2018 and 2019, the Group had €274,581, €208,553, and €278,474 respectively, in cash and cash equivalents and other financial assets. The Company does not believe it is exposed to short-term liquidity risk. The Company believes that the Group's cash and cash equivalents and current financial instruments are sufficient to ensure its financing, in light of its current projects and obligations, for at least the next twelve months. If the Group's funds are insufficient to cover any additional financing needs, the Group would require additional financing. The conditions and arrangements for any such new financing would depend, among other factors, on economic and market conditions that are beyond the Group's control. 5 .4. Credit risk Credit risk is the risk of financial loss if a customer or counterparty to a financial asset defaults on their contractual commitments. The Group is exposed to credit risk due to trade receivables and other financial assets. The Group's policy is to manage this risk by transacting with third parties with good credit standards.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2019
Cash And Cash Equivalents [Abstract]
Cash and Cash Equivalents	6 . CASH AND CASH EQUIVALENTS The main components of cash equivalents were: • UCITS and interest-bearing current accounts, available immediately; • Term accounts, available within the contractual maturities or by the way of early exit; and • Negotiable medium-term notes, available with a quarterly maturity or by the way of early exit. These investments, summarized in the tables below, are short-term, highly liquid and subject to insignificant risk of changes in value. Cash and cash equivalents As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Short-term deposits 244,279 201,522 263,147 Cash on hand and bank accounts 29,541 5,718 13,601 TOTAL 273,820 207,240 276,748 Short-term deposits As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 UCITS 38,052 29,189 3,096 TERM ACCOUNTS 138,967 124,316 215,018 NEGOTIABLE MEDIUM-TERM NOTES 4,150 — — INTEREST-BEARING CURRENT ACCOUNT 63,110 48,017 45,033 TOTAL 244,279 201,522 263,147

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2019
Disclosure Of Intangible Assets [Abstract]
Intangible Assets	7 . INTANGIBLE ASSETS Intangible assets consist mainly of office and administrative software as well as scientific software purchased by the Group. The following tables show the variations in intangible assets for the years ended December 31, 2017, 2018 and 2019: As of As of Intangible assets—Variations January 1, December 31, (in thousands of euros) 2017 Increase Decrease 2017 Gross Software 1,688 268 (56 ) 1,900 Patents 21 — — 21 TOTAL – Gross 1,709 268 (56 ) 1,921 Accumulated depreciation and impairment Software (1,020 ) (298 ) 54 (1,264 ) Patents (21 ) — — (21 ) TOTAL - Accumulated depreciation and impairment (1,042 ) (298 ) 54 (1,285 ) TOTAL – Net 668 (29 ) (2 ) 636 As of As of Intangible assets—Variations January 1, December 31, (in thousands of euros) 2018 Increase Decrease 2018 Gross Software 1,900 216 (67 ) 2,049 Patents 21 — — 21 Other intangibles — 313 — 313 TOTAL—Gross 1,921 529 (67 ) 2,384 Accumulated depreciation and impairment Software (1,264 ) (370 ) 67 (1,567 ) Patents (21 ) — — (21 ) Other intangibles — — — — TOTAL - Accumulated depreciation and impairment (1,285 ) (370 ) 67 (1,588 ) TOTAL – Net 636 159 — 796 7. INTANGIBLE ASSETS (continued) Intangible assets – Variations As of Translation As of (in € thousands) 2018/12/31 Increase Decrease adjustments Reclassification 2019/12/31 Gross Software 2,049 340 (29 ) — 378 2,739 Patents 21 70 — — — 91 Other intangibles 313 65 — — (378 ) — TOTAL – Gross 2,384 475 (29 ) — — 2,830 Accumulated depreciation and impairment Software (1,567 ) (350 ) 29 — — (1,888 ) Patents (21 ) — — — — (21 ) Other intangibles — — — — — — TOTAL - Accumulated depreciation and impairment (1,588 ) (350 ) 29 — — (1,910 ) TOTAL – Net 796 125 — — — 920

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2019
Disclosure Of Property Plant And Equipment [Abstract]
Property, plant and equipment	8 . PROPERTY, PLANT AND EQUIPMENT The following tables show the variations in tangible assets for the years ended December 31, 2017,2018 and 2019: Property, plant & equipment—Variations (in thousands of euros) As of January 1, 2017 Increase Decrease Reclassification As of December 31, 2017 Gross Buildings on non-freehold land — 11 — — 11 Scientific equipment 6,078 3,546 (49 ) — 9,576 Fittings 988 138 — — 1,126 Vehicles 82 61 (44 ) — 99 Computer equipment 1,475 211 (12 ) 281 1,954 Furniture 317 40 — — 357 In progress — 281 (281 ) — TOTAL - Gross 8,940 4,287 (105 ) — 13,123 Accumulated depreciation and impairment Scientific equipment (4,438 ) (673 ) 48 — (5,063 ) Fittings (657 ) (65 ) — — (722 ) Vehicles (29 ) (17 ) 22 — (24 ) Computer equipment (530 ) (184 ) 11 — (703 ) Furniture (276 ) (9 ) — — (285 ) In progress — — — — — TOTAL - Depreciation and impairment (5,930 ) (949 ) 81 — (6,798 ) TOTAL - Net 3,010 3,338 (24 ) — 6,324 8 . PROPERTY, PLANT AND EQUIPMENT (continued) Property, plant and equipment—Variations (in thousands of euros) As of January 1, 2018 Increase Decrease Reclassification As of December 31, 2018 Gross Buildings on non-freehold land 11 — — 1,447 1,458 Scientific equipment 9,576 1,484 (235 ) 54 10,879 Fittings 1,126 443 (43 ) 5 1,531 Vehicles 99 — — — 99 Computer equipment 1,954 200 (5 ) (702 ) 1,446 Furniture 357 8 (4 ) — 361 In progress — 805 — (804 ) — TOTAL - Gross 13,123 2,939 (288 ) — 15,774 Accumulated depreciation and impairment Buildings on non-freehold land — (1 ) — — (1 ) Scientific equipment (5,063 ) (1,142 ) 218 — (5,988 ) Fittings (722 ) (91 ) 43 — (769 ) Vehicles (24 ) (21 ) 0 — (45 ) Computer equipment (703 ) (216 ) 4 — (915 ) Furniture (285 ) (11 ) 4 — (292 ) In progress — — — — — TOTAL - Depreciation and impairment (6,798 ) (1,481 ) 270 — (8,010 ) TOTAL - Net 6,324 1,459 (18 ) — 7,764 8 . PROPERTY, PLANT AND EQUIPMENT (continued) Property, plant and equipment - Variations As of Translation As of (in € thousands) 2018/12/31 Increase Decrease adjustments Reclassification 2019/12/31 Gross Buildings on non-freehold land 1,458 12,218 — — (1,447 ) 12,229 Scientific equipment 10,879 556 (120 ) — (54 ) 11,260 Fittings 1,531 66 — — (5 ) 1,592 Vehicles 99 — — — — 99 Computer equipment 1,446 227 (15 ) — 11 1,669 Furniture 361 31 (3 ) — — 389 In progress 0 241 (1,737 ) — 1,496 — TOTAL - Gross 15,774 13,339 (1,875 ) — — 27,238 Accumulated depreciation and impairment Buildings on non-freehold land (1 ) (1,215 ) — — — (1,216 ) Scientific equipment (5,988 ) (1,303 ) 119 — — (7,172 ) Fittings (769 ) (105 ) — — — (875 ) Vehicles (45 ) (21 ) — — — (66 ) Computer equipment (915 ) (252 ) 12 — — (1,155 ) Furniture (292 ) (13 ) 3 — — (303 ) In progress — — — — — — TOTAL - Depreciation and impairment (8,010 ) (2,909 ) 133 — — (10,785 ) TOTAL - Net 7,764 10,429 (1,741 ) — — 16,453 Assets related to contracts that were classified as finance leases under IAS 17 are scientific equipment. As mentioned above, these contracts are accounted for in the same manner under IFRS 16. Their net carrying value as of December 31, 2017, 2018 and 2019 amounted to €1,895, €1,889, and €1,413 respectively. In May 2018, Genfit signed an agreement with the lessor of its corporate headquarters to extend in 2019 the current lease, that was set to expire in 2022, for another ten years and to lease for ten years a new building to be built on the same premises. The new lease agreement is non-cancellable for a nine year period beginning in 2019. Pursuant to the agreement, Genfit acted as agent of the lessor for the construction of the new building and is responsible for the cost of its construction. The agreement provides that the lessor must reimburse Genfit for costs of construction up to €2.5 million. All costs incurred above €2.5 million will be assumed by Genfit. As of December 31, 2018, the costs incurred to date by Genfit for the construction were €1.4 million and classified as property, plant and equipment in progress. In 2019, Genfit incurred additional costs of €1.3 million. The extension of the corporate headquarters was delivered on April 30, 2019 and the lessor reimbursed Genfit for €2.5 million for the construction costs incurred. The resulting difference of €0.3 million euros is classified as leasehold improvements and will be amortized over 10 years. On January 1, 2019, upon adoption of IFRS 16, the right of use asset and lease liability related to the existing headquarters were recognized for an amount of €7.8 million. In May 2019, the right of use asset and lease liability related to the new building were recognized for an amount of €2.2 million. 8 . PROPERTY, PLANT AND EQUIPMENT (continued) GENFIT CORP signed a new lease agreement, starting from July 1, 2019, in order to accompany the growth of its activities and workforce. In accordance with IFRS 16, the Group has chosen not to present the “right of use” separately from other assets and added them to assets of the same type as the underlying leased assets. The right of use asset and depreciation as of December 31, 2019 in the table above are related to : • The line item “Building on non freehold land”, of € 11,974 and € 1,196, respectively; • The line item "Scientific equipment", at € 4,346 and € 2,933, respectively.

Trade and Other Receivables

Trade and Other Receivables	12 Months Ended
	Dec. 31, 2019
Trade And Other Receivables [Abstract]
Trade and Other Receivables	9 . TRADE AND OTHER RECEIVABLES Trade and other receivables consisted of the following: Trade and other receivables - Total As of December 31, (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Trade receivables, net 61 25 207 Research tax credit 8,466 8,785 9,585 Social security costs receivables 3 10 5 VAT receivables 994 1,103 1,814 Grants receivables 13 (0 ) 3 Other receivables 340 361 420 TOTAL 9,876 10,284 12,033 Trade and other receivables - Current As of December 31, (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Trade receivables, net 61 25 207 Research tax credit 6,545 7,295 9,585 Social security costs receivables 3 10 5 VAT receivables 994 1,103 1,814 Grants receivables 13 (1 ) 3 Other receivables 340 361 420 TOTAL 7,955 8,794 12,033 Trade and other receivables - Non-current As of December 31, (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Trade receivables, net — — — Research tax credit 1,921 1,489 — Social security costs receivables — — — VAT receivables — — — Grants receivables — — — Other receivables — — — TOTAL 1,921 1,489 — Research tax credit The research tax credit due for 2018 was received on November 18, 2019. The research tax credit receivable of €9,585 as of December 31, 2019 includes: • a partial payment of the assessment (€333 ) due to an ongoing tax audit • the balance of the amount due for the 2014 fiscal year (€1,140 ) • the balance of the amount due for the 2016 fiscal year (€447), the two amounts are used as partial compensation with the assessment notices and the tax notice related to the 2014 CIR, as described in Note 24, "Litigation and contingent liabilities"; • the amount received following the favorable decision of the Montreuil court (€432) and (€29) having been deducted and • in addition to the amount related to the dispute with the French tax authorities discussed in note 24 “Litigation and contingent liabilities” should be added to the amount of the 2019 research tax credit of €8.125 million. A provision of €1,892 was recognized at the closing, including an allocation of €1,785 during the first half of 2019 and appears as a liability in the consolidated statement of financial position in relation to the Research Tax Credit dispute (see note 19 herein). Other receivables • The line item “other receivables” primarily consists of credit notes from suppliers for €408, €235 and €174 respectively as of December 31, 2019, as of December 31,2018 and as of December 31,2017.

Other Financial Assets

Other Financial Assets	12 Months Ended
	Dec. 31, 2019
Disclosure Of Other Financial Assets [Abstract]
Other Financial Assets	10 . OTHER FINANCIAL ASSETS Other financial assets consisted of the following: Financial assets - Total As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Financial investments — — — Loans 219 259 307 Loan related security deposit — — — Deposits and guarantees 274 284 396 Liquidity contract 267 770 1,023 TOTAL 760 1,313 1,727 Financial assets - Current As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Financial investments — — — Loans — — — Loan related security deposit 0 — — Deposits and guarantees 31 — — Liquidity contract — — — TOTAL 31 — — Financial assets - Non current As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Financial investments — — — Loans 219 259 307 Loan related security deposit (0 ) — (0 ) Deposits and guarantees 243 284 396 Liquidity contract 267 770 1,023 TOTAL 729 1,313 1,727 The liquidity contract consists of a share buyback program contracted to an investment service provider in order to facilitate the listing of the Group's shares. As of December 31, 2019, the liquidity account had a cash balance of €1,023. As of December 31, 2018, the liquidity account had a cash balance of €770 As of December 31, 2019, CMC-CIC Market Solutions holds on behalf of Genfit 18,132 shares, recorded as a deduction from equity. As of December 31, 2018, CMC-CIC Market Solutions holds on behalf of Genfit 27,911 shares, recorded as a deduction from equity. During the period, Genfit made an additional contribution of €1.0 million to the liquidity agreement with CMC-CIC Market Solution.

Other Assets

Other Assets	12 Months Ended
	Dec. 31, 2019
Miscellaneous Assets [Abstract]
Other Assets	11 . OTHER ASSETS Other assets of €1,761, €2,078 and €1,968 at December 31, 2017, 2018 and 2019, respectively, consisted of prepaid expenses related to current operating expenses.

Loans and Borrowings

Loans and Borrowings	12 Months Ended
	Dec. 31, 2019
Borrowing Costs [Abstract]
Loans and Borrowings	12. LOANS AND BORROWINGS 12.1. Breakdown of convertible loan On October 16, 2017, the Company issued 6,081,081 OCEANEs at par with a nominal unit value of €29.60 per bond for an aggregate nominal amount of €180 million. The exchange or conversion premium is 30% of the reference share price of €22.77. Annual nominal interest rate is a fixed 3.5% payable semi-annually in arrears. The effective interest rate is 7.2%. The OCEANEs are due October 16, 2022. Redemption prior to maturity is at the option of the Company from November 6, 2020 if the arithmetic volume-weighted average price of the Company's share price and the then-prevailing conversion ratio (over a 20-day trading period) exceeds 150% of the nominal value of the OCEANEs. As of December 31, 2017, 2018 and 2019, the Group recorded a liability of €155,868, €160,489 and €165,454 respectively, related to the OCEANEs net of the equity portion and debt issue costs. Of this amount, €1,329, €1,312 and €1,312 respectively, was classified as current and €154,539, €159,176 and €164,142 respectively, was classified as non-current. The conversion of all of the convertible bonds would result in a dilution of 15.6% (expressed as a percentage of share capital at December 31, 2019). 12. LOANS AND BORROWINGS (continued) 12.2. Breakdown of other loans and borrowings Other loans and borrowings consisted of the following: Other loans and borrowings - Total As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Refundable and conditional advances 3,407 3,229 3,229 Bank loans 3,488 3,964 2,645 Development loans with participation feature — — Renewable credit facility — — — Obligations under leases 1,890 1,900 12,281 Accrued interests 3 3 1 Other financial loans and borrowings 24 7 7 Bank overdrafts — — — TOTAL 8,812 9,104 18,165 Other loans and borrowings - Current As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Refundable and conditional advances 178 — — Bank loans 1,209 1,319 1,105 Development loans with participation feature — — — Renewable credit facility — — — Obligations under leases 420 520 2,112 Accrued interests 3 3 1 Other financial loans and borrowings 24 7 7 Bank overdrafts — — — TOTAL 1,834 1,848 3,226 Other loans and borrowings - Non current As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Refundable and conditional advances 3,229 3,229 3,229 Bank loans 2,279 2,645 1,540 Development loans with participation feature — — — Renewable credit facility — — — Obligations under leases 1,469 1,381 10,169 Accrued interests — — — Other financial loans and borrowings — — — Bank overdrafts — — — TOTAL 6,978 7,255 14,939 12. LOANS AND BORROWINGS (continued) The line item “obligations and leases” is impacted by the adoption of IFRS 16. See Note 4.7 “Leases”. 12.2.1. Refundable and conditional advances General overview From 2006 to 2010, the Company received conditional advances from BPI France. Advances are subject to no or low interest rates and are intended to finance research programs described in Note 3.19.1, "Government grants". The following table summarizes advances outstanding at December 31, 2019, 2018 and 2017 Total Net book Refundable and conditional advances - general overview Grant amount Effects of value (in € thousands) date allocated Receipts Repayments discounting 12/31/2019 BPI FRANCE - IT-DIAB 12/23/2008 3,229 3,229 — — 3,229 Development of a global strategy for the prevention and management of type 2 diabetes TOTAL 3,229 Net book Total value as of Refundable and conditional advances—general overview amount Effects of December 31, (in thousands of euros) Grant date allocated Receipts Repayments discounting 2018 BPI FRANCE—IT-DIAB 12/23/2008 3,229 3,229 — — 3,229 Development of a global strategy for the prevention and management of type 2 diabetes TOTAL 3,229 12. LOANS AND BORROWINGS (continued) Net book Refundable and conditional Total value as of advances—general overview amount Effects of December 31, (in € thousands) Grant date allocated Receipts Repayments discounting 2017 BPI FRANCE—IT-DIAB 12/23/2008 3,229 3,229 — — 3,229 Development of a global strategy for the prevention and management of type 2 diabetes BPI FRANCE—ADVANCE N°1—OLNORME II—1 11/24/2010 250 200 (134 ) (2 ) 64 BPI FRANCE—ADVANCE N°2—OLNORME II—2 11/24/2010 250 200 (134 ) (2 ) 64 BPI FRANCE—ADVANCE N°3—OLNORME II—3 11/24/2010 200 160 (108 ) (2 ) 51 Research of pharmaceutical entities in plant extracts for the treatment of inflammatory diseases ​ ​ TOTAL 3,407 Receipts and repayments of refundable and conditional advances During the years ended December 31, 2017 and 2018, the Group repaid €166 and €183, respectively, of refundable and conditional advances. 12. LOANS AND BORROWINGS (continued) Main terms of the contracts BPI FRANCE IT-DIAB On December 23, 2008, the Group received an advance from BPI France (the BPI France IT-DIAB) as part of a framework innovation aid agreement involving several scientific partners and for which the Group was the lead partner. The contribution expected at each stage by each of the partners in respect of work carried out and results achieved is defined in the framework agreement. With respect to the Group, the aid consisted of a €3,229 conditional advance and a €3,947 non-repayable government grant. The conditional advance is not refundable except in the event of success. The program ended on December 31, 2014. In the event of success, defined as the commercial spin-offs of the IT-Diab program which involves products for the treatment or diagnosis of type 2 diabetes, in that case, the financial returns generated will be used initially to repay the €3,229 conditional advance and the agreement stipulates that the conditional advance will be regarded as repaid in full when the total payments made in this regards by the recipient, discounted at the rate of 5.19%, equal the total amount, discounted at the same rate, of the aid paid. Any further amounts will be classified as additional payments, up to a maximum amount of €14,800. BPI FRANCE ADVANCE N°1— These non-interest bearing advances are repayable in full (at 100% of their nominal amount) in the event of technical and/or commercial success. The balance of these advances (in an amount of €66) were reimbursed during 2018. BPI FRANCE ADVANCE N°2— These non-interest bearing advances are repayable in full (at 100% of their nominal amount) in the event of technical and/or commercial success. The balance of these advances (in an amount of €66) were reimbursed during 2018. BPI FRANCE ADVANCE N°3— These non-interest bearing advances are repayable in full (at 100% of their nominal amount) in the event of technical and/or commercial success. The balance of these advances (in an amount of €52) were reimbursed during 2018. 12. LOANS AND BORROWINGS (continued) 12.2.2. Bank loans Bank loans are primarily used to finance research and laboratory equipment. Bank loans consisted of the following as of December 31, 2017: Available Outstanding as of as of Bank loans Loan Facility Interest December 31, December 31, (in € thousands) date size rate 2017 Installments 2017 CIC 5 July 2017 1,000 0.69 % 500 60 monthly 451 CDN 4 June 2017 600 0.36 % — 48 monthly 525 BNP 4 April 2017 800 0.87 % 800 60 monthly — CIC 4 December 2016 264.6 0.69 % — 60 monthly 217 BNP 3 October 2016 1,050 0.80 % — 20 quarterly 945 NEUFLIZE 2 June 2016 500 1.10 % — 12 quarterly 252 BNP 2 June 2016 500 0.80 % — 20 quarterly 377 CDN 3 April 2016 500 0.72 % — 60 monthly 335 CIC 3 March 2015 500 0.85 % — 16 quarterly 158 BNP December 2014 500 2.00 % — 20 quarterly 205 Other 23 TOTAL 3,488 Bank loans consisted of the following as of December 31, 2018: Available Outstanding Bank loans Loan Facility Interest As of As of (in € thousands) date size rate 2018/12/31 Installments 2018/12/31 CDN 5 November 2018 500 0.46 % — 48 monthly 490 CIC 5 July 2017 1000 0.69 % 0 60 monthly 753 CDN 4 June 2017 600 0.36 % 0 48 monthly 376 BNP 4 April 2017 800 0.87 % 0 60 monthly 695 CIC 4 December 2016 265 0.69 % — 60 monthly 164 BNP 3 October 2016 1050 0.80 % 0 20 quarterly 735 NEUFLIZE 2 June 2016 500 1.10 % 0 12 quarterly 84 BNP 2 June 2016 500 0.80 % 0 20 quarterly 277 CDN 3 April 2016 500 0.72 % — 60 monthly 236 CIC 3 March 2015 500 0.85 % 0 16 quarterly 32 BNP December 2014 500 2.00 % 0 20 quarterly 103 Other 19 TOTAL 3,964 12. LOANS AND BORROWINGS (continued) Bank loans consisted of the following as of December 31, 2019: Available Outstanding Bank loans Loan Facility Interest As of As of (in € thousands) date size rate 2019/12/31 Installments 2019/12/31 CDN 5 November 2018 500 0.46 % — 48 monthly 365 CIC 5 July 2017 1000 0.69 % 0 60 monthly 554 CDN 4 June 2017 600 0.36 % 0 48 monthly 226 BNP 4 April 2017 800 0.87 % 0 60 monthly 537 CIC 4 December 2016 265 0.69 % — 60 monthly 111 BNP 3 October 2016 1050 0.80 % 0 20 quarterly 525 NEUFLIZE 2 June 2016 500 1.10 % 0 12 quarterly 0 BNP 2 June 2016 500 0.80 % 0 20 quarterly 177 CDN 3 April 2016 500 0.72 % — 60 monthly 135 CIC 3 March 2015 500 0.85 % 0 16 quarterly 0 BNP December 2014 500 2.00 % 0 20 quarterly 0 Other 14 TOTAL 2,645 12.3. Development agreements with participation feature In June 2010, BPI France granted the Company a development agreement with participation feature amounting to €2.3 million over a 7-year period with a fixed interest rate of 4.46%. No repayment of principal was scheduled during the first two years. The loan agreement has a provision applicable during the reimbursement period which provides for additional remuneration to BPI France depending on whether the Company had industrial income. This additional remuneration amounts to 0.2294% of sales. However, this loan was repaid in its entirety in June 2017. 12. LOANS AND BORROWINGS (continued) 12.4. Maturities of financial liabilities Maturity of financial liabilities As of Less than Less than Less than Less than Less than More than (in € thousands) 2019/12/31 1 year 2 years 3 years 4 years 5 years 5 years BPI FRANCE - IT-DIAB 3,229 — — — — — 3,229 TOTAL - Refundable and conditional advances 3,229 — — — — — 3,229 Convertible loans 165,454 1,312 — 164,142 — — — Bank loans 2,645 1,105 942 544 54 — — Development loans with participation feature — — — — — — — Renewable credit facility — — — — — — — Leases 12,281 2,112 2,118 1,575 1,151 1,103 4,223 Accrued interests 1 1 — — — — — Other financial loans and borrowings 7 7 — — — — — Bank overdrafts — — — — — — — TOTAL - Other loans and borrowings 180,390 4,539 3,060 166,260 1,205 1,103 4,223 TOTAL 183,619 4,539 3,060 166,260 1,205 1,103 7,452 The convertible bond results in the payment of yearly interest of €6,300 and a reimbursement at par in October 2022. The nominal amount of the convertible loan of €180 million is due in less than 3 years.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2019
Disclosure Of Financial Instruments [Abstract]
Fair Value of Financial Instruments	1 3 . FAIR VALUE OF FINANCIAL INSTRUMENTS The following tables provide the financial assets and liabilities carrying values by category and fair values as of December 31, 2017, 2018 and 2019: As of December 31, 2017 Carrying value Fair value (in thousands of euros) As per statement of financial position Assets at fair value through profit & loss Loans & receivables Debt at amortized cost Level 1 Level 2 Level 3 Assets Loans 219 — 219 — — 219 — Deposits and guarantees 274 — 274 — — 274 — Trade receivables 61 — 61 — — 61 — Cash and cash equivalents 273,820 273,820 — — 273,820 — — TOTAL—Assets 274,375 273,820 555 — 273,820 555 — Liabilities Conditional advances 3,407 — — 3,407 — — 3,407 Convertible loans 155,868 — — 155,868 — 155,868 — Bank loans 3,488 — — 3,488 — 3,488 — Obligations under finance leases 1,890 — — 1,890 — 1,890 — Accrued interests 3 — — 3 — 3 — Other financial loans and borrowings 24 — — 24 — 24 — Trade payables 19,053 — — 19,053 — 19,053 — Other payables 34 — — 34 — 34 — TOTAL—Liabilities 183,766 — — 183,766 — 180,359 3,407 13. FAIR VALUE OF FINANCIAL INSTRUMENTS (continued) As of December 31, 2018 Carrying value Fair value As per Assets at statement of fair value financial through Loans and Debt at (in € thousands) position profit and loss receivables amortized cost Level 1 Level 2 Level 3 Assets Financial investments — — — Loans 259 259 259 Loan related security deposit — — — Deposits and guarantees 284 284 284 Trade receivables 25 25 25 Cash and cash equivalents 207,240 207,240 207,240 TOTAL - Assets 207,808 207,240 568 — 207,240 568 — Liabilities — Conditional advances 3,229 3,229 3,229 Convertible loans 160,489 160,489 160,489 Bank loans 3,964 3,964 3,964 Participating development loan — — — Renewable credit facility — — — Obligations under finance leases 1,900 1,900 1,900 Accrued interests 3 3 3 Other financial loans and borrowings 7 7 7 Bank overdrafts — — — Trade payables 32,649 32,649 32,649 Other payables 71 71 71 TOTAL - Liabilities 202,313 — — 202,313 — 199,084 3,229 13. FAIR VALUE OF FINANCIAL INSTRUMENTS (Continued) As of December 31, 2019 Carrying value Fair value As per Assets at statement of fair value financial through Loans and Debt at (in € thousands) position profit and loss receivables amortized cost Level 1 Level 2 Level 3 Assets Financial investments — — — Loans 307 307 307 Loan related security deposit — — — Deposits and guarantees 396 396 396 Trade receivables 207 207 207 Cash and cash equivalents 276,748 276,748 276,748 TOTAL - Assets 277,658 276,748 911 — 276,748 911 — Liabilities — Conditional advances 3,229 3,229 3,229 Convertible loans 165,454 165,454 165,454 Bank loans 2,645 2,645 2,645 Participating development loan — — — Renewable credit facility — — — Obligations under finance leases 12,281 12,281 12,281 Accrued interests 1 1 1 Other financial loans and borrowings 7 7 7 Bank overdrafts — — — Trade payables 32,753 32,753 32,753 Other payables 527 527 527 TOTAL - Liabilities 216,898 — — 216,898 — 213,669 3,229

Trade and Other Payables

Trade and Other Payables	12 Months Ended
	Dec. 31, 2019
Disclosure Of Trade And Other Payables [Abstract]
Trade and Other Payables	1 4 . TRADE AND OTHER PAYABLES Trade and other payables consisted of the following: Trade and other payables - Total As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Trade payables 19,053 32,649 32,753 Social security costs payables 4,217 2,949 3,581 Employee profit sharing 17 17 17 VAT payables 19 1 2 Taxes payables 241 286 487 Other payables 34 71 527 TOTAL 23,580 35,974 37,368 Trade and other payables - Current As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Trade payables 19,053 32,649 32,753 Social security costs payables 4,217 2,949 3,581 Employee profit sharing 17 17 17 VAT payables 19 1 2 Taxes payables 241 286 487 Other payables 34 71 76 TOTAL 23,580 35,974 36,917 Trade and other payables - Non current As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Trade payables — — — Social security costs payables — — — Employee profit sharing — — — VAT payables — — — Taxes payables — — — Other payables — −− 450 TOTAL — 450

Provisions

Provisions	12 Months Ended
	Dec. 31, 2019
Provisions [Abstract]
Provisions	1 5 . PROVISIONS At December 31, 2017, 2018 and 2019, this line item amounted to €361, €112, and €2,061 respectively. The accruals recorded are mainly related to the research tax credit. See Note 24, "Litigation and contingent liabilities".

Employee Benefits

Employee Benefits	12 Months Ended
	Dec. 31, 2019
Disclosure Of Information About Defined Benefit Plans [Abstract]
Employee Benefits	1 6 . EMPLOYEE BENEFITS In France, pension funds are generally financed by employer and employee contributions and are accounted for as a defined contribution plan with the employer contributions recognized as expense as incurred. The Group has no actuarial liabilities in connection with these plans. Expenses recorded for the years ended December 31, 2017, 2018 and 2019 amounted to €543, €765, and €927 respectively. French law also requires payment of a lump sum retirement indemnity to employees based on years of service and annual compensation at retirement, which are accounted for as a defined benefit plan. Benefits do not vest prior to retirement. The liability is calculated as the present value of estimated future benefits to be paid, applying the projected unit credit method whereby each period of service is seen as giving rise to an additional unit of benefit entitlement, each unit being measured separately to build up the final. At December 31, 2017, 2018 and 2019 pension provisions recorded were €936, €1,085 and €1,408, respectively. As part of the measurement of the retirement indemnity to employees, the following assumptions were used for all categories of employees: Population Permanent staff Retirement age 65 Terms of retirement Initiated by the employee Life expectancy On the basis of the INSEE table Probability of continued presence in the company at retirement age On the basis of the DARES table (1) INSEE is the French National Institute of Statistics; DARES is the French Bureau of Studies and Statistics Rate As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Salary growth rate - in 2020 5.8% 5.80 % 5.80 % Salary growth rate - beyond 3.0% 3.00 % 3.00 % Discount rate 1.5% 1.53 % 0.75 % The discount rates are based on the market yield at December 31, 2017, 2018 and 2019 on high quality corporate bonds. The following table presents the changes in the present value of the defined benefit obligation: Changes in the present value of the defined benefit obligation (in € thousands) Defined benefit obligation as of January 1, 2017 849 Current service cost 76 Interest cost on benefit obligation 13 Actuarial losses on obligation 210 Past service costs (211 ) Defined benefit obligation as of December 31, 2017 936 Current service cost 104 Interest cost on benefit obligation 14 Actuarial losses on obligation 31 Past service costs — Defined benefit obligation as of December 31, 2018 1,085 Current service cost 138 Interest cost on benefit obligation 17 Actuarial losses / (gains) on obligation 168 Past service costs — Defined benefit obligation as of December 31, 2019 1,408 The actuarial differences are mainly explained by the changes in personnel observed against the hypothesis used in the actuarial calculation. Sensitivity of the Group’s retirement and post-employment benefits to a variation of the discount rate : Retirement and post-employment benefits in thousands of euros Changes in assumptions/discount rate Impact/present value of the undertaking +0.25% -51 -0.25% 53 .

Equity

Equity	12 Months Ended
	Dec. 31, 2019
Disclosure Of Classes Of Share Capital [Abstract]
Equity	1 7 . EQUITY Ordinary shares are classified under shareholders' equity. Any shareholder, regardless of nationality, whose shares are fully paid-in and registered for at least two years, is entitled to double voting rights under the conditions prescribed by law (Article 32 of the Company's bylaws) At December 31, 2019, 2,311,439 shares have been held for more than two years and entitle their holders to double voting rights (5.95% of the issued share capital). Changes in share capital in 2017 On October 16, 2017, the Company issued bonds convertible or exchangeable into new or existing shares (OCEANEs) due October 16, 2022 for a nominal amount of €180 million. This transaction is recorded as a liability component and an equity component; the latter is measured at €14,312 net of deferred taxes (see Note 12.2, "Breakdown of other loans and borrowings"). Changes in share capital in 2018 On December 27, 2018, the Board of Directors of the Company determined that some of the performance conditions for the AGA D 2016-1 and all of the performance conditions for the AGA S 2016-1 were met, and therefore 17,484 ordinary shares were definitively acquired by their beneficiaries, and the share capital was increased by the nominal amount. Changes in share capital in 2019 The Chairman and CEO, acting on a decision and delegation from the Board of Directors on March 13, 2019, decided on March 26, 2019, in accordance with the 17th and 18th resolutions of the Shareholders Meeting of June 15, 2018, to proceed with a capital increase by offering ordinary shares in the form of American Depositary Shares in the United States and a private placement of ordinary shares in Europe and other countries outside the United States. This transaction led to the issuance of 7,647,500 new shares representing a subscription of a gross amount of €137.6 million. Settlement-delivery took place on March 29, 2019 and the share capital has been increased accordingly. See note 2.1 “ “ Initial Public Offering on the Nasdaq Global Select Market ”. In addition, the Chief Executive Officer, acting on a decision and delegation from the Board of Directors on November 27, 2019, determined on December 16, 2019, with retroactive effect to December 15, 2019, that some of the performance and attendance conditions of the AGA D 2016-1 and AGA D 2016-2 and all of the AGA S 2016-2 free shares had been satisfied. 7,796 free shares were thus definitively vested and the same number of new shares were created. The share capital was increased accordingly. Finally, the Chief Executive Officer, acting on a decision and delegation from the Board of Directors on November 21, 2017, determined on January 2, 2020, with retroactive effect to December 31, 2019, that some of the performance and attendance conditions of the AGA D 2017-1 and all of the AGA S 2017-1 free shares has been satisfied. As a result, 19,400 free shares definitively vested and the same number of new shares were created and the share capital was increased accordingly. At December 31, 2019, the total number of shares comprising the share capital, taking into account the above, was 38,858,617 shares.

Other Income

Other Income	12 Months Ended
	Dec. 31, 2019
Disclosure Of Other Income [Abstract]
Other Income	1 8 . OTHER INCOME Other income consisted of the following: Other income Year ended (in € thousands) 2017/12/31 2018/12/31 2019/12/31 CIR tax credit 6,545 7,295 8,125 Other operating income (including CICE tax credit )- 171 130 1,992 Government grants and subsidies 21 — 5 TOTAL 6,737 7,425 10,122 During 2019, the Group recognized in “Other operating income” €1,985 for exchange gains on trade receivables linked to services denominated in US dollars (€38 were recognized as financial income in 2018). During the 2017 and 2018 fiscal years, the Group recognized in other operating income €170 and €122, respectively, relating to the CICE ( Crédit d'impôt pour la compétitivité et l'emploi ), which is a tax credit implemented to enhance the competitiveness of businesses through the promotion of certain activities and employment. In 2017 and 2018, the tax credit was equal to 7% and 6%, respectively, of all wages paid to employees during the year in respect of salaries that do not exceed 2.5 times the French minimum wage. During the year ended December 31, 2019 we had foreign exchange gains related to trade receivables linked to services denominated in U.S dollars, which amount to €1,985 which is recorded as other operating income. The CICE was discontinued on January 1, 2019.

Operating Expense

Operating Expense	12 Months Ended
	Dec. 31, 2019
Operating Expense [Abstract]
Operating Expense	1 9 . OPERATING EXPENSE Year Ended December 31, 2017 Contracted research & Gain / Operating expenses and other operating Raw development activities Other expenses Depreciation, (loss) on disposal of income (expenses) (in thousands of Year ended materials& consumables conducted by third Employee (maintenance, fees, travel, amortization & impairment plant & property, euros) 2017/12/31 used parties expenses taxes) charges equipment Research and development expenses (54,189 ) (2,117 ) (35,088 ) (7,915 ) (7,973 ) (1,095 ) — General and administrative expenses (9,421 ) (112 ) (7 ) (5,491 ) (3,374 ) (437 ) — Other operating income (expenses) 60 — — — 68 — (8 ) TOTAL (63,550 ) (2,229 ) (35,095 ) (13,406 ) (11,280 ) (1,532 ) (8 ) 19. OPERATING EXPENSE (Continued) Year Ended December 31, 2018 Of which: Contracted Gain / Raw research and Other Depreciation, (loss) on materials development expenses amortization disposal of and activities (maintenance, and property, Operating expenses and other operating income (expenses) Year ended consumables conducted by Employee fees, travel, impairment plant and (in € thousands) 2018/12/31 used third parties expenses taxes…) charges equipment Research and development expenses (67,024 ) (1,724 ) (47,659 ) (9,431 ) (6,502 ) (1,707 ) — General and administrative expenses (9,076 ) (126 ) (2 ) (3,778 ) (5,451 ) 283 — Marketing and market access expenses (717 ) (4 ) — (416 ) (287 ) (11 ) — Other operating income and (expenses) (162 ) — — — (164 ) — 2 TOTAL (76,979 ) (1,855 ) (47,662 ) (13,625 ) (12,403 ) (1,435 ) 2 Of which: Contracted Gain / Raw research and Other Depreciation, (loss) on materials development expenses amortization disposal of and activities (maintenance, and property, Operating expenses and other operating income (expenses) Year ended consumables conducted by Employee fees, travel, impairment plant and (in € thousands) 2019/12/31 used third parties expenses taxes…) charges equipment Research and development expenses (66,170 ) (2,017 ) (41,509 ) (11,740 ) (6,188 ) (4,716 ) — General and administrative expenses (17,265 ) (177 ) (59 ) (7,598 ) (8,972 ) (458 ) — Marketing and market access expenses (13,708 ) (8 ) (0 ) (1,645 ) (11,979 ) (76 ) — Other operating income (expenses) (1,649 ) — — — (1,668 ) — 19 TOTAL (98,793 ) (2,202 ) (41,568 ) (20,984 ) (28,807 ) (5,251 ) 19 19. OPERATING EXPENSE (Continued) Research and development expenses at each reporting date take into account estimates for ongoing activities subcontracted as part of the clinical trials and not yet invoiced, on the basis of detailed information provided by subcontractors and reviewed by the Group’s internal departments. The accuracy of these estimates for some types of expenses improves with the progression of the trials and the review of their determination methods. In 2019, the CRO (Clinical Research Organization) commissioned as part of the RESOLVE- IT trial updated its investigator cost estimation model by refining certain assumptions on the basis of historical data. These changes constitute a change in accounting estimate within the meaning of IAS 8 and have led to a reduction in the amount recognized for invoices not received related to these specific costs in an amount of €6,994 compared to the previous model. The subcontracting costs in 2019 are mainly due to the start of new satellite studies in the RESOLVE-IT Phase 3 study, the work required to prepare the marketing authorization dossier for elafibranor in NASH, and the increase in the production volume of the active ingredient necessary for the realization of the various clinical trials. The impact of the changes in estimation of investigator costs for the RESOLVE-IT study led to a stabilization in R&D expenses in 2019. The increase in employee-related costs results mainly from the increase in headcount (194 at December 31, 2019 versus 148 as of December 2018), the change in employee profiles and the associated increase in compensation, and the bonuses that were awarded to employees in 2019 for their involvement in the development of the Group. The change in other expenses in 2019 is related in particular to the costs related to the preparation of commercialization of elafibranor in NASH and NIS4, costs related to the purchase of two civil liability insurance policies in connection with the listing of shares on the NASDAQ, fees of financial advisors and statutory auditors, and intellectual property expenses. In 2017, the donation to The NASH Education Program (€1,808) was classified as a research & development expense because the 2017 donation was primarily related to the creation of a NASH patient registry in particular to increase understanding of the prevalence and natural history of NASH/ NAFLD, and the development of co-morbidities historically linked to NASH/NAFLD, which information is to be used as part of the efforts to collect RWE (Real World Evidence) data to better address the needs of the patients, which information could be utilized by the Company in its research & development efforts. The increase in contracted research and development activities conducted by third parties in the 2018 period was primarily the result of the progression of the research and development pipeline; and mainly operational outsourcing costs related to the Phase 3 RESOLVE-IT clinical trial of elafibranor for the treatment of NASH and, to a lesser extent, those related to the Phase 2 trial of elafibranor in PBC and the launch of the Phase 2 trial in NTZ. The increase in employee expenses in 2018 is mainly due to the evolution of employee profiles (specialized and more experienced), the increase in compensation, and the increase in the number of employees. Other operating expenses include costs related to facilities and their maintenance, intellectual property costs, and expenses related to the preparation of marketing of elafibranor in NASH. In 2018, the Company's donation to The Nash Education Program endowment fund (€959) was dedicated mainly to the organization of the first international NASH Day. In this context, in 2018, the Company has classified this charge as general and administrative expenses. 19. OPERATING EXPENSE (Continued) 1 9 .1. Employee expenses Employee expenses and number of employees were as follows: Employee expenses Year ended (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Wages and salaries (9,267 ) (9,012 ) (14,018 ) Social security costs (3,996 ) (3,722 ) (5,171 ) Changes in pension provision 135 (104 ) (138 ) Individual training entitlement — — — Share-based compensation (278 ) (787 ) (1,657 ) TOTAL (13,406 ) (13,625 ) (20,984 ) Year ended Number of employees at year-end - detail 2017/12/31 2018/12/31 2019/12/31 Average number of employees 123 135 175 Average age of employees 38 years 4 months 38 years 11 months 37 years 1 month Number of employees Research and development 77 84 108 Services related to research and development 15 16 19 Administration and management 33 48 60 Marketing and commercial — — 7 TOTAL 125 148 194 Number of employees Senior staff 92 115 144 Staff 29 30 45 Others (apprentices) 4 3 5 TOTAL 125 148 194 Number of employees Male 45 57 78 Female 80 91 116 TOTAL 125 148 194

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]
Share-Based Compensation	20 . SHARE-BASED COMPENSATION Share-based compensation is granted by the Group to employees, executive officers, board members and consultants. Share-based compensation granted to employees and executive officers in 2014 through 2019 corresponds to redeemable share warrants (" Bons de Souscriptions et/ou d'Acquisition d'Actions actions gratuites Share-based compensation granted to board members and consultants in 2014, 2015, 2017 and 2019 corresponds to share warrants (" Bons de Souscriptions d'Actions For the measurement of this share-based compensation, the Group has determined that under IFRS its consultants were not equivalent to employees. Under these programs, holders of vested instruments are entitled to subscribe to shares of the Company at a pre-determined exercise price. All of the plans are equity settled. No instruments were exercised during 2017, 2018 and 2019. New plans were put in place in 2019 under the terms and conditions discussed below. The expense recognized pursuant to IFRS 2 was €1,645 in 2019, €787 in 2018 and €278 in 2017. The Group has revised its estimate of the number of equity instruments expected to be vested taking into account the number of lapsed instruments noted after 4 years of successive plans. As a result, Genfit revised the turnover rate assumption, which was estimated at 15%, to a rate of 0%, taking into account recent observations and the actual number of lapsed instruments at each closing. The table below shows the share-based compensation under each plan according to the change in estimate mentioned above . Year ended Total expense Total expense Share-based compensation - Annual expense 2017/12/31 2018/12/31 2019/12/31 calculated remaining BSA 2014-A — — — 945 — Of which : expense related to non-executive officers — — — 365 — Of which : expense related to consultants — — — 581 — BSA 2014-B — — — 1,045 — Of which : expense related to non-executive officers — — — 365 — Of which : expense related to consultants — — — 680 — BSAAR 2014-A — — — 43 — Of which : expense related to non-executive officers — — — 9 — Of which : expense related to consultants — — — 34 — BSAAR 2014-B — — — 191 0 Of which : expense related to non-executive officers — — — 35 0 Of which : expense related to consultants — — — 156 — BSAAR 2014-C — — — 189 0 Of which : expense related to non-executive officers — — — 35 — Of which : expense related to consultants — — — 154 0 Year ended Total expense Total expense Share-based compensation - Annual expense 2017/12/31 2018/12/31 2019/12/31 calculated remaining BSA 2015-A — — — 335 — Of which : expense related to non-executive officers — — — 178 — Of which : expense related to consultants — — — 157 — BSA 2015-B — — — 315 — Of which : expense related to non-executive officers — — — 178 — Of which : expense related to consultants — — — 138 — Year ended Total expense Total expense Share-based compensation - Annual expense 2017/12/31 2018/12/31 2019/12/31 calculated remaining BSAAR 2016-A — — — — — Of which : expense related to executive officers — — — — — Of which : expense related to employees — — — — — BSAAR 2016-B — — — — — Of which : expense related to executive officers — — — — — Of which : expense related to employees — — — — — AGA D 2016-1 38 127 — 166 0 Of which : expense related to executive officers 7 25 — 32 0 Of which : expense related to employees 31 101 — 133 0 AGA D 2016-2 17 17 39 74 — Of which : expense related to executive officers 3 3 8 14 — Of which : expense related to employees 14 14 31 59 — AGA S 2016-1 44 151 — 197 — Of which : expense related to executive officers — — — — — Of which : expense related to employees 44 151 — 197 — AGA S 2016-2 22 22 44 88 — Of which : expense related to executive officers — — — — — Of which : expense related to employees 22 22 44 88 — SO 2016-1 83 83 213 383 — Of which : expense related to executive officers 13 13 36 63 — Of which : expense related to employees 70 70 176 319 — SO 2016-2 38 38 93 170 — Of which : expense related to executive officers 6 6 16 28 — Of which : expense related to employees 32 32 77 142 — SO US 2016-1 12 12 (24 ) — — Of which : expense related to executive officers — — — — — Of which : expense related to employees 12 12 (24 ) — — SO US 2016-2 5 5 (11 ) — — Of which : expense related to executive officers — — — — — Of which : expense related to employees 5 5 (11 ) — — Year ended Total expense Total expense Share-based compensation - Annual expense 2017/12/31 2018/12/31 2019/12/31 calculated remaining BSA 2017-A 6 63 — 69 — Of which : expense related to non-executive officers 4 43 — 47 — Of which : expense related to employees 2 20 — 22 — BSA 2017-B 3 66 — 70 0 Of which : expense related to non-executive officers 2 46 — 48 0 Of which : expense related to employees 1 21 — 22 0 AGA D 2017-1 1 17 199 217 — Of which : expense related to executive officers 0 2 28 30 — Of which : expense related to employees 1 15 171 187 — AGA D 2017-2 2 29 56 131 44 Of which : expense related to executive officers 0 3 8 18 6 Of which : expense related to employees 2 26 48 113 37 AGA S 2017-1 — — 209 209 — Of which : expense related to executive officers — — — — — Of which : expense related to employees — — 209 209 — AGA S 2017-2 2 24 45 104 34 Of which : expense related to executive officers — — — — — Of which : expense related to employees 2 24 45 104 34 SO 2017-1 2 28 27 61 4 Of which : expense related to executive officers 0 5 5 11 1 Of which : expense related to employees 2 23 22 50 4 SO 2017-2 3 48 2 81 28 Of which : expense related to executive officers 1 8 0 15 5 Of which : expense related to employees 3 39 2 66 23 SO US 2017-1 0 3 (4 ) — 0 Of which : expense related to executive officers — — — — — Of which : expense related to employees 0 3 (4 ) — 0 SO US 2017-2 0 5 (6 ) — 0 Of which : expense related to executive officers — — — — — Of which : expense related to employees 0 5 (6 ) — 0 Year ended Total expense Total expense Share-based compensation - Annual expense 2017/12/31 2018/12/31 2019/12/31 calculated remaining AGA D 2018 — 10 135 277 132 Of which : expense related to executive officers — 2 21 43 21 Of which : expense related to employees — 9 114 234 111 AGA S 2018 — 12 148 305 145 Of which : expense related to executive officers — — — — — Of which : expense related to employees — 12 148 305 145 SO 2018 — 24 285 849 539 Of which : expense related to executive officers — 3 40 118 75 Of which : expense related to employees — 21 245 730 464 SO US 2018 — 3 25 76 48 Of which : expense related to executive officers — — — — — Of which : expense related to employees — 3 25 76 48 Year ended Total expense Total expense Share-based compensation - Annual expense 2017/12/31 2018/12/31 2019/12/31 calculated remaining BSA 2019 — — 7 26 20 Of which : expense related to executive officers — — — — — Of which : expense related to employees — — 7 26 20 AGA D 2019 — — 35 242 207 Of which : expense related to executive officers — — 5 38 33 Of which : expense related to employees — — 29 204 175 AGA S 2019 — — 41 288 246 Of which : expense related to executive officers — — — — — Of which : expense related to employees — — 41 288 246 SO 2019 — — 86 599 513 Of which : expense related to executive officers — — 10 68 58 Of which : expense related to employees — — 76 531 455 SO US 2019 — — 1 43 42 Of which : expense related to executive officers — — — — — Of which : expense related to employees — — 1 43 42 Year ended Total expense Total expense Share-based compensation - Annual expense 2017/12/31 2018/12/31 2019/12/31 calculated remaining TOTAL 278 787 1,645 7,787 2,004 20 .1. Share warrants ( bons de souscription d'actions The key terms and conditions related to each program are detailed in the following tables: Share-base compensation 2019 2017 2015 2014 Share warrants ( BSA ) BSA 2017-A BSA 2017-B BSA 2015-A BSA 2015-B BSA 2014-A BSA 2014-B Date of the Shareholders meeting 06/15/2018 06/16/2017 04/02/2014 04/02/2014 Date of the Management Board meeting 01/09/2015 07/24/2014 Date of the decision and delegation of the Board of Directors to the CEO 10/18/2019 11/21/2017 Date of the CEO decision 10/31/2019 12/06/2017 Beneficiaries Consultants Consultants and officers Consultants and officers Consultants and officers Total number of BSAAR subscribed 35,070 18,345 18,345 12,860 12,860 46,765 46,765 Total number of BSAAR voided 0 0 0 12,860 12,860 46,765 46,765 Total number of BSAAR remaining 35,070 18,345 18,345 0 0 0 0 Issue Price €1.23 €2.00 €0.01 €0.01 Excercise price €12.32 €19.97 €35.95 €23.50 Estimated fair value - according to IFRS 2 €0.75 €3.78 €3.81 €25.33 /€26.89 €25.33 /€26.31 €15.61 /€24.84 €15.61 /€24.85 End of exercise period 05/31/2024 06/30/2022 07/15/2022 05/31/2019 11/30/2019 09/30/2018 02/28/2019 Valuation method used Black & Scholes Expected dividends 0% 0% 0% 0% Expected volatility 40.0% 36.4% 35.7% 74.9% 74.9% Risk-free interest rate 0% 0.0% 0.4% 0.4% Expected life 0.7 years 6 years 4 years 4 years The services performed by the consultants are mainly: • to evaluate product development plans and propose, if necessary, changes to strategic or technical approaches; • to advise the Company's management and the Scientific Board in identifying strategies and selecting drug candidates, based in particular on the scientific results obtained by the Group (new therapeutic targets, new compounds); and • to assist and advise the Group in its alliance strategies, such as external growth-supporting synergies (acquisition of new competencies and the purchase of operating rights, drug candidates and innovative technologies, etc.). 20 .2. Redeemable warrants ( bons de souscription et/ou d'acquisition d'actions remboursables Share-Based compensation 2 016 2 014 Redeemable share subscription warrants ( BSAAR ) BSAAR 2016-A and B BSAAR 2014-A - B and C Employees Employees and Officers Date of the Shareholders' meeting 02/24/2015 04/02/2014 Date of the Management Board Meeting 07/22/2016 09/16/2014 Date of the decision and delegation of the Board of Directors to the CEO Date of the CEO decision Total number of BSAAR subscribed 10,800 62,717 Total number of BSAAR voided 0 61,484 Total number of BSAAR exercised 0 1,233 Total number of BSAAR remaining 10,800 0 Issue Price €23.5 €23.5 Exercise period From 01/01/2018 to 27/07/2020 voided on 09.2018 - 05.2019 and 07.2019 Estimated fair value - valued by expert opinion €4.60 from €8.44 to €11.29 Valuation method used Black & Scholes Black & Scholes Expected dividends 0% 0% Expected volatility 75.4% 75.4% Risk-free interest rate 0.0% 0.4% Expected life 4 years 4 years The exercise of the BSAAR 2016-A is subject to the following performance condition: the Group will have, at the date it receives the exercise notice accompanied by the payment of the exercise price, the financial means to carry out its research and development programs, and at a minimum its development program for elafibranor in NASH until at least the end of 2018. The exercise of the BSAAR 2016-B is subject to the following performance condition: the Group will have published, on the date it receives the exercise notice accompanied by the exercise price, the main results of the RESOLVE-IT clinical trial for which it is the sponsor. 20 .3. Free shares ( actions gratuites attribuées The key terms and conditions related to each program are detailed in the following tables: Share-based compensation 2 019 2 019 2 018 2 017 2 016 Free shares (AGA) AGA D AGA S Officers(1) Employees Officers(1) Employees AGA D and S AGA D and S 2017-1 and 2017-2 AGA D and S 2016-1 and 2016-2 Date of the Shareholders meeting 06/15/2018 06/15/2018 06/16/2017 06/21/2016 Date of the Management Board meeting 12/15/2016 Date of the decision and delegation of the Board of Directors to the CEO 07/18/2019 11/07/2018 11/22/2017 Date of the Executive Board Meeting 07/18/2019 11/22/2018 12/06/2017 Total number of AGA subscribed 3,000 16,070 0 17,556 35,800 41,196 30,709 Total number of AGA voided 0 450 0 702 1,872 9,846 5,429 Total number of AGA definitively vested 0 0 0 0 0 19,403 25,280 Total number of AGA remaining 3,000 15,620 0 16,854 33,928 11,947 0 Acquisition period From 07/18/2019 to 09/16/2022 From 11/22/2018 to 12/31/2020 From 12/06/2017 to 12/31/2020 From 12/15/2016 to 12/15/2019 Valuation method used Monte Carlo Price of the share at the time of allocation €17.06 € 20.02 € 21.95 € 20.78 Expected dividends 0% 0% 0% 0% Expected volatility 40.16% 38.0% 53.7% 63.0% Risk-free interest rate 0.0% 0.0% 0.0% 0.0% Turnover rate 0.00% 15.00% 15.00% 15.00% (1) : Chairman and CEO The terms and conditions of the 2016 to 2018 allocations to the Chairman and CEO are provided in the Universal Registration Document or the financial statements for the relevant periods. (1) : Chief executive officer The final allocation of free shares is subject to continued employment with the Group and performance conditions. These performance conditions are described in item 6 B 20 .4. Stock options ( options de souscription d'actions The key terms and conditions related to each program are detailed in the following tables: Share-based compensation 2 019 2 018 2 017 2 016 Stock-options (SO) SO SO US 1 SO US 2 SO 2018 SO US 2018 SO 1 et 2 2017 SO US 2017 SO 1 et 2 2016 SO US 2016 Officers(1) Employees Employees Employees Employees and Offices Employees Employees and Offices Employees Employees and Offices Employees Date of the Shareholders meeting 06/15/2018 11/27/2019 06/15/2018 06/16/2017 06/21/2016 Date of the Management Board meeting 12/15/2016 Date of the decision and delegation of the Board of Directors to the CEO 07/18/2019 11/27/2019 11/07/2018 11/21/2017 Date of the CEO decision 07/18/2019 11/27/2019 11/07/2018 12/06/2017 Total number of SO subscribed 15,130 92,750 30,620 13,350 122,000 17,500 96,250 13,000 62,875 10,500 Total number of SO voided 0 1,780 0 0 2,000 3,000 21,577 13,000 13,169 10,500 Total number of SO definitively vested 0 0 0 0 0 0 0 0 49,706 0 Total number of SO remaining 15,130 90,970 30,620 13,350 120,000 14,500 74,673 0 0 0 Excercise price €13.99 €16.9 €14.31 €16.00 €21.65 €17.91 €22.54 €15.79 €21.12 Vesting period From 07/18/2019 to 09/16/2022 From 11/27/2019 to 01/16/2023 From 11/07/2018 to 12/31/2021 From 12/06/2017 to 12/31/2020 From 12/15/2016 to 12/15/2019 Exercise period From 09/17/2022 to 09/17/2029 From 01/17/2023 to 01/17/2030 From 01/01/2022 to 12/31/2028 From 01/01/2021to 12/31/2027 From 12/16/2019 to 12/16/2026 Fair value €4.59 €3.67 €3.23 €9.32 €6.9 €9.32 €10.3 €8.52 Valuation method used Monte Carlo Price of the share at the time of allocation €17.06 €14.5 €22.12 €21.95 €20.79 Expected dividends 0% 0% 0% 0% 0% Expected volatility 40.16% 40.0% 44.07% 53.7% 63.0% Risk-free interest rate 0.0% 0.0% 0.0% 0.0% 0.0% Turnover rate 0.00% 0.00% 15.00% 15.00% 15.00% Volatility assumptions in the above tables are determined by reference to the Company's historical share price observed on the grant date over a two- and 3-years period prior to the grant date, adjusted for extreme variations, if any. See note 4.22 share based compensation. Definitive vesting is subject to continued employment with the Group and performance conditions. These performance conditions are described in item 6 B 20 .5. Performance conditions The SO and SO US stock option plans as well as certain free share plans (AGA "D") implemented in 2016, 2017, 2018 and 2019 are subject to internal performance conditions related to the progress of the Group's research and development programs, and to external performance conditions related to the evolution of the Company's stock price. The other free share plans (AGA "S") are subject only to internal performance conditions. 20 .5.1. Performance conditions of the 2019 plans Plans Evaluation date for performance conditions Nature of internal conditions SO 2019 SO US 2019 AGA D 2019 07/31/2022 66 2/3% of the instruments will be exercisable or definitively vested, and 100% of the free shares for the AGA S 2019 will be vested, regardless of the variation of the stock market price of the Company’s shares, if at least one of the three following conditions is fulfilled: (i) if a marketing authorization is granted or an application for marketing authorization is examined: • by the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA) for elafibranor for NASH; or: • by the U.S. Food and Drug Administration (FDA)/the competent European authorities in the field of IVD for NIS4 for NASH; or: (ii) if at least two of the four clinical trial among the following trials have delivered their principal results or are ongoing: • Phase III clinical trials for elafibranor for PBC; or • clinical trial evaluating elafibranor’s efficacy in NASH pediatric patients; or • Phase IIb clinical trial or clinical trial aimed at registration for NTZ in fibrosis; or • Clinical trial evaluating elafibranor or NTZ in combination therapy for NASH or for hepatic fibrosis; or: (iii) if at least a new licensing agreement, on one or another of Genfit’s products in one or several territories, is entered into by the Company. Nature of external conditions 33 1/3 % of the instruments will be exercisable or definitively vested, in proportion to the variation of the Company’s stock market price as per the following breakdown: (i) if the Final Price is strictly lower than the Initial Price, the number of the Stock Options exercisable is equal to 0; (ii) if the Final Price is between (i) a value equal to or higher than the Initial Price and (ii) a value lower than the Ceiling Price, the number of Stock Options exercisable is equal to: [(Final Price / Initial Price)-1]/2 x 1/3 of number of Stock Options; (iii) if the Final Price is equal to or higher than the Ceiling Price, the number of Stock Options exercisable is equal to the entire one-third of the Stock Options allocated SO US 2019-2 01/09/2023 Nature of internal conditions 66 2/3 % of the instruments will be exercisable if at least if at least one of the three following conditions is fulfilled: (i) if elafibranor has been granted marketing authorization by the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA) in NASH or PBC or NIS4 has been authorized by FDA or received CE marking from the EMA; (ii) a licensing agreement pertaining to elafibranor or NTZ has been signed for the U.S. market and/or for at least two of the five major European markets (Germany, France, Italy, United Kingdom, Spain) and/or Japan; (iii) at least two clinical trials for drug registration are underway. Nature of external conditions 33 1/3 % of the instruments will be exercisable, in proportion to the variation of the Company’s stock market price as per the following breakdown: (i) if the Final Price is strictly lower than the Initial Price, the number of the Stock Options exercisable is equal to 0; (ii) if the Final Price is between (i) a value equal to or higher than the Initial Price and (ii) a value lower than the Ceiling Price, the number of Stock Options exercisable is equal to: [(Final Price / Initial Price)-1]/2 x 1/3 of number of Stock Options; (iii) if the Final Price is equal to or higher than the Ceiling Price, the number of Stock Options exercisable is equal to the entire one-third of the Stock Options allocated. Nature of internal conditions AGA S 2019 07/31/2022 The free shares will definitively vest upon the same internal performance conditions as the SO 2019, SO US 2019 and AGA D 2019 plans

Financial Income and Expenses

Financial Income and Expenses	12 Months Ended
	Dec. 31, 2019
Financial Income And Expenses [Abstract]
Financial Income and Expenses	2 1 . FINANCIAL INCOME AND EXPENSES Financial income and expenses Year ended (in € thousands) 2017/12/31 2018/12/31 2019/12/31 (*) (*) Financial income Interest income 389 202 2,626 Foreign exchange gain 59 101 2,272 Other financial income 195 425 324 TOTAL - Financial income 642 728 5,221 Financial expenses Interest expenses (2,309 ) (10,955 ) (11,289 ) Interest expenses for leases (10 ) (21 ) (148 ) Foreign exchange losses (764 ) (127 ) (1,657 ) Other financial expenses (13 ) (14 ) (17 ) TOTAL - Financial expenses (3,096 ) (11,118 ) (13,110 ) FINANCIAL GAIN (LOSS) (2,453 ) (10,391 ) (7,889 ) • * The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard. Financial expenses for loans and borrowings are due to the interest on the OCEANEs, mainly due to interest payments at a rate of 3.5% and the discounting of the bond debt at an effective interest rate of 7.2%. The discounting of bond debt consists of bringing the amount of the debt component of the bond issue to the amount that will be repaid (or converted) at maturity, by the recognition of a theoretical annual interest expense resulting from the accretion over the period of an amount equivalent to the equity component at an effective interest rate. The increase in financial income is due to the increase in interest on term accounts. GENFIT has decided to keep some of its cash in US dollars. See note 6.6 “Cash and cash equivalents”.

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2019
Deferred Tax Expense Income [Abstract]
Income Tax	2 2 . INCOME TAX 2 2 .1. Losses available for offsetting against future taxable income At December 31, 2017, 2018 and 2019, the tax loss carry forwards for the Company amounted to €226,708, €305,530 and €384,471, respectively. Such carry forwards can be offset against future taxable profit within a limit of €1.0 million per year plus 50% of the profit exceeding this limit. Remaining unused losses will continue to be carried forward indefinitely. 2 2 .2 Deferred tax assets and liabilities The Group's main sources of deferred tax assets and liabilities as of December 31, 2017 and 2018 related to: Tax loss carry forwards: €226,708 and €305,530, respectively; • Temporary differences: • related to the OCEANE: a net deferred tax liability for €2,165 and €1,773 as of December 31, 2017 and 2018, respectively and • related to post-employment benefits: €936 and €1,085, respectively, or an impact on deferred tax assets of €262 and €304, respectively. The Group’s main sources of deferred tax assets and liabilities as of December 31, 2019 related to: • Tax losses carry forwards: €384,471 (compared to €305,530 as of December 31, 2018); • Temporary o the OCEANE: a deferred tax liability of €3,182 and an asset of €1,989, i.e., a net deferred tax liability of €1,193; and o post-employment benefits: a deferred tax liability of €352 offset by an asset of the same amount; The Company offsets its deferred tax assets and liabilities (€1,988 and €3,182, respectively), as permitted by IAS 12, resulting in a net deferred tax liability of €1,193. The income tax benefit for the period is mainly due to the decrease in the net deferred tax liability over the period. Oher than as it relates to deferred tax assets recognized based on the available deferred tax liabilities, no other deferred tax asset has been recognized as it is not probable that taxable profit will be available to offset deductible temporary differences and tax loss carry forwards.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	2 3 . EARNINGS (LOSS) PER SHARE The components of the earnings (loss) per share computation are as follows: Basic loss per share is equal to diluted loss per share. Year ended 2017 2018/12/31 2019/12/31 Earnings per share (*) (*) Profit (loss) for the period (in € thousands) (55,728 ) (79,521 ) (65,144 ) Weighted average number of ordinary shares for the period 31,166,437 31,167,203 36,987,982 Profit (loss) per share (in €) (1.79 ) (2.55 ) (1.76 ) Weighted average number of ordinary shares used in the above calculation 31,166,437 31,167,203 36,987,982 • * The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Litigation and Contingent Liabi

Litigation and Contingent Liabilities	12 Months Ended
	Dec. 31, 2019
Disclosure Of Contingent Liabilities [Abstract]
Litigation and Contingent Liabilities	2 4 . LITIGATION AND CONTINGENT LIABILITIES Dispute over research tax credit calculation Context In 2014, the Company was under a tax audit at the end of which the French tax authorities questioned part of the Research Tax Credit (CIR) received by the Company for the 2010 fiscal year. The tax audit was extended to the CIR for the 2011 and 2012 fiscal years. This tax audit was also extended to the 2014 CIR as part of a documentary audit the purpose of which was to apply the rules described below. Subject matter of the dispute The dispute with the French tax authorities pertained mainly to collaborative research alliances with partners in the pharmaceutical industry. The tax authorities contended that, in these alliances, the Company was acting as a sub-contractor, which should reduce the basis on which the CIR was computed by deducting amounts billed by the Company to the other party. The Company maintained that the contracts governing the collaborative research alliances included reciprocal provisions concerning intellectual property, the shared governance of the research programs, risk sharing, conditions governing the termination of the agreements and the terms of compensation, which demonstrated that they were not sub-contracting agreements. On April 5, 2018, the Administrative Court of Montreuil partially accepted the Company’s claims on the CIR for 2010, 2011 and 2012, in particular, on the qualification of collaborative research. On June 28, 2018, the Administrative Court of Montreuil accepted the Company’s claim on the CIR for 2014. On September 11, 2018, following the judgment, the Company was repaid €432. On July 25, 2018, and then on October 28, 2018, the Company was informed that the Ministry of Action and Public Accounts, appealed the aforementioned judgments. On June 18, 2019, the Court of Appeals of Montreuil delivered its judgment on the first judgment and gave the Company the right to take into account the depreciation of certain assets eligible for the CIR but reversed the decision of the Administrative Court as it relates to the collaboration research for the CIRs received in connection with the 2010, 2011 and 2012 fiscal years. The Company will have to reduce the basis of its CIR claims by the amounts invoiced to its partners. Provision The Company has decided not to appeal the Court of Appeals decision, and therefore has recognized a provision totaling €1,892, which includes adjustments to the 2014 CIR, and for which it did not seek to continue before the court of appeals during a hearing in March 2020. The provision replaces in full the potential debts mentioned in the 2018 annual financial statements.

Related Parties

Related Parties	12 Months Ended
	Dec. 31, 2019
Disclosure Of Transactions Between Related Parties [Abstract]
Related Parties	2 5 . RELATED PARTIES Biotech Avenir SAS and The NASH Epidemiology Institute TM The registered office of Biotech Avenir SAS and that of The NASH Epidemiology Institute TM Biotech Avenir Biotech Avenir SAS is a holding company incorporated in 2001 by the Company's founders. Most of its share capital is currently held by individuals, i.e., the four co-founders of the Company and approximately thirteen Company employees. Jean-François Mouney, the Chairman of the Company, is also the Chairman of Biotech Avenir SAS. At December 31, 2019, Biotech Avenir SAS held 4.86% of the share capital of the Company. The Company did not carry out any transactions with Biotech Avenir in 2017, 2018 or 2019, with the exception of the domiciliation without charge. The NASH Epidemiology Institute TM The NASH Education Program TM TM The transactions carried out in 2017, 2018 and 2019 between the Group and The NASH Education Program TM TM TM Frédéric Desdouits Mr. Frédéric Desdouits, member of the Genfit Board of Directors since June 2014 , was appointed CEO of PCAS Group in March 2019. Elafibranor’s active principal ingredient has been made by a PCAS Group production unit since 2013, and since Mr. Frédéric Desdouits became PCAS Group’s CEO, has become a related party as defined by IAS 24.9 since March 2019. In 2019, we paid PCAS Group a total of €1.7 million (tax included). In January 2020, the Company signed a Memorandum of Understanding with PCAS settings out the conditions under which the PCAS Group will: • set up a second manufacturing source for the active ingredient used in the composition of elafibranor, as part of initiatives to secure Genfit’s supply chain; • carry out technology transfers between the current manufacturing unit and the second source; and • undertake the necessary investments to carry out this goal and to increase the production capacity of the active ingredient in view of a potential future marketing authorization for elafibranor.

Compensation of Corporate Offic

Compensation of Corporate Officers	12 Months Ended
	Dec. 31, 2019
Disclosure Of Compensation Of Corporate Officers [Abstract]
Disclosure of Compensation of Corporate Officers Explanatory	2 6 . COMPENSATION OF CORPORATE OFFICERS By resolution of the General Shareholders Meeting on June 16, 2017, the shareholders adopted the change in mode of administration and management of the Company and elected to change from a historical two-tiered board structure (Executive Board and Supervisory Board) to a single board (Board of Directors). As a result, the table below provides details of the compensation paid to the Chairman and CEO, as well as that paid to the members of the Executive Board during the first half of 2017 (prior to the change in mode of governance) and for the financial years in which the relevant amounts were recognized in the statements of operations. On September 2, 2019, the Board of Directors accepted the resignation of the Chairman and Chief Executive Officer of the Company and decided to separate the roles of Chairman of the Board of Directors and Chief Executive Officer of Genfit SA with effect from September 16, 2019. At the same meeting, the Board of Directors appointed the Chief Executive Officer of the Company and confirmed the former Chairman and Chief Executive Officer in his functions as Chairman of the Board of Directors and member of certain committees of the Company's Board of Directors. Under these conditions, the following table details the compensation paid to the Chairman and Chief Executive Officer in 2017, 2018 and during the period from January 1, 2019 to September 16, 2019, and the compensation paid to the Chief Executive Officer during the period from September 16 to December 31, 2019 (after the change in governance) and the years in which the amounts were recognized in the statement of operations. Compensation paid to the Chairman and Chief Executive Officer Year ended in 2017 and 2018 and during the period from January 1, 2019 to September 16, 2019 2017/12/31 2018/12/31 2019/12/31 (1) Short-term employee benefits (gross + employer's social contributions, paid) 1,476 1,569 1,338 Post-employment pension & medical benefits 199 — — Attendance fees — — Share-based payment transactions 51 104 109 Director fees Genfit Corp (net) 37 30 22 TOTAL 1,763 1,703 1,469 Compensation paid to the Chief Executive Officer Year ended in 2018 and during the period from September 16, 2019 to December 31, 2019 2017/12/31 2018/12/31 2019/12/31 Short-term employee benefits (gross + employer's social contributions, paid) — — 140 Post-employment pension & medical benefits — — — Attendance fees — — — Share-based payment transactions — — — Director fees Genfit Corp (net) — — — TOTAL — — 140 (1) 26. COMPENSATION OF CORPORATE OFFICERS (continued) The Chairman of the Board of Directors, Jean-François Mouney, receives a fixed compensation. He also has use of a company vehicle and the Group’s insurance and disability plan. These benefits are totaled in the table above in the "Other compensation" line. The Chairman of the Board of Directors also receives attendance fees granted for his participation in the work of some of the committees of the Board of Directors. The Chief Executive Officer’s corporate contract contains a clause whereby, in the event of termination, he would receive a non-compete indemnity equal to: (i) twelve (12) months of fixed compensation, calculated on the basis of the gross amounts due for the past twelve months ended and (ii) increased, where applicable, by the amount of the annual variable compensation due for the previous year. This compensation is intended to compensate the prohibition made to the Chief Executive Officer, for a period of 12 months following the termination of his functions, for whatever reason, to work in any way whatsoever with certain companies carrying out a directly competitive activity of the Company. In addition, the Chief Executive Officer, except in the event of gross negligence within the meaning of labor law, shall receive severance pay equal to: (i) twelve (12) months of fixed compensation, calculated on the basis of the gross amounts due for the twelve past completed months and (ii) increased, where applicable, by the amount of annual variable compensation due for the previous year. This compensation will be paid one month after his effective termination of activity within the Group. The compensation will not be paid if, on his initiative, the Chief Executive Officer leaves the Company to exercise new functions or changes functions within the Group, or even if he has the possibility of asserting in the short term his retirement rights. It is also specified that any sum paid under the non-competition clause will be deducted from the sums due under the severance pay and vice versa. The total and maximum commitment represented by this indemnity (gross, employer charges and payroll tax) as of December 31, 2019 would amount to €341. 26. COMPENSATION OF CORPORATE OFFICERS (continued) The directors' fees and other compensation due and paid to the non executive directors are as follows: Amounts due* Amounts paid* Amounts due* Amounts paid* Amounts due* Amounts paid* During the year ended December 31, Attendance fees and other forms of remuneration payable to each of the non executive officer (in euros) 2017(4) 2018 2019 Jean-François MOUNEY(1) Attendance fees — — — — 14,791 633 Other remuneration (except his compensation as CEO between January 1, and September 16, 2019)(5) — — — — 88,874 88,874 Total — — — — 103,665 89,507 Xavier GUILLE DES BUTTES Attendance fees 30,218 24,688 53,330 41,311 68,016 67,580 Other remuneration — — — — — — Total 30,218 24,688 53,330 41,311 68,016 67,580 Charles WOLER(2) Attendance fees 5,925 5,925 — — — — Other remuneration — — — — — — Total 5,925 5,925 — — — — Frédéric DESDOUITS Attendance fees 13,627 11,258 21,174 17,113 33,136 30,302 Other remuneration — — — — — — Total 13,627 11,258 21,174 17,113 33,136 30,302 BIOTECH AVENIR Represented by Florence Séjourné Attendance fees — — — — — — Other remuneration — — — — — — Total — — — — — — Philippe MOONS Attendance fees 18,763 14,023 29,704 22,345 36,188 41,202 Other remuneration — — — — — — Total 18,763 14,023 29,704 22,345 36,188 41,202 Anne-Hélène MONSELLATO(3) Attendance fees 14,813 10,468 37,075 24,307 44,472 53,410 Other remuneration — — — — — — Total 14,813 10,468 37,075 24,307 44,472 53,410 Catherine LARUE(3) Attendance fees 11,258 8,098 21,256 17,985 33,136 28,122 Other remuneration — — — — — — Total 11,258 8,098 21,256 17,985 33,136 28,122 TOTAL 94,602 74,458 162,539 123,061 318,613 310,123 26. COMPENSATION OF CORPORATE OFFICERS (continued) 2017(4) 2018 2018 IFRS 2 valuation of share warrants granted during the financial year 94,875 — — * After applying a required 21% withholding (1) Jean-François MOUNEY joined the Board of Directors on June 16, 2017 as Chairman. (2) Since the Shareholders' Meeting on June 16, 2017, Charles WOLER is no longer a board member. (3) Anne-Hélène MONSELLATO and Catherine LARUE were appointed to the Board of Directors by the shareholders at the June 16, 2017 Shareholders' Meeting. (4) The remuneration received by Xavier GUILLE DES BUTTES, Frédéric DESDOUITS, Biotech Avenir and Philippe MOONS until June 16, 2017 was in their capacities as members of the Supervisory Board. (5) The attendance fees and other remuneration for Jean-François Mouney above correspond to amounts due for the period from September 16, 2019 to December 31, 2019. In addition, the Company has provided corporate officers, directors and members of the Executive Committee a “directors and officers” insurance against claims relating to certain actions they may take in the performance of their duties. For the 12-month period starting in March 2019, the insurance premium including the IPO insurance policy premium for the implementation of this insurance coverage amounted to €3,146 and is being amortized over the coverage period.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2019
Disclosure Of Commitments [Abstract]
Commitments	2 7 . COMMITMENTS Subcontracting agreements The Group enters into contracts in the normal course of business with clinical research organizations (CROs) for clinical trials, as well as with Contract Manufacturing Organizations (CMOs) for clinical and commercial supply manufacturing, commercial and pre-commercial activities, research and development activities and other services and products for operating purposes. The Group’s agreements generally provide for termination with specified periods of advance notice. Such agreements are generally cancelable contracts and not included in the description of the Group’s contractual obligations and commitments. In 2019, the Company signed a Memorandum of Understanding –(MoU) with one of its CMOs to be followed by an implementation contract with the CMO to set up a second supply and manufacture source of elafibranor. The costs related to the transfer of technology required for the establishment of the second source of supply and manufacturing, as well as the costs of manufacturing the registration lots are borne by the CMO and serve as a basis for calculating the penalties that would be payable by the Group in certain cases of early termination of the MoU or its implementation contract. The amount of these penalties could reach a maximum of €1,360. Deposits and guarantees The Company has guaranteed its rental payment obligation under the lease agreement for the headquarters in Loos, France in the amount of€542 at December 31, 2019 and €455 at December 31, 2018 and €455 at December 31,2017. Obligations in respect of the co-ownership of intellectual property rights To date, the Company has not been required to license any third-party intellectual property to develop drug candidates and biomarker candidates that comprise its portfolio of proprietary programs and products. The Company ensures, with regard to these programs, that the collaboration or subcontracting agreements that it is required to enter into, systematically stipulate that the results of the research are the Company's property. This is particularly the case for research consortia, in which the Group is associated with university laboratories and other biotechnology companies. It therefore holds all the intellectual property rights over its portfolio of proprietary programs and products. 27. COMMITMENTS (continued) On the other hand, the agreements signed in the framework of the Company's historical co-research alliances with partners in the pharmaceutical industry provided that the intellectual property rights of the drug candidates developed under these alliances belonged to the partners. These agreements also provided that the Company had intellectual property rights over the innovative technologies discovered on this occasion, even if it had to grant a royalty free and non-exclusive license to the industrial partner for the purpose of developing drug candidates discovered under the co-research programs. To date, Sanofi remains the only industrial partner likely to still have exploitation rights on a drug candidate developed as part of its historical co-research alliance with the Company and therefore able to use on a royalty-free basis, but not exclusively, technologies developed by the Company under this program. The other historic partners have informed the Company of their decision not to exploit or stop exploiting the results of joint research. Nevertheless, to date, Sanofi has not communicated to the Company its desire to continue the development of this program despite the last research phase shared with the Company's teams having ended in May 2015. Other liabilities Pursuant to an agreement with effect from July 1, 2016, the Company decided to finance the creation by Pinnacle Clinical Research of a registry of NAFLD/NASH patients, which diseases are targeted by certain of the Company's drug and biomarker candidates. This donation, for a maximum amount of USD $1,582 is being paid over the course of the creation of the registry on the basis of reporting periods. The Company's goal in supporting the creation of this registry was to contribute to the improvement of scientific and medical knowledge around NAFLD and NASH. As a result, the Company decided on December 22, 2016, with effect from December 31, 2016, to assign the benefit and obligations of this agreement to its endowment fund, The NASH Education Program TM TM In 2017, 2018 and 2019, the Company granted to The NASH Education Program TM TM

Events after the Reporting Peri

Events after the Reporting Period	12 Months Ended
	Dec. 31, 2019
Disclosure Of Nonadjusting Events After Reporting Period [Abstract]
Events after the Reporting Period	2 8 . EVENTS AFTER THE REPORTING PERIOD In May 2020, the Company published the top-line results of the interim analysis of the RESOLVE-IT Phase 3 trial of elafibranor in NASH. Elafibranor did not demonstrate a statistically significant effect on the primary endpoint of NASH resolution without worsening of fibrosis or on the key secondary endpoints. GENFIT continues to review the data and will be conducting additional analyses. The Company will share its conclusions with regulatory authorities and with their guidance, determine a final decision regarding the continuation of the RESOLVE-IT trial. In parallel, we continue as planned with our NIS4 and Phase 3 PBC programs, which are independent of our NASH program with elafibranor. On May 14, 2020, following our announcement that elafibranor had not achieved the primary or key secondary endpoints of the RESOLVE-IT trial, a purported shareholder class action complaint, captioned Schwartz v. Genfit S.A. et al. The financial impact of this class action complaint cannot be quantified at this time. 28. EVENTS AFTER THE REPORTING PERIOD A new coronavirus strain, COVID-19, was identified in Wuhan, China in December 2019. Since then and particularly since the closing date, the COVID-19 coronavirus has spread to several countries, including the United States and several European countries, including countries in which the Company has clinical trials in progress, in countries where it plans to conduct clinical trials and in countries in which major subcontractors for carrying out its clinical trials and the production units of the active ingredient suppliers and therapeutic units of elafibranor, its most advanced drug candidate, are located. In March 2020, the Company published a press release outlining the main impacts of this unprecedented spread of COVID-19 on its activities: • RESOLVE-IT Phase 3 trial of elafibranor in NASH with fibrosis continues ; Working with our contract research organization, we have implemented appropriate measures to ensure the safety of patients who are already participating in the study: virtual clinic visits, local laboratory assessment, home delivery of study drug, and halting the screening of new patients. • All phase 1 trials – which include pharmacokinetic, food effect and bioequivalence studies – have been put on hold. These studies are necessary to support the elafibranor NDA submission for NASH. • Enrollment of patients in the PK/PD trial in pediatric patients with NASH as well as the Phase 2 study addressing liver fat have also been paused. • The initiation of the Phase 2 combination study, as well as that of the Phase 3 study in patients with PBC, have been put on hold. • NIS4 continues to be deployed in the clinical research field through our commercial partner Labcorp/Covance. There may be some limits in test utilization due to delays potentially experienced by some NIS4 clients as the result of the current COVID-19 situation. GENFIT teams are progressing the in-vitro diagnostic (IVD) aspect of the program in parallel. • Although the COVID-19 pandemic is rapidly evolving, and our plans may change accordingly, at this stage we do not anticipate any supply disruption for any of our current or planned studies. • All supporting activities pertaining to continuation of ongoing studies or the initiation of new studies will continue in order to minimize potential delays when the pandemic crisis subsides. The financial impact of COVID-19 cannot be quantified at this time. .

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Voluntary Change In Accounting Policy [Abstract]
Use of estimates and judgments	4 .1. Use of estimates and judgments In preparing these consolidated financial statements, management makes judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, incomes and expenses. Actual amounts may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. The estimates and underlying assumptions mainly relate to research tax credits (see Note 4.19.2, "Research tax credit", employee benefits (see Note 4.18, "Employee benefits"), share-based payments (see Note 20, "Share-based compensation"), accruals related to clinical trials (see Note 19, "Operating expenses") and convertible loans (see Note 12, "Loans and Borrowings").
Consolidation	4 .2. Consolidation The Group controls an entity when it is exposed to variable returns from its involvement with the entity, and it has the ability to affect those returns through its power over the entity. The Group controls all the entities included in the scope of consolidation.
Foreign currency	4 .3. Foreign currency 4 .3.1. Foreign currency transactions Transactions in foreign currencies are translated into the respective functional currencies of the entities of the Group at the exchange rates applicable at the transaction dates. Monetary assets and liabilities denominated in foreign currencies are translated into the functional currency at the reporting date. The resulting exchange gains or losses are recognized in the statements of operations. 4 .3.2. Translation of foreign subsidiary financial statements The assets and liabilities of foreign operations having a functional currency different from the euro are translated into euros at the closing exchange rate. The income and expenses of foreign operations are translated into euros at the exchange rates effective at the transaction dates or using the average exchange rate for the reporting period, unless this method cannot be applied due to significant exchange rate fluctuations. Gains and losses arising from foreign operations are recognized in the statement of other comprehensive loss. When a foreign operation is partly or fully divested, the associated share of gains and losses recognized in the currency translation reserve is transferred to the statements of operations. The Group’s presentation currency is the euro, which is also the functional currency of GENFIT S.A. The functional currency of GENFIT CORP is the U.S. dollar. The applicable exchange rates used to translate the financial statements of this entity for each of the periods are as follows: Year ended Year ended Year ended Ratio : 1 US dollars (USD) = x euros (EUR) 2017/12/31 2018/12/31 2019/12/31 Exchange rate at period end 0.83382 0.87336 0.89015 Average exchange rate for the period 0.88704 0.84758 0.89341
Revenues	4.4 Revenues from ongoing activities under client agreements The Group signed an agreement with Terns Pharmaceuticals on June 24, 2019. The Group’s accounting policies associated with revenue are as follows: 4.4.1. IFRS 15 Under IFRS 15, revenue is recognized when the Company fulfills a performance obligation by providing separate goods or services to a customer, i.e., when the customer obtains control of those goods or services. An asset is transferred when the customer obtains control of that asset or service. Under this standard, each contract must be analyzed, on a case-by-case basis, in order to verify whether it contains performance obligations towards third parties, and, if applicable, to identify their nature in order to determine the appropriate accounting of amounts that the Company has received or is entitled to receive from third parties, for example: • The transfer of control over the intellectual property, via a license granted by the Company, as it exists at the time of the sale, the date of which will determine that of the revenue recognition; • If the license is considered as a right of access to the intellectual property of the Company over the life of the license, the revenue would be recognized over this lifetime; • The supply of products whose revenues would be recognized at the time of transfer of control of the delivered products, • Potential revenue from milestones, or from royalties or royalties based on sales, would not be recognized until the achievement of the milestone or completion of the sale. 4.4.2 Application to the Terns Pharmaceuticals license agreement The Company identified three performance obligations under the license agreement with Terns: • An exclusive license, with the right to sub-license, to develop, manufacture, distribute and promote elafibranor in NASH and PBC in Greater China; • A transfer to Terns Pharmaceuticals of the Company’s Licensed Know-How and data regarding elafibranor and related support until the Marketing Authorization Application by Terns Pharmaceuticals; and • Supply by the Company to Terns Pharmaceuticals of drug product to carry out its clinical trials in Greater China. The supply of drug product following the market authorization would be subject to a separate agreement if applicable. Under the terms of the licensing agreement, the Company has received or could potentially receive: • A $35 million non-refundable Upfront Payment payable within 10 business days from June 24, 2019 upon the transfer of the existing Company’s Licensed Know-How. This Upfront Payment was received on July 3, 2019; • Development Milestone Payments upon the achievement of the development milestones for the licensed product; • Commercial Milestone Payments upon the achievement of commercial milestones depending on reaching certain aggregate thresholds; • Mid-teen percentage Royalties based on sales by Terns Pharmaceuticals in Greater China; and • Compensation for the supply of drug product for the clinical trials on a cost-plus basis. The potential Development and Commercial Milestone payments may represent up to $193 million. Under IFRS 15, the allocation and recognition of revenue was determined as follows based on the fair value of each of the performance obligations: • The $35 million upfront payment was allocated to the license and the transfer of the existing know-how and related support to Terns Pharmaceuticals based on an estimate of the latter measured as the maximum estimated value to be incurred by the Company’s employees and management for the support given to Terns Pharmaceuticals. On this basis, $34.9 million was recognized as revenue in 2019 and $0.1 million was deferred to future periods. • Development and Commercial Milestones Payments whose payment depends on the achievement of certain scientific, regulatory or commercial objectives, as provided in the contract, are variable compensation that will be recognized as revenue when the milestones are met. No amounts were recognized in 2019. • Royalties on commercial sales by Terns Pharmaceuticals will be recognized as revenue pursuant to information given to the Company by Terns Pharmaceuticals, under the terms and timeframes set out in the agreement. No amounts were recognized in 2019. • Revenue on Supply for drug product will be recognized based on the delivery of drug product to Terns Pharmaceuticals. No amounts were recognized in 2019. As part of this agreement, Genfit and Terns Pharmaceuticals will also undertake joint research and development projects in liver disease, including the development of elafibranor in combination with Terns Pharmaceuticals’ proprietary compounds. This collaboration agreement is only potential at the date of signing the license agreement and does not yet constitute a reciprocal commitment at December 31, 2019. It therefore has no accounting impact at this time. This contract contains several delivery obligations. As a result, the Company has ensured, as required by IFRS 15, that the revenue allocation of the transaction corresponds to the fair value of each obligation.
Intangible assets	4.5 . Intangible assets Intangible assets mainly consist of software and operating licenses acquired by the Group. They are recognized at cost less accumulated amortization and impairment. Amortization expense is recorded on a straight-line basis over the estimated useful lives of the intangible assets. The estimated useful lives of both software and license agreements are between 1 and 8 years.
Property, plant and equipment	4.6 . Property, plant and equipment Property, plant and equipment are initially recognized at cost. Cost includes expenditures that are directly attributable to the acquisition of the asset. Routine maintenance costs are expensed as incurred. Subsequently, depreciation expense is recognized on a straight-line basis over the estimated useful lives of the assets. If components of property, plant and equipment have different useful lives, they are accounted for separately. Depreciation methods, useful lives and residual values are reviewed at each reporting date and adjusted, if appropriate. Estimated useful lives are as follows: Building on non-freehold land 10 years Fittings and fixtures Between 9 and 25 years Scientific equipment Between 2 and 12 years Computer equipment Between 2 and 5 years Furniture Between 4 and 10 years Vehicles Between 4 and 6 years Any gain or loss on disposal of an item of property, plant and equipment is determined by comparing the proceeds from disposal with the carrying amount of the item. The net amount is recognized in the consolidated statements of operations under the line item "Other operating income (expenses)."
Leases	4.7 . Leases 4.7.1 IFRS 16 and IAS 17 The Group has applied IFRS 16 in accordance with the modified retrospective method, under which the cumulative effect of the adoption of IFRS 16 is recorded as an adjustment to the balance of accumulated deficit as at January 1, 2019. As a result, comparative information presented for 2018 has not been restated and is therefore presented, as before, in accordance with the principles of IAS 17 and its interpretations. The resulting changes in accounting policies are explained in detail below. Significant accounting policies of IAS 17 Finance leases When substantially all of the risks and rewards of ownership are transferred from the lessor to the lessee, the leases are classified as finance leases, resulting in the initial recognition of an asset equal to the fair value of the relevant property or the present value of the minimum future payments due under the contract, whichever is lower. They are subsequently amortized or depreciated, as the case may be. The resulting financial liabilities are recorded in current and non current “other loans and borrowings”. Operating leases A lease agreement is qualified as an operating lease when substantially all of the risks and rewards of ownership are not transferred to the lessee. Payments under operating leases are recognized as an expense on a straight-line basis over the term of the lease. Benefits received from the lessor such as rent suspensions or variable payments are allocated on a straight-line basis over the term of the lease. Significant accounting policies under IFRS 16 IFRS 16 introduces for the lessee a single model of accounting on the balance sheet for leases. The lessee recognizes a "right of use" asset which represents its right to use the underlying asset, and a lease liability for its obligation to pay the rent. The Group recognizes a "right of use" asset and a lease liability at the start of the lease term. The "right of use" asset is initially measured at cost and then at cost less any amortization and accumulated impairment losses. The amount can be adjusted based on certain revaluations of the lease liability. The lease liability is initially measured at the discounted value of the rents owed and not yet paid at the start date of the contract. The discount rate used is the implicit interest rate of the contract or, if it cannot be easily determined, the Company’s incremental borrowing rate. The Group generally uses the latter as the discount rate. The lease liability is then adjusted by the interest expense minus the amounts of rent paid. It is revalued in the event of a change in future rents following a change in the index or rate, a new estimate of the amount to be paid under a residual value guarantee or, where applicable, a revaluation of the exercise of an option to purchase or to extend, or the non-exercise of an option to terminate (which then becomes reasonably certain). The Group has exercised its judgment in determining the term of the lease agreements that provide for extension options. The fact that the Group has determined that it is reasonably certain to exercise such options has an impact on the lease term used and has a significant impact on the amount of lease debt and the "right of use" asset in the accounts. 4.7.2 Application of the new IFRS 16 standard IFRS 16 “Leases”, adopted by the European Union on October 31, 2017, is mandatorily applicable for the reporting periods starting on or after January 1, 2019. It replaces IAS 17 “Leases” and its interpretations. This new standard removes the concepts of finance lease and operating lease for the lessee and requires all leases to be recognized on the lessee's balance sheet in the form of a "right of use" asset with the corresponding entry for a financial debt. The Group's leases, formerly classified as operating leases in accordance with IAS 17, concern real estate assets, including the Group's corporate headquarters. Contracts formerly classified as finance leases include, in particular, scientific equipment. As part of the transition, the Group adopted the "modified retrospective" method and chose to apply some of the practical expedients offered by IFRS 16, namely: • The exclusion of contracts of less than 12 months duration; • Exclusion of low value contracts; • Carryforward of contracts previously accounted for as finance lease contracts under IAS 17 "Leases". The new standard is implemented as follows: • The lease term for a contract corresponds to its non-cancellable period, extended, as the case may be, based on the Group's assessment of the reasonably certain nature of the exercise of contractual renewal or cancellation options; • The discount rate applied is the incremental borrowing rate corresponding to the duration of the contract, in the absence of an implicit rate in the contract. To determine the incremental borrowing rate, the Group determined the remaining term of the contracts as from January 1, 2019. The weighted average incremental borrowing rate at January 1, 2019 was 1.26%. Duration is the average life of financial flows weighted by their discounted value. "Right of use" assets and lease liabilities were recognized in the Group's balance sheet as at January 1, 2019 for € 9,227 and € 8,947, respectively. In accordance with IFRS 16, the Group has chosen to present the “right of use” assets in the same line item as property, plant and equipment as the assets of the same type. As of December 31, 2018, the differences between the commitments related to operating leases presented in application of IAS 17 and the lease liability estimated in accordance with IFRS 16 can be explained as follows: In € thousands 12/31/2018 Operating lease commitments as a lessee, as of 12/31/2018 as published 4,791 Differences related to extension options for which the exercise is reasonably certain 5,264 Differences in the amounts retained for the calculation of commitments and lease liability (396) Expenses not included in the lease liability but included in the commitments (190) Undiscounted lease liability estimated under IFRS 16 at 1/1/2019 9,469 Impact of discount (522) Lease liability estimated under IFRS 16 at 1/1/2019 8,947 The impact of the duration is entirely attributable to the Group's headquarters, where an agreement to extend the building led to a revision of the commitment period for Genfit and the lessor under this lease. The lease expense that would have been recognized in 2019 if IAS 17 had applied would have amounted to € 1,480. Under IFRS 16, expenses recognized in 2019 amounted to € 1,241 in depreciation for right of use assets and € 128 in interest expense.
Impairment of tangible assets, intangible assets and goodwill	4.8 . Impairment of tangible assets, intangible assets and goodwill If indicators of impairment are identified, amortizable intangible assets and depreciable tangible assets are subject to an impairment test under the provisions of IAS 36, Impairment of Assets The Company does not have any goodwill.
Financial instruments	4.9. IFRS 9 “Financial Instruments” replaces IAS39 “ Financial Instruments: Recognition and Measurement” starting from the 2018 financial year and takes into account three aspects of booking financial instruments: • Classification and measurement; • Impairment; • Hedge accounting. As was the case in the previous periods, application of IFRS 9 does not have an impact on the Group’s financial statements. Loans and borrowings are initially measured at fair value and subsequently recorded at amortized cost.
Inventories	4.10 . Inventories The Company recognizes inventories of laboratory consumables in connection with its former co-research agreements. These inventories are measured at the lower of cost and net realizable value. Cost is determined using the weighted average cost method.
Trade and other receivables	4.11 . Trade and other receivables Trade and other receivables are recognized at fair value, which is the nominal value of invoices unless payment terms require a material adjustment for the time value discounting effect at market interest rates. Trade receivables are subsequently measured at amortized cost. A valuation allowance for trade receivables is recognized if their recoverable amount is less than their carrying amount. Receivables are classified as current assets, except for those with a maturity exceeding 12 months after the reporting date.
Other financial assets	4 .12 . Other financial assets Loans and receivables are financial assets with fixed or determinable payments that are not listed on an active market and are valued using the amortized cost method. A gain or loss arising from a change in the fair value of an available-for-sale financial asset is recognized in other comprehensive income (loss) except for impairment losses and foreign exchange gains and losses, until the financial asset is derecognized. At that time the cumulative gain or loss previously recognized in other comprehensive income (loss) is reclassified from equity to profit or loss as a reclassification adjustment.
Cash and cash equivalents	4.13 . Cash and cash equivalents Cash and cash equivalents comprise cash on hand, bank accounts and term deposits, together with short-term deposits and highly liquid investments. They are readily convertible to a known amount of cash and thus present a negligible risk of a change in value. They also include Undertakings for Collective Investments in Transferable Securities (UCITs) whose characteristics allow them to be classified as cash and cash equivalents. Initially recognized at their purchase cost at the transaction date, investments are subsequently measured at fair value. Changes in fair value are recognized in net financial income (expenses).
Equity	4.14 . Equity Share capital comprises ordinary shares and ordinary shares with double voting rights classified in equity. Costs directly attributable to the issue of ordinary shares or share options are recognized as a reduction in the share premium. The liquidity agreement consists of a share buyback program contracted to an investment service provider. Purchases and sales of the Company's shares carried out under the contract are recognized directly in shareholders’ equity under treasury shares. See note 10 “Other financial income”.
Loans and borrowings	4.15 . Loans and borrowings Financial liabilities are initially recognized at fair value, net of directly attributable transaction costs, and are subsequently measured at amortized cost using the effective interest rate method. The Group derecognizes financial liabilities when the contractual obligations are discharged, cancelled or expire. The bonds convertible or exchangeable into new or existing shares (OCEANE—see Section 12.1, "Breakdown of convertible loan") are recognized as follows: in accordance with IAS 32, Financial Instruments—Presentation The liability component is measured, at the date of issuance, at its fair value on the basis of future contractual cash flows discounted at market rates (taking into consideration the issuer's credit risk) of a debt having similar characteristics but without having the conversion option. The value of the conversion option is measured by the difference between the bond's issue price and the fair value of the liability component. After deduction of the pro rata portion of expenses related to the transaction, this amount is recognized in the line item "Share premium" under shareholders' equity and is subject to a calculation of deferred tax according to IAS 12.28. The liability component (after deduction of the portion of the expenses related to the transaction pro rata portion to the respective parts attributed to liability and the conversion option) is measured at amortized cost. A non-monetary interest expense, recorded in net loss is calculated using an effective interest rate to progressively bring the debt component up to the amount which will be repaid (or converted) at maturity. A deferred tax liability is calculated on the basis of this amount. The shareholders' equity component is not remeasured.
Trade and other payables	4.16 . Trade and other payables Trade and other payables are initially recognized at the fair value of the amount due. This value is usually the nominal value, due to the relatively short period of time between the recognition of the instrument and its repayment.
Provisions	4.17 . Provisions Provisions are recognized when the Group has a present obligation (legal, regulatory, contractual or constructive) as a result of a past event, for which it is probable that an outflow of resources will be required to settle the obligation, and of which the amount can be estimated reliably. The amount recognized as a provision is the best estimate at the reporting date of the expenditure required to settle the present obligation. Provisions are discounted when the time value effect is material.
Employee benefits	4.18 . Employee benefits The Group's pension schemes and other post-employment benefits consist of defined benefit plans and defined contribution plans. 4.18 .1. Defined benefit plans Defined benefit plans relate to French retirement benefit plans under which the Group is committed to guaranteeing a specific amount or level of contractually defined benefits. The obligation arising from these plans is measured on an actuarial basis using the projected unit credit method. The method consists of measuring the obligation based on a projected end-of-career salary and vested rights at the measurement date, according to the provisions of the collective bargaining agreement, corporate agreements and applicable law. Actuarial assumptions are used to determine the benefit obligations. The amount of future payments is determined on the basis of demographic and financial assumptions such as mortality, staff turnover, pay increases and age at retirement, and then discounted to their present value. The discount rate used is the yield at the reporting date on AA credit-rated bonds with maturity dates that approximate the expected payments for the Group's obligations. Re-measurements of the net defined benefit liability which comprise actuarial gains and losses are recognized in the statements of other comprehensive loss. The Group determines the net interest expense on the net defined benefit liability for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability, taking into account any changes in the net defined benefit liability during the period as a result of contributions and benefit payments. 4.18 .2. Defined contribution plans Under defined contribution plans, the management of plans is performed by an external organization, to which the Group pays regular contributions. Payments made by the Group in respect of these plans are recognized as an expense for the period in the statements of operations. 4.18 .3. Short-term employee benefits A liability is recognized for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Group has a present legal or constructive obligation to pay the amount as a result of past service provided by the employee, and the obligation can be estimated reliably.
Other income	4 .19. Other income 4 .19.1. Government grants The Group received until 2016 various forms of government grants. This government aid is provided for and managed by French state-owned entities, and specifically "BPI France" (" Banque Publique d'Investissement Subsidies received are non-refundable. Conditional advances received are interest-free or are subject to low interest rates depending on contractual provisions. Grants related to assets Grants related to assets are intended to finance the purchase of long-term assets. They are presented in the statements of financial position as deferred income and recognized in the line item "Other income" in the statements of operations on a systematic basis over the useful life of the related asset. Grants related to income Grants related to income are intended to finance research programs. They are presented in the statements of financial position as deferred income and recognized in the line item "Other income" in the statements of operations as and when costs related to the research programs are incurred. Conditional advances related to research programs Conditional advances that are interest-free or subject to low interest rates are intended to finance research program’s needs. In accordance with IAS 20, Accounting for Government Grants and Disclosure of Government Assistance The grant portion of conditional advances is treated as a grant related to income. For advances granted by BPI France, repayment is required in the event of commercial success. In addition, if the Group decides to stop the research program, the conditional advance may be required to be repaid. If a program is unsuccessful, a pre-determined amount may be repayable. If a program is unsuccessful, a predetermined amount may be repayable The remaining amount, if any, is then considered as a grant and written off in the line item "Other income" in the statements of operations. 4 .19.2. Research tax credit The Research Tax Credit (" Crédit d'Impôt Recherche The Group applies for CIR for research expenditures incurred in each fiscal year and recognizes the amount claimed in the line item "Other income" in the statements of operations in the same fiscal year. In the notes to the financial statements, the amount claimed is recognized under the heading "Research tax credit" (see Note 9, "Trade and other receivables" and Note 18, "Revenue and other income"). The CIR for fiscal years 2010, 2011, 2012 and 2014 was under audit by the tax authorities and a provision was made in the accounts. (see Note 24, "Litigation and contingent liabilities").
Research and development expenses	4 .20. Research and development expenses Research expenses are recorded in the financial statements as expenses (see Note 19, "Operating expense"). In accordance with IAS 38, Intangible Assets • Technical feasibility necessary for the completion of the development project; • Intention on the Group's part to complete the project and to utilize it; • Capacity to utilize the intangible asset; • Proof of the probability of future economic benefits associated with the asset; • Availability of the technical, financial, and other resources for completing the project; and • Reliable evaluation of the expenses attributed to the intangible asset during its development.
Classification of operating expenses	4 .21. Classification of operating expenses Research and development expenses include: • employee-related costs; • costs related to external employees seconded to the Company (such as clinical development, biometrics and IT…); • lab supplies and facility costs; • donations to The NASH Epidemiology Institute endowment fund, in particular to fund the creation of patient registry; • fees paid to scientific advisers and contracted research and development activities conducted by third parties; • intellectual property fees corresponding to the filing of the Group's patents and, • provision in relation to the Research Tax Credit dispute (see note 24 to our financial consolidated statements ) Contracted research and development activities conducted by third parties include services subcontracted to research partners for technical and/or regulatory reasons. In particular, this includes the production of active ingredients and therapeutic units, all or a part of clinical trials and pre-clinical trials that are necessary to the development of GENFIT's drug candidates and biomarker candidates. General and administrative expenses include: • employee-related costs for executive, business development, intellectual property, finance, legal and human resources and communications functions; • facility-related costs; • marketing, legal, audit and accounting fees; • press relations and communications firm fees; • the cost of external employees seconded to the Company (such as security, reception, and accounting..); • other service costs (recruitment, etc.); • grants to the endowment fund, The NASH Epidemiology Institute TM • intellectual property fees corresponding to the maintenance of the Group's patents. Marketing and market access expenses include: • employee-related costs for marketing and business development, functions; • facility-related costs; • marketing, and market access firm fees; • the cost of external employees seconded to the Company (market access..) and • other service costs (recruitment, etc);
Share-based compensation	4 .22. Share-based compensation The fair value of equity-settled share-based compensation granted to employees, officers, board members and consultants as determined on the grant date is recognized as a compensation expense with a corresponding increase in equity, over the vesting period. The amount recognized as an expense is adjusted to reflect the actual number of awards for which the related service and non-market performance conditions are expected to be met. The fair values of equity-settled share-based compensation granted to employees are measured using the Black-Scholes model with respect to the share warrants (BSA) and redeemable share warrants (BSAAR) and using the Monte Carlo model for the stock options (SO) and free shares (AGA). Measurement inputs include share price on the measurement date, the exercise price of the instrument, expected volatility, expected maturity of the instruments, expected dividends, and the risk-free interest rate (based on government bonds). With respect to the redeemable share warrants, service and non-market performance conditions attached to the transactions are not taken into consideration in determining fair value but are taken into consideration related to recognition of expense. Regarding the stock options and free shares, market conditions are taken into account in the determination of the fair value of the plans award. For share-based compensation awards with non-vesting conditions, the grant date fair value of the share-based compensation is measured to reflect such conditions and there is no adjustment for differences between expected and actual outcomes. GENFIT may also grant equity-settled share-based compensation in exchange for services to consultants who are not considered employees. In such cases, the value of the services is measured when they are rendered by the consultants and the share-based compensation exchanged for the services is measured at an equal amount. If the value of the services cannot be measured reliably, then such value is measured with reference to the fair value of the equity instruments granted. Share-based compensation granted to consultants consists of share warrants, some of which may be redeemed at GENFIT's discretion. Share-based compensation granted to employees consists of redeemable share warrants, stock options and free shares
Income tax	4 .23. Income tax Income tax expense (or benefit) comprises current tax expense (or benefit) and deferred tax expense (or benefit), as applicable. Deferred taxes are recognized for all the temporary differences arising from the difference between the tax basis and the accounting basis of assets and liabilities. Deferred tax assets are recognized for unused tax losses, unused tax credits and temporary deductible differences to the extent that: • it is probable that future taxable profit will be available against which they can be used; or • if there are deferred tax liabilities for the same entity in the same tax jurisdiction on which they can be applied.
Earnings (loss) per share	4 .24. Earnings (loss) per share Basic earnings (loss) per share are calculated by dividing profit or loss attributable to the Company's ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per share are calculated by adjusting profit attributable to ordinary shareholders and the average number of ordinary shares outstanding weighted for the effects of all potentially dilutive instruments (share warrants, redeemable share warrants, free shares, stock options and bonds convertible into new and/or existing shares).
Operating segments	4. 25. Operating segments The Board of Directors and Chief Executive Officer are the chief operating decision makers. The Board of Directors and the Chief Executive Officer oversee the operations and manage the business as one segment with a single activity; namely, the research and development of innovative medicines, the marketing of which depends on the success of the clinical development phase.

Major Events In The Period (Tab

Major Events In The Period (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Major Events In Period [Abstract]
Schedule of Expenses Incurred and Deducted from Issue Premium by Break Down	The expenses incurred and deducted from the issue premium are broken down as follows: Expenses related to the global offering (in € thousands) Registration, filling, listing fees (290 ) Underwriting (9,634 ) Legal fees and expenses (1,225 ) Accounting fees and expenses (1,045 ) Printing expenses (160 ) TOTAL (12,354 )

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Voluntary Change In Accounting Policy [Abstract]
Summary of Functional Currency	The Group’s presentation currency is the euro, which is also the functional currency of GENFIT S.A. The functional currency of GENFIT CORP is the U.S. dollar. The applicable exchange rates used to translate the financial statements of this entity for each of the periods are as follows: Year ended Year ended Year ended Ratio : 1 US dollars (USD) = x euros (EUR) 2017/12/31 2018/12/31 2019/12/31 Exchange rate at period end 0.83382 0.87336 0.89015 Average exchange rate for the period 0.88704 0.84758 0.89341
Summary of Estimated Useful Lives	Estimated useful lives are as follows: Building on non-freehold land 10 years Fittings and fixtures Between 9 and 25 years Scientific equipment Between 2 and 12 years Computer equipment Between 2 and 5 years Furniture Between 4 and 10 years Vehicles Between 4 and 6 years
Summary of Commitments Related to Operating and Lease Liability Estimated	As of December 31, 2018, the differences between the commitments related to operating leases presented in application of IAS 17 and the lease liability estimated in accordance with IFRS 16 can be explained as follows: In € thousands 12/31/2018 Operating lease commitments as a lessee, as of 12/31/2018 as published 4,791 Differences related to extension options for which the exercise is reasonably certain 5,264 Differences in the amounts retained for the calculation of commitments and lease liability (396) Expenses not included in the lease liability but included in the commitments (190) Undiscounted lease liability estimated under IFRS 16 at 1/1/2019 9,469 Impact of discount (522) Lease liability estimated under IFRS 16 at 1/1/2019 8,947

Financial Risks Management (Tab

Financial Risks Management (Tables)	12 Months Ended
	Dec. 31, 2019
Foreign Exchange Rates [Abstract]
Summary of Sensitivity of Cash and Cash Equivalents and Expenses to Variation of Ten Percent of the US Dollars Against the Euro	5. FINANCIAL RISKS MANAGEMENT (Continued) The following table shows the sensitivity of the Group's cash and cash equivalent and expenses in U.S. dollars to a variation of 10% of the U.S. dollar against the euro in 2017, 2018 and 2019: Sensitivity of the Group's cash and cash equivalents to a variation of +/- 10% of the US dollar against the euro As of (in € thousands or in US dollar thousands, as applicable) 2017/12/31 2018/12/31 2019/12/31 Cash and cash equivalents denominated in US dollars 3,611 1,188 153,438 Equivalent in euros, on the basis of the exchange rate described below 3,011 1,038 136,582 Equivalent in euros, in the event of an increase of 10% of US dollar vs euro 3,345 1,153 151,758 Equivalent in euros, in the event of a decrease of 10% of US dollar vs euro 2,737 944 124,166 Sensitivity of the Group's expenses to a variation of +/- 10% of the US dollar against the euro Year ended (in € thousands or in US dollar thousands, as applicable) 2017/12/31 2018/12/31 2019/12/31 Expenses denominated in US dollars 5,993 9,613 40,355 Equivalent in euros, on the basis of the exchange rate described below 4,997 8,396 35,922 Equivalent in euros, in the event of an increase of 10% of US dollar vs euro 5,552 9,328 39,914 Equivalent in euros, in the event of a decrease of 10% of US dollar vs euro 4,543 7,632 32,657 2019/12/31 : Equivalent in euros, on the basis of a 1 euro = 1.1234 US dollar ratio 2018/12/31 : Equivalent in euros, on the basis of a 1 euro = 1.145 US dollar ratio 2017/12/31 : Equivalent in euros, on the basis of a 1 euro = 1.1993 US dollar ratio
Summary of Cash, Cash Equivalents and Financial Assets	Cash, cash equivalents and financial assets As of (in € thousands or in US dollar thousands, as applicable) 2017/12/31 2018/12/31 2019/12/31 At origin, denominated in EUR Cash and cash equivalents 270,210 206,199 139,863 Current and non current financial assets 729 1,303 1,614 Total 270,939 207,502 141,477 At origin, denominated in USD Cash and cash equivalents 3,611 1,041 136,884 Current and non current financial assets 31 10 113 Total 3,642 1,051 136,997 Total, in EUR Cash and cash equivalents 273,820 207,240 276,748 Current and non current financial assets 760 1,313 1,727 Total 274,581 208,553 278,474

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2019
Cash And Cash Equivalents [Abstract]
Summary of Cash and Cash Equivalents	These investments, summarized in the tables below, are short-term, highly liquid and subject to insignificant risk of changes in value. Cash and cash equivalents As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Short-term deposits 244,279 201,522 263,147 Cash on hand and bank accounts 29,541 5,718 13,601 TOTAL 273,820 207,240 276,748 Short-term deposits As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 UCITS 38,052 29,189 3,096 TERM ACCOUNTS 138,967 124,316 215,018 NEGOTIABLE MEDIUM-TERM NOTES 4,150 — — INTEREST-BEARING CURRENT ACCOUNT 63,110 48,017 45,033 TOTAL 244,279 201,522 263,147

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Intangible Assets [Abstract]
Schedule of Variations in Intangible Assets	The following tables show the variations in intangible assets for the years ended December 31, 2017, 2018 and 2019: As of As of Intangible assets—Variations January 1, December 31, (in thousands of euros) 2017 Increase Decrease 2017 Gross Software 1,688 268 (56 ) 1,900 Patents 21 — — 21 TOTAL – Gross 1,709 268 (56 ) 1,921 Accumulated depreciation and impairment Software (1,020 ) (298 ) 54 (1,264 ) Patents (21 ) — — (21 ) TOTAL - Accumulated depreciation and impairment (1,042 ) (298 ) 54 (1,285 ) TOTAL – Net 668 (29 ) (2 ) 636 As of As of Intangible assets—Variations January 1, December 31, (in thousands of euros) 2018 Increase Decrease 2018 Gross Software 1,900 216 (67 ) 2,049 Patents 21 — — 21 Other intangibles — 313 — 313 TOTAL—Gross 1,921 529 (67 ) 2,384 Accumulated depreciation and impairment Software (1,264 ) (370 ) 67 (1,567 ) Patents (21 ) — — (21 ) Other intangibles — — — — TOTAL - Accumulated depreciation and impairment (1,285 ) (370 ) 67 (1,588 ) TOTAL – Net 636 159 — 796 7. INTANGIBLE ASSETS (continued) Intangible assets – Variations As of Translation As of (in € thousands) 2018/12/31 Increase Decrease adjustments Reclassification 2019/12/31 Gross Software 2,049 340 (29 ) — 378 2,739 Patents 21 70 — — — 91 Other intangibles 313 65 — — (378 ) — TOTAL – Gross 2,384 475 (29 ) — — 2,830 Accumulated depreciation and impairment Software (1,567 ) (350 ) 29 — — (1,888 ) Patents (21 ) — — — — (21 ) Other intangibles — — — — — — TOTAL - Accumulated depreciation and impairment (1,588 ) (350 ) 29 — — (1,910 ) TOTAL – Net 796 125 — — — 920

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Property Plant And Equipment [Abstract]
Summary of Variations in Tangible Assets	The following tables show the variations in tangible assets for the years ended December 31, 2017,2018 and 2019: Property, plant & equipment—Variations (in thousands of euros) As of January 1, 2017 Increase Decrease Reclassification As of December 31, 2017 Gross Buildings on non-freehold land — 11 — — 11 Scientific equipment 6,078 3,546 (49 ) — 9,576 Fittings 988 138 — — 1,126 Vehicles 82 61 (44 ) — 99 Computer equipment 1,475 211 (12 ) 281 1,954 Furniture 317 40 — — 357 In progress — 281 (281 ) — TOTAL - Gross 8,940 4,287 (105 ) — 13,123 Accumulated depreciation and impairment Scientific equipment (4,438 ) (673 ) 48 — (5,063 ) Fittings (657 ) (65 ) — — (722 ) Vehicles (29 ) (17 ) 22 — (24 ) Computer equipment (530 ) (184 ) 11 — (703 ) Furniture (276 ) (9 ) — — (285 ) In progress — — — — — TOTAL - Depreciation and impairment (5,930 ) (949 ) 81 — (6,798 ) TOTAL - Net 3,010 3,338 (24 ) — 6,324 8 . PROPERTY, PLANT AND EQUIPMENT (continued) Property, plant and equipment—Variations (in thousands of euros) As of January 1, 2018 Increase Decrease Reclassification As of December 31, 2018 Gross Buildings on non-freehold land 11 — — 1,447 1,458 Scientific equipment 9,576 1,484 (235 ) 54 10,879 Fittings 1,126 443 (43 ) 5 1,531 Vehicles 99 — — — 99 Computer equipment 1,954 200 (5 ) (702 ) 1,446 Furniture 357 8 (4 ) — 361 In progress — 805 — (804 ) — TOTAL - Gross 13,123 2,939 (288 ) — 15,774 Accumulated depreciation and impairment Buildings on non-freehold land — (1 ) — — (1 ) Scientific equipment (5,063 ) (1,142 ) 218 — (5,988 ) Fittings (722 ) (91 ) 43 — (769 ) Vehicles (24 ) (21 ) 0 — (45 ) Computer equipment (703 ) (216 ) 4 — (915 ) Furniture (285 ) (11 ) 4 — (292 ) In progress — — — — — TOTAL - Depreciation and impairment (6,798 ) (1,481 ) 270 — (8,010 ) TOTAL - Net 6,324 1,459 (18 ) — 7,764 8 . PROPERTY, PLANT AND EQUIPMENT (continued) Property, plant and equipment - Variations As of Translation As of (in € thousands) 2018/12/31 Increase Decrease adjustments Reclassification 2019/12/31 Gross Buildings on non-freehold land 1,458 12,218 — — (1,447 ) 12,229 Scientific equipment 10,879 556 (120 ) — (54 ) 11,260 Fittings 1,531 66 — — (5 ) 1,592 Vehicles 99 — — — — 99 Computer equipment 1,446 227 (15 ) — 11 1,669 Furniture 361 31 (3 ) — — 389 In progress 0 241 (1,737 ) — 1,496 — TOTAL - Gross 15,774 13,339 (1,875 ) — — 27,238 Accumulated depreciation and impairment Buildings on non-freehold land (1 ) (1,215 ) — — — (1,216 ) Scientific equipment (5,988 ) (1,303 ) 119 — — (7,172 ) Fittings (769 ) (105 ) — — — (875 ) Vehicles (45 ) (21 ) — — — (66 ) Computer equipment (915 ) (252 ) 12 — — (1,155 ) Furniture (292 ) (13 ) 3 — — (303 ) In progress — — — — — — TOTAL - Depreciation and impairment (8,010 ) (2,909 ) 133 — — (10,785 ) TOTAL - Net 7,764 10,429 (1,741 ) — — 16,453

Trade and Other Receivables (Ta

Trade and Other Receivables (Tables)	12 Months Ended
	Dec. 31, 2019
Trade And Other Receivables [Abstract]
Summary of Trade and Other Receivables	Trade and other receivables consisted of the following: Trade and other receivables - Total As of December 31, (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Trade receivables, net 61 25 207 Research tax credit 8,466 8,785 9,585 Social security costs receivables 3 10 5 VAT receivables 994 1,103 1,814 Grants receivables 13 (0 ) 3 Other receivables 340 361 420 TOTAL 9,876 10,284 12,033 Trade and other receivables - Current As of December 31, (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Trade receivables, net 61 25 207 Research tax credit 6,545 7,295 9,585 Social security costs receivables 3 10 5 VAT receivables 994 1,103 1,814 Grants receivables 13 (1 ) 3 Other receivables 340 361 420 TOTAL 7,955 8,794 12,033 Trade and other receivables - Non-current As of December 31, (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Trade receivables, net — — — Research tax credit 1,921 1,489 — Social security costs receivables — — — VAT receivables — — — Grants receivables — — — Other receivables — — — TOTAL 1,921 1,489 —

Other Financial Assets (Tables)

Other Financial Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Other Financial Assets [Abstract]
Summary of Other Financial Assets	Other financial assets consisted of the following: Financial assets - Total As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Financial investments — — — Loans 219 259 307 Loan related security deposit — — — Deposits and guarantees 274 284 396 Liquidity contract 267 770 1,023 TOTAL 760 1,313 1,727 Financial assets - Current As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Financial investments — — — Loans — — — Loan related security deposit 0 — — Deposits and guarantees 31 — — Liquidity contract — — — TOTAL 31 — — Financial assets - Non current As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Financial investments — — — Loans 219 259 307 Loan related security deposit (0 ) — (0 ) Deposits and guarantees 243 284 396 Liquidity contract 267 770 1,023 TOTAL 729 1,313 1,727

Loans and Borrowings (Tables)

Loans and Borrowings (Tables)	12 Months Ended
	Dec. 31, 2019
Borrowing Costs [Abstract]
Summary of Other Loans and Borrowings	Other loans and borrowings consisted of the following: Other loans and borrowings - Total As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Refundable and conditional advances 3,407 3,229 3,229 Bank loans 3,488 3,964 2,645 Development loans with participation feature — — Renewable credit facility — — — Obligations under leases 1,890 1,900 12,281 Accrued interests 3 3 1 Other financial loans and borrowings 24 7 7 Bank overdrafts — — — TOTAL 8,812 9,104 18,165 Other loans and borrowings - Current As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Refundable and conditional advances 178 — — Bank loans 1,209 1,319 1,105 Development loans with participation feature — — — Renewable credit facility — — — Obligations under leases 420 520 2,112 Accrued interests 3 3 1 Other financial loans and borrowings 24 7 7 Bank overdrafts — — — TOTAL 1,834 1,848 3,226 Other loans and borrowings - Non current As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Refundable and conditional advances 3,229 3,229 3,229 Bank loans 2,279 2,645 1,540 Development loans with participation feature — — — Renewable credit facility — — — Obligations under leases 1,469 1,381 10,169 Accrued interests — — — Other financial loans and borrowings — — — Bank overdrafts — — — TOTAL 6,978 7,255 14,939
Summary of Refundable and Conditional Advances	The following table summarizes advances outstanding at December 31, 2019, 2018 and 2017 Total Net book Refundable and conditional advances - general overview Grant amount Effects of value (in € thousands) date allocated Receipts Repayments discounting 12/31/2019 BPI FRANCE - IT-DIAB 12/23/2008 3,229 3,229 — — 3,229 Development of a global strategy for the prevention and management of type 2 diabetes TOTAL 3,229 Net book Total value as of Refundable and conditional advances—general overview amount Effects of December 31, (in thousands of euros) Grant date allocated Receipts Repayments discounting 2018 BPI FRANCE—IT-DIAB 12/23/2008 3,229 3,229 — — 3,229 Development of a global strategy for the prevention and management of type 2 diabetes TOTAL 3,229 12. LOANS AND BORROWINGS (continued) Net book Refundable and conditional Total value as of advances—general overview amount Effects of December 31, (in € thousands) Grant date allocated Receipts Repayments discounting 2017 BPI FRANCE—IT-DIAB 12/23/2008 3,229 3,229 — — 3,229 Development of a global strategy for the prevention and management of type 2 diabetes BPI FRANCE—ADVANCE N°1—OLNORME II—1 11/24/2010 250 200 (134 ) (2 ) 64 BPI FRANCE—ADVANCE N°2—OLNORME II—2 11/24/2010 250 200 (134 ) (2 ) 64 BPI FRANCE—ADVANCE N°3—OLNORME II—3 11/24/2010 200 160 (108 ) (2 ) 51 Research of pharmaceutical entities in plant extracts for the treatment of inflammatory diseases ​ ​ TOTAL 3,407
Summary of Bank Loans	Bank loans are primarily used to finance research and laboratory equipment. Bank loans consisted of the following as of December 31, 2017: Available Outstanding as of as of Bank loans Loan Facility Interest December 31, December 31, (in € thousands) date size rate 2017 Installments 2017 CIC 5 July 2017 1,000 0.69 % 500 60 monthly 451 CDN 4 June 2017 600 0.36 % — 48 monthly 525 BNP 4 April 2017 800 0.87 % 800 60 monthly — CIC 4 December 2016 264.6 0.69 % — 60 monthly 217 BNP 3 October 2016 1,050 0.80 % — 20 quarterly 945 NEUFLIZE 2 June 2016 500 1.10 % — 12 quarterly 252 BNP 2 June 2016 500 0.80 % — 20 quarterly 377 CDN 3 April 2016 500 0.72 % — 60 monthly 335 CIC 3 March 2015 500 0.85 % — 16 quarterly 158 BNP December 2014 500 2.00 % — 20 quarterly 205 Other 23 TOTAL 3,488 Bank loans consisted of the following as of December 31, 2018: Available Outstanding Bank loans Loan Facility Interest As of As of (in € thousands) date size rate 2018/12/31 Installments 2018/12/31 CDN 5 November 2018 500 0.46 % — 48 monthly 490 CIC 5 July 2017 1000 0.69 % 0 60 monthly 753 CDN 4 June 2017 600 0.36 % 0 48 monthly 376 BNP 4 April 2017 800 0.87 % 0 60 monthly 695 CIC 4 December 2016 265 0.69 % — 60 monthly 164 BNP 3 October 2016 1050 0.80 % 0 20 quarterly 735 NEUFLIZE 2 June 2016 500 1.10 % 0 12 quarterly 84 BNP 2 June 2016 500 0.80 % 0 20 quarterly 277 CDN 3 April 2016 500 0.72 % — 60 monthly 236 CIC 3 March 2015 500 0.85 % 0 16 quarterly 32 BNP December 2014 500 2.00 % 0 20 quarterly 103 Other 19 TOTAL 3,964 12. LOANS AND BORROWINGS (continued) Bank loans consisted of the following as of December 31, 2019: Available Outstanding Bank loans Loan Facility Interest As of As of (in € thousands) date size rate 2019/12/31 Installments 2019/12/31 CDN 5 November 2018 500 0.46 % — 48 monthly 365 CIC 5 July 2017 1000 0.69 % 0 60 monthly 554 CDN 4 June 2017 600 0.36 % 0 48 monthly 226 BNP 4 April 2017 800 0.87 % 0 60 monthly 537 CIC 4 December 2016 265 0.69 % — 60 monthly 111 BNP 3 October 2016 1050 0.80 % 0 20 quarterly 525 NEUFLIZE 2 June 2016 500 1.10 % 0 12 quarterly 0 BNP 2 June 2016 500 0.80 % 0 20 quarterly 177 CDN 3 April 2016 500 0.72 % — 60 monthly 135 CIC 3 March 2015 500 0.85 % 0 16 quarterly 0 BNP December 2014 500 2.00 % 0 20 quarterly 0 Other 14 TOTAL 2,645
Summary of Maturities of Financial Liabilities	Maturity of financial liabilities As of Less than Less than Less than Less than Less than More than (in € thousands) 2019/12/31 1 year 2 years 3 years 4 years 5 years 5 years BPI FRANCE - IT-DIAB 3,229 — — — — — 3,229 TOTAL - Refundable and conditional advances 3,229 — — — — — 3,229 Convertible loans 165,454 1,312 — 164,142 — — — Bank loans 2,645 1,105 942 544 54 — — Development loans with participation feature — — — — — — — Renewable credit facility — — — — — — — Leases 12,281 2,112 2,118 1,575 1,151 1,103 4,223 Accrued interests 1 1 — — — — — Other financial loans and borrowings 7 7 — — — — — Bank overdrafts — — — — — — — TOTAL - Other loans and borrowings 180,390 4,539 3,060 166,260 1,205 1,103 4,223 TOTAL 183,619 4,539 3,060 166,260 1,205 1,103 7,452 The convertible bond results in the payment of yearly interest of €6,300 and a reimbursement at par in October 2022. The nominal amount of the convertible loan of €180 million is due in less than 3 years.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Financial Instruments [Abstract]
Summary of Financial Assets And Liabilities Carrying Values By Category And Fair Values	The following tables provide the financial assets and liabilities carrying values by category and fair values as of December 31, 2017, 2018 and 2019: As of December 31, 2017 Carrying value Fair value (in thousands of euros) As per statement of financial position Assets at fair value through profit & loss Loans & receivables Debt at amortized cost Level 1 Level 2 Level 3 Assets Loans 219 — 219 — — 219 — Deposits and guarantees 274 — 274 — — 274 — Trade receivables 61 — 61 — — 61 — Cash and cash equivalents 273,820 273,820 — — 273,820 — — TOTAL—Assets 274,375 273,820 555 — 273,820 555 — Liabilities Conditional advances 3,407 — — 3,407 — — 3,407 Convertible loans 155,868 — — 155,868 — 155,868 — Bank loans 3,488 — — 3,488 — 3,488 — Obligations under finance leases 1,890 — — 1,890 — 1,890 — Accrued interests 3 — — 3 — 3 — Other financial loans and borrowings 24 — — 24 — 24 — Trade payables 19,053 — — 19,053 — 19,053 — Other payables 34 — — 34 — 34 — TOTAL—Liabilities 183,766 — — 183,766 — 180,359 3,407 13. FAIR VALUE OF FINANCIAL INSTRUMENTS (continued) As of December 31, 2018 Carrying value Fair value As per Assets at statement of fair value financial through Loans and Debt at (in € thousands) position profit and loss receivables amortized cost Level 1 Level 2 Level 3 Assets Financial investments — — — Loans 259 259 259 Loan related security deposit — — — Deposits and guarantees 284 284 284 Trade receivables 25 25 25 Cash and cash equivalents 207,240 207,240 207,240 TOTAL - Assets 207,808 207,240 568 — 207,240 568 — Liabilities — Conditional advances 3,229 3,229 3,229 Convertible loans 160,489 160,489 160,489 Bank loans 3,964 3,964 3,964 Participating development loan — — — Renewable credit facility — — — Obligations under finance leases 1,900 1,900 1,900 Accrued interests 3 3 3 Other financial loans and borrowings 7 7 7 Bank overdrafts — — — Trade payables 32,649 32,649 32,649 Other payables 71 71 71 TOTAL - Liabilities 202,313 — — 202,313 — 199,084 3,229 13. FAIR VALUE OF FINANCIAL INSTRUMENTS (Continued) As of December 31, 2019 Carrying value Fair value As per Assets at statement of fair value financial through Loans and Debt at (in € thousands) position profit and loss receivables amortized cost Level 1 Level 2 Level 3 Assets Financial investments — — — Loans 307 307 307 Loan related security deposit — — — Deposits and guarantees 396 396 396 Trade receivables 207 207 207 Cash and cash equivalents 276,748 276,748 276,748 TOTAL - Assets 277,658 276,748 911 — 276,748 911 — Liabilities — Conditional advances 3,229 3,229 3,229 Convertible loans 165,454 165,454 165,454 Bank loans 2,645 2,645 2,645 Participating development loan — — — Renewable credit facility — — — Obligations under finance leases 12,281 12,281 12,281 Accrued interests 1 1 1 Other financial loans and borrowings 7 7 7 Bank overdrafts — — — Trade payables 32,753 32,753 32,753 Other payables 527 527 527 TOTAL - Liabilities 216,898 — — 216,898 — 213,669 3,229

Trade and Other Payables (Table

Trade and Other Payables (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Trade And Other Payables [Abstract]
Schedule of Trade and Other Payables	Trade and other payables consisted of the following: Trade and other payables - Total As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Trade payables 19,053 32,649 32,753 Social security costs payables 4,217 2,949 3,581 Employee profit sharing 17 17 17 VAT payables 19 1 2 Taxes payables 241 286 487 Other payables 34 71 527 TOTAL 23,580 35,974 37,368 Trade and other payables - Current As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Trade payables 19,053 32,649 32,753 Social security costs payables 4,217 2,949 3,581 Employee profit sharing 17 17 17 VAT payables 19 1 2 Taxes payables 241 286 487 Other payables 34 71 76 TOTAL 23,580 35,974 36,917 Trade and other payables - Non current As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Trade payables — — — Social security costs payables — — — Employee profit sharing — — — VAT payables — — — Taxes payables — — — Other payables — −− 450 TOTAL — 450

Employee Benefits (Tables)

Employee Benefits (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Information About Defined Benefit Plans [Abstract]
Summary of Assumptions Used for Employees for the Measurement of Retirement Indemnity to Employees	As part of the measurement of the retirement indemnity to employees, the following assumptions were used for all categories of employees: Population Permanent staff Retirement age 65 Terms of retirement Initiated by the employee Life expectancy On the basis of the INSEE table Probability of continued presence in the company at retirement age On the basis of the DARES table (1) INSEE is the French National Institute of Statistics; DARES is the French Bureau of Studies and Statistics Rate As of (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Salary growth rate - in 2020 5.8% 5.80 % 5.80 % Salary growth rate - beyond 3.0% 3.00 % 3.00 % Discount rate 1.5% 1.53 % 0.75 %
Summary of Changes in Present Value of Defined Benefit Obligation	The following table presents the changes in the present value of the defined benefit obligation: Changes in the present value of the defined benefit obligation (in € thousands) Defined benefit obligation as of January 1, 2017 849 Current service cost 76 Interest cost on benefit obligation 13 Actuarial losses on obligation 210 Past service costs (211 ) Defined benefit obligation as of December 31, 2017 936 Current service cost 104 Interest cost on benefit obligation 14 Actuarial losses on obligation 31 Past service costs — Defined benefit obligation as of December 31, 2018 1,085 Current service cost 138 Interest cost on benefit obligation 17 Actuarial losses / (gains) on obligation 168 Past service costs — Defined benefit obligation as of December 31, 2019 1,408
Summary of Sensitivity of the Retirement and Post-Employment Benefits to a Variation of the Discount Rate	Retirement and post-employment benefits in thousands of euros Changes in assumptions/discount rate Impact/present value of the undertaking +0.25% -51 -0.25% 53

Other Income (Tables)

Other Income (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Other Income [Abstract]
Schedule of Other Income	Other income consisted of the following: Other income Year ended (in € thousands) 2017/12/31 2018/12/31 2019/12/31 CIR tax credit 6,545 7,295 8,125 Other operating income (including CICE tax credit )- 171 130 1,992 Government grants and subsidies 21 — 5 TOTAL 6,737 7,425 10,122

Operating Expense (Tables)

Operating Expense (Tables)	12 Months Ended
	Dec. 31, 2019
Operating Expense [Abstract]
Summary of Operating Expenses and Other Operating Income	Contracted research & Gain / Operating expenses and other operating Raw development activities Other expenses Depreciation, (loss) on disposal of income (expenses) (in thousands of Year ended materials& consumables conducted by third Employee (maintenance, fees, travel, amortization & impairment plant & property, euros) 2017/12/31 used parties expenses taxes) charges equipment Research and development expenses (54,189 ) (2,117 ) (35,088 ) (7,915 ) (7,973 ) (1,095 ) — General and administrative expenses (9,421 ) (112 ) (7 ) (5,491 ) (3,374 ) (437 ) — Other operating income (expenses) 60 — — — 68 — (8 ) TOTAL (63,550 ) (2,229 ) (35,095 ) (13,406 ) (11,280 ) (1,532 ) (8 ) Of which: Contracted Gain / Raw research and Other Depreciation, (loss) on materials development expenses amortization disposal of and activities (maintenance, and property, Operating expenses and other operating income (expenses) Year ended consumables conducted by Employee fees, travel, impairment plant and (in € thousands) 2018/12/31 used third parties expenses taxes…) charges equipment Research and development expenses (67,024 ) (1,724 ) (47,659 ) (9,431 ) (6,502 ) (1,707 ) — General and administrative expenses (9,076 ) (126 ) (2 ) (3,778 ) (5,451 ) 283 — Marketing and market access expenses (717 ) (4 ) — (416 ) (287 ) (11 ) — Other operating income and (expenses) (162 ) — — — (164 ) — 2 TOTAL (76,979 ) (1,855 ) (47,662 ) (13,625 ) (12,403 ) (1,435 ) 2 Of which: Contracted Gain / Raw research and Other Depreciation, (loss) on materials development expenses amortization disposal of and activities (maintenance, and property, Operating expenses and other operating income (expenses) Year ended consumables conducted by Employee fees, travel, impairment plant and (in € thousands) 2019/12/31 used third parties expenses taxes…) charges equipment Research and development expenses (66,170 ) (2,017 ) (41,509 ) (11,740 ) (6,188 ) (4,716 ) — General and administrative expenses (17,265 ) (177 ) (59 ) (7,598 ) (8,972 ) (458 ) — Marketing and market access expenses (13,708 ) (8 ) (0 ) (1,645 ) (11,979 ) (76 ) — Other operating income (expenses) (1,649 ) — — — (1,668 ) — 19 TOTAL (98,793 ) (2,202 ) (41,568 ) (20,984 ) (28,807 ) (5,251 ) 19
Summary of Employee Expenses and Number of Employees	Employee expenses and number of employees were as follows: Employee expenses Year ended (in € thousands) 2017/12/31 2018/12/31 2019/12/31 Wages and salaries (9,267 ) (9,012 ) (14,018 ) Social security costs (3,996 ) (3,722 ) (5,171 ) Changes in pension provision 135 (104 ) (138 ) Individual training entitlement — — — Share-based compensation (278 ) (787 ) (1,657 ) TOTAL (13,406 ) (13,625 ) (20,984 ) Year ended Number of employees at year-end - detail 2017/12/31 2018/12/31 2019/12/31 Average number of employees 123 135 175 Average age of employees 38 years 4 months 38 years 11 months 37 years 1 month Number of employees Research and development 77 84 108 Services related to research and development 15 16 19 Administration and management 33 48 60 Marketing and commercial — — 7 TOTAL 125 148 194 Number of employees Senior staff 92 115 144 Staff 29 30 45 Others (apprentices) 4 3 5 TOTAL 125 148 194 Number of employees Male 45 57 78 Female 80 91 116 TOTAL 125 148 194

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Summary of Share-based Compensation Under Each Plan According to Change in Estimate	The table below shows the share-based compensation under each plan according to the change in estimate mentioned above . Year ended Total expense Total expense Share-based compensation - Annual expense 2017/12/31 2018/12/31 2019/12/31 calculated remaining BSA 2014-A — — — 945 — Of which : expense related to non-executive officers — — — 365 — Of which : expense related to consultants — — — 581 — BSA 2014-B — — — 1,045 — Of which : expense related to non-executive officers — — — 365 — Of which : expense related to consultants — — — 680 — BSAAR 2014-A — — — 43 — Of which : expense related to non-executive officers — — — 9 — Of which : expense related to consultants — — — 34 — BSAAR 2014-B — — — 191 0 Of which : expense related to non-executive officers — — — 35 0 Of which : expense related to consultants — — — 156 — BSAAR 2014-C — — — 189 0 Of which : expense related to non-executive officers — — — 35 — Of which : expense related to consultants — — — 154 0 Year ended Total expense Total expense Share-based compensation - Annual expense 2017/12/31 2018/12/31 2019/12/31 calculated remaining BSA 2015-A — — — 335 — Of which : expense related to non-executive officers — — — 178 — Of which : expense related to consultants — — — 157 — BSA 2015-B — — — 315 — Of which : expense related to non-executive officers — — — 178 — Of which : expense related to consultants — — — 138 — Year ended Total expense Total expense Share-based compensation - Annual expense 2017/12/31 2018/12/31 2019/12/31 calculated remaining BSAAR 2016-A — — — — — Of which : expense related to executive officers — — — — — Of which : expense related to employees — — — — — BSAAR 2016-B — — — — — Of which : expense related to executive officers — — — — — Of which : expense related to employees — — — — — AGA D 2016-1 38 127 — 166 0 Of which : expense related to executive officers 7 25 — 32 0 Of which : expense related to employees 31 101 — 133 0 AGA D 2016-2 17 17 39 74 — Of which : expense related to executive officers 3 3 8 14 — Of which : expense related to employees 14 14 31 59 — AGA S 2016-1 44 151 — 197 — Of which : expense related to executive officers — — — — — Of which : expense related to employees 44 151 — 197 — AGA S 2016-2 22 22 44 88 — Of which : expense related to executive officers — — — — — Of which : expense related to employees 22 22 44 88 — SO 2016-1 83 83 213 383 — Of which : expense related to executive officers 13 13 36 63 — Of which : expense related to employees 70 70 176 319 — SO 2016-2 38 38 93 170 — Of which : expense related to executive officers 6 6 16 28 — Of which : expense related to employees 32 32 77 142 — SO US 2016-1 12 12 (24 ) — — Of which : expense related to executive officers — — — — — Of which : expense related to employees 12 12 (24 ) — — SO US 2016-2 5 5 (11 ) — — Of which : expense related to executive officers — — — — — Of which : expense related to employees 5 5 (11 ) — — Year ended Total expense Total expense Share-based compensation - Annual expense 2017/12/31 2018/12/31 2019/12/31 calculated remaining BSA 2017-A 6 63 — 69 — Of which : expense related to non-executive officers 4 43 — 47 — Of which : expense related to employees 2 20 — 22 — BSA 2017-B 3 66 — 70 0 Of which : expense related to non-executive officers 2 46 — 48 0 Of which : expense related to employees 1 21 — 22 0 AGA D 2017-1 1 17 199 217 — Of which : expense related to executive officers 0 2 28 30 — Of which : expense related to employees 1 15 171 187 — AGA D 2017-2 2 29 56 131 44 Of which : expense related to executive officers 0 3 8 18 6 Of which : expense related to employees 2 26 48 113 37 AGA S 2017-1 — — 209 209 — Of which : expense related to executive officers — — — — — Of which : expense related to employees — — 209 209 — AGA S 2017-2 2 24 45 104 34 Of which : expense related to executive officers — — — — — Of which : expense related to employees 2 24 45 104 34 SO 2017-1 2 28 27 61 4 Of which : expense related to executive officers 0 5 5 11 1 Of which : expense related to employees 2 23 22 50 4 SO 2017-2 3 48 2 81 28 Of which : expense related to executive officers 1 8 0 15 5 Of which : expense related to employees 3 39 2 66 23 SO US 2017-1 0 3 (4 ) — 0 Of which : expense related to executive officers — — — — — Of which : expense related to employees 0 3 (4 ) — 0 SO US 2017-2 0 5 (6 ) — 0 Of which : expense related to executive officers — — — — — Of which : expense related to employees 0 5 (6 ) — 0 Year ended Total expense Total expense Share-based compensation - Annual expense 2017/12/31 2018/12/31 2019/12/31 calculated remaining AGA D 2018 — 10 135 277 132 Of which : expense related to executive officers — 2 21 43 21 Of which : expense related to employees — 9 114 234 111 AGA S 2018 — 12 148 305 145 Of which : expense related to executive officers — — — — — Of which : expense related to employees — 12 148 305 145 SO 2018 — 24 285 849 539 Of which : expense related to executive officers — 3 40 118 75 Of which : expense related to employees — 21 245 730 464 SO US 2018 — 3 25 76 48 Of which : expense related to executive officers — — — — — Of which : expense related to employees — 3 25 76 48 Year ended Total expense Total expense Share-based compensation - Annual expense 2017/12/31 2018/12/31 2019/12/31 calculated remaining BSA 2019 — — 7 26 20 Of which : expense related to executive officers — — — — — Of which : expense related to employees — — 7 26 20 AGA D 2019 — — 35 242 207 Of which : expense related to executive officers — — 5 38 33 Of which : expense related to employees — — 29 204 175 AGA S 2019 — — 41 288 246 Of which : expense related to executive officers — — — — — Of which : expense related to employees — — 41 288 246 SO 2019 — — 86 599 513 Of which : expense related to executive officers — — 10 68 58 Of which : expense related to employees — — 76 531 455 SO US 2019 — — 1 43 42 Of which : expense related to executive officers — — — — — Of which : expense related to employees — — 1 43 42 Year ended Total expense Total expense Share-based compensation - Annual expense 2017/12/31 2018/12/31 2019/12/31 calculated remaining TOTAL 278 787 1,645 7,787 2,004
Share Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Summary of Key Terms and Conditions of Share-Based Compensation Based	The key terms and conditions related to each program are detailed in the following tables: Share-base compensation 2019 2017 2015 2014 Share warrants ( BSA ) BSA 2017-A BSA 2017-B BSA 2015-A BSA 2015-B BSA 2014-A BSA 2014-B Date of the Shareholders meeting 06/15/2018 06/16/2017 04/02/2014 04/02/2014 Date of the Management Board meeting 01/09/2015 07/24/2014 Date of the decision and delegation of the Board of Directors to the CEO 10/18/2019 11/21/2017 Date of the CEO decision 10/31/2019 12/06/2017 Beneficiaries Consultants Consultants and officers Consultants and officers Consultants and officers Total number of BSAAR subscribed 35,070 18,345 18,345 12,860 12,860 46,765 46,765 Total number of BSAAR voided 0 0 0 12,860 12,860 46,765 46,765 Total number of BSAAR remaining 35,070 18,345 18,345 0 0 0 0 Issue Price €1.23 €2.00 €0.01 €0.01 Excercise price €12.32 €19.97 €35.95 €23.50 Estimated fair value - according to IFRS 2 €0.75 €3.78 €3.81 €25.33 /€26.89 €25.33 /€26.31 €15.61 /€24.84 €15.61 /€24.85 End of exercise period 05/31/2024 06/30/2022 07/15/2022 05/31/2019 11/30/2019 09/30/2018 02/28/2019 Valuation method used Black & Scholes Expected dividends 0% 0% 0% 0% Expected volatility 40.0% 36.4% 35.7% 74.9% 74.9% Risk-free interest rate 0% 0.0% 0.4% 0.4% Expected life 0.7 years 6 years 4 years 4 years
Redeemable Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Summary of Key Terms and Conditions of Share-Based Compensation Based	Share-Based compensation 2 016 2 014 Redeemable share subscription warrants ( BSAAR ) BSAAR 2016-A and B BSAAR 2014-A - B and C Employees Employees and Officers Date of the Shareholders' meeting 02/24/2015 04/02/2014 Date of the Management Board Meeting 07/22/2016 09/16/2014 Date of the decision and delegation of the Board of Directors to the CEO Date of the CEO decision Total number of BSAAR subscribed 10,800 62,717 Total number of BSAAR voided 0 61,484 Total number of BSAAR exercised 0 1,233 Total number of BSAAR remaining 10,800 0 Issue Price €23.5 €23.5 Exercise period From 01/01/2018 to 27/07/2020 voided on 09.2018 - 05.2019 and 07.2019 Estimated fair value - valued by expert opinion €4.60 from €8.44 to €11.29 Valuation method used Black & Scholes Black & Scholes Expected dividends 0% 0% Expected volatility 75.4% 75.4% Risk-free interest rate 0.0% 0.4% Expected life 4 years 4 years
Free Shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Summary of Key Terms and Conditions of Share-Based Compensation Based	The key terms and conditions related to each program are detailed in the following tables: Share-based compensation 2 019 2 019 2 018 2 017 2 016 Free shares (AGA) AGA D AGA S Officers(1) Employees Officers(1) Employees AGA D and S AGA D and S 2017-1 and 2017-2 AGA D and S 2016-1 and 2016-2 Date of the Shareholders meeting 06/15/2018 06/15/2018 06/16/2017 06/21/2016 Date of the Management Board meeting 12/15/2016 Date of the decision and delegation of the Board of Directors to the CEO 07/18/2019 11/07/2018 11/22/2017 Date of the Executive Board Meeting 07/18/2019 11/22/2018 12/06/2017 Total number of AGA subscribed 3,000 16,070 0 17,556 35,800 41,196 30,709 Total number of AGA voided 0 450 0 702 1,872 9,846 5,429 Total number of AGA definitively vested 0 0 0 0 0 19,403 25,280 Total number of AGA remaining 3,000 15,620 0 16,854 33,928 11,947 0 Acquisition period From 07/18/2019 to 09/16/2022 From 11/22/2018 to 12/31/2020 From 12/06/2017 to 12/31/2020 From 12/15/2016 to 12/15/2019 Valuation method used Monte Carlo Price of the share at the time of allocation €17.06 € 20.02 € 21.95 € 20.78 Expected dividends 0% 0% 0% 0% Expected volatility 40.16% 38.0% 53.7% 63.0% Risk-free interest rate 0.0% 0.0% 0.0% 0.0% Turnover rate 0.00% 15.00% 15.00% 15.00% (1) : Chairman and CEO The terms and conditions of the 2016 to 2018 allocations to the Chairman and CEO are provided in the Universal Registration Document or the financial statements for the relevant periods. (1) : Chief executive officer
Stock Options
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Summary of Key Terms and Conditions of Share-Based Compensation Based	The key terms and conditions related to each program are detailed in the following tables: Share-based compensation 2 019 2 018 2 017 2 016 Stock-options (SO) SO SO US 1 SO US 2 SO 2018 SO US 2018 SO 1 et 2 2017 SO US 2017 SO 1 et 2 2016 SO US 2016 Officers(1) Employees Employees Employees Employees and Offices Employees Employees and Offices Employees Employees and Offices Employees Date of the Shareholders meeting 06/15/2018 11/27/2019 06/15/2018 06/16/2017 06/21/2016 Date of the Management Board meeting 12/15/2016 Date of the decision and delegation of the Board of Directors to the CEO 07/18/2019 11/27/2019 11/07/2018 11/21/2017 Date of the CEO decision 07/18/2019 11/27/2019 11/07/2018 12/06/2017 Total number of SO subscribed 15,130 92,750 30,620 13,350 122,000 17,500 96,250 13,000 62,875 10,500 Total number of SO voided 0 1,780 0 0 2,000 3,000 21,577 13,000 13,169 10,500 Total number of SO definitively vested 0 0 0 0 0 0 0 0 49,706 0 Total number of SO remaining 15,130 90,970 30,620 13,350 120,000 14,500 74,673 0 0 0 Excercise price €13.99 €16.9 €14.31 €16.00 €21.65 €17.91 €22.54 €15.79 €21.12 Vesting period From 07/18/2019 to 09/16/2022 From 11/27/2019 to 01/16/2023 From 11/07/2018 to 12/31/2021 From 12/06/2017 to 12/31/2020 From 12/15/2016 to 12/15/2019 Exercise period From 09/17/2022 to 09/17/2029 From 01/17/2023 to 01/17/2030 From 01/01/2022 to 12/31/2028 From 01/01/2021to 12/31/2027 From 12/16/2019 to 12/16/2026 Fair value €4.59 €3.67 €3.23 €9.32 €6.9 €9.32 €10.3 €8.52 Valuation method used Monte Carlo Price of the share at the time of allocation €17.06 €14.5 €22.12 €21.95 €20.79 Expected dividends 0% 0% 0% 0% 0% Expected volatility 40.16% 40.0% 44.07% 53.7% 63.0% Risk-free interest rate 0.0% 0.0% 0.0% 0.0% 0.0% Turnover rate 0.00% 0.00% 15.00% 15.00% 15.00%
Performance Conditions
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Summary of Key Terms and Conditions of Share-Based Compensation Based	The SO and SO US stock option plans as well as certain free share plans (AGA "D") implemented in 2016, 2017, 2018 and 2019 are subject to internal performance conditions related to the progress of the Group's research and development programs, and to external performance conditions related to the evolution of the Company's stock price. The other free share plans (AGA "S") are subject only to internal performance conditions. 20 .5.1. Performance conditions of the 2019 plans Plans Evaluation date for performance conditions Nature of internal conditions SO 2019 SO US 2019 AGA D 2019 07/31/2022 66 2/3% of the instruments will be exercisable or definitively vested, and 100% of the free shares for the AGA S 2019 will be vested, regardless of the variation of the stock market price of the Company’s shares, if at least one of the three following conditions is fulfilled: (i) if a marketing authorization is granted or an application for marketing authorization is examined: • by the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA) for elafibranor for NASH; or: • by the U.S. Food and Drug Administration (FDA)/the competent European authorities in the field of IVD for NIS4 for NASH; or: (ii) if at least two of the four clinical trial among the following trials have delivered their principal results or are ongoing: • Phase III clinical trials for elafibranor for PBC; or • clinical trial evaluating elafibranor’s efficacy in NASH pediatric patients; or • Phase IIb clinical trial or clinical trial aimed at registration for NTZ in fibrosis; or • Clinical trial evaluating elafibranor or NTZ in combination therapy for NASH or for hepatic fibrosis; or: (iii) if at least a new licensing agreement, on one or another of Genfit’s products in one or several territories, is entered into by the Company. Nature of external conditions 33 1/3 % of the instruments will be exercisable or definitively vested, in proportion to the variation of the Company’s stock market price as per the following breakdown: (i) if the Final Price is strictly lower than the Initial Price, the number of the Stock Options exercisable is equal to 0; (ii) if the Final Price is between (i) a value equal to or higher than the Initial Price and (ii) a value lower than the Ceiling Price, the number of Stock Options exercisable is equal to: [(Final Price / Initial Price)-1]/2 x 1/3 of number of Stock Options; (iii) if the Final Price is equal to or higher than the Ceiling Price, the number of Stock Options exercisable is equal to the entire one-third of the Stock Options allocated SO US 2019-2 01/09/2023 Nature of internal conditions 66 2/3 % of the instruments will be exercisable if at least if at least one of the three following conditions is fulfilled: (i) if elafibranor has been granted marketing authorization by the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA) in NASH or PBC or NIS4 has been authorized by FDA or received CE marking from the EMA; (ii) a licensing agreement pertaining to elafibranor or NTZ has been signed for the U.S. market and/or for at least two of the five major European markets (Germany, France, Italy, United Kingdom, Spain) and/or Japan; (iii) at least two clinical trials for drug registration are underway. Nature of external conditions 33 1/3 % of the instruments will be exercisable, in proportion to the variation of the Company’s stock market price as per the following breakdown: (i) if the Final Price is strictly lower than the Initial Price, the number of the Stock Options exercisable is equal to 0; (ii) if the Final Price is between (i) a value equal to or higher than the Initial Price and (ii) a value lower than the Ceiling Price, the number of Stock Options exercisable is equal to: [(Final Price / Initial Price)-1]/2 x 1/3 of number of Stock Options; (iii) if the Final Price is equal to or higher than the Ceiling Price, the number of Stock Options exercisable is equal to the entire one-third of the Stock Options allocated. Nature of internal conditions AGA S 2019 07/31/2022 The free shares will definitively vest upon the same internal performance conditions as the SO 2019, SO US 2019 and AGA D 2019 plans

Financial Income and Expenses (

Financial Income and Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Financial Income And Expenses [Abstract]
Summary of Financial Income and Expenses	Financial income and expenses Year ended (in € thousands) 2017/12/31 2018/12/31 2019/12/31 (*) (*) Financial income Interest income 389 202 2,626 Foreign exchange gain 59 101 2,272 Other financial income 195 425 324 TOTAL - Financial income 642 728 5,221 Financial expenses Interest expenses (2,309 ) (10,955 ) (11,289 ) Interest expenses for leases (10 ) (21 ) (148 ) Foreign exchange losses (764 ) (127 ) (1,657 ) Other financial expenses (13 ) (14 ) (17 ) TOTAL - Financial expenses (3,096 ) (11,118 ) (13,110 ) FINANCIAL GAIN (LOSS) (2,453 ) (10,391 ) (7,889 )

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Summary of Earnings (Loss) Per Share	The components of the earnings (loss) per share computation are as follows: Basic loss per share is equal to diluted loss per share. Year ended 2017 2018/12/31 2019/12/31 Earnings per share (*) (*) Profit (loss) for the period (in € thousands) (55,728 ) (79,521 ) (65,144 ) Weighted average number of ordinary shares for the period 31,166,437 31,167,203 36,987,982 Profit (loss) per share (in €) (1.79 ) (2.55 ) (1.76 ) Weighted average number of ordinary shares used in the above calculation 31,166,437 31,167,203 36,987,982

Compensation of Corporate Off_2

Compensation of Corporate Officers (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Compensation Of Corporate Officers [Abstract]
Summary of Compensation Paid to Officers	As a result, the table below provides details of the compensation paid to the Chairman and CEO, as well as that paid to the members of the Executive Board during the first half of 2017 (prior to the change in mode of governance) and for the financial years in which the relevant amounts were recognized in the statements of operations. Compensation paid to the Chairman and Chief Executive Officer Year ended in 2017 and 2018 and during the period from January 1, 2019 to September 16, 2019 2017/12/31 2018/12/31 2019/12/31 (1) Short-term employee benefits (gross + employer's social contributions, paid) 1,476 1,569 1,338 Post-employment pension & medical benefits 199 — — Attendance fees — — Share-based payment transactions 51 104 109 Director fees Genfit Corp (net) 37 30 22 TOTAL 1,763 1,703 1,469 Compensation paid to the Chief Executive Officer Year ended in 2018 and during the period from September 16, 2019 to December 31, 2019 2017/12/31 2018/12/31 2019/12/31 Short-term employee benefits (gross + employer's social contributions, paid) — — 140 Post-employment pension & medical benefits — — — Attendance fees — — — Share-based payment transactions — — — Director fees Genfit Corp (net) — — — TOTAL — — 140
Schedule of Director's Fees and Other Compensation Due and Paid to Non Executive Directors	26. COMPENSATION OF CORPORATE OFFICERS (continued) The directors' fees and other compensation due and paid to the non executive directors are as follows: Amounts due* Amounts paid* Amounts due* Amounts paid* Amounts due* Amounts paid* During the year ended December 31, Attendance fees and other forms of remuneration payable to each of the non executive officer (in euros) 2017(4) 2018 2019 Jean-François MOUNEY(1) Attendance fees — — — — 14,791 633 Other remuneration (except his compensation as CEO between January 1, and September 16, 2019)(5) — — — — 88,874 88,874 Total — — — — 103,665 89,507 Xavier GUILLE DES BUTTES Attendance fees 30,218 24,688 53,330 41,311 68,016 67,580 Other remuneration — — — — — — Total 30,218 24,688 53,330 41,311 68,016 67,580 Charles WOLER(2) Attendance fees 5,925 5,925 — — — — Other remuneration — — — — — — Total 5,925 5,925 — — — — Frédéric DESDOUITS Attendance fees 13,627 11,258 21,174 17,113 33,136 30,302 Other remuneration — — — — — — Total 13,627 11,258 21,174 17,113 33,136 30,302 BIOTECH AVENIR Represented by Florence Séjourné Attendance fees — — — — — — Other remuneration — — — — — — Total — — — — — — Philippe MOONS Attendance fees 18,763 14,023 29,704 22,345 36,188 41,202 Other remuneration — — — — — — Total 18,763 14,023 29,704 22,345 36,188 41,202 Anne-Hélène MONSELLATO(3) Attendance fees 14,813 10,468 37,075 24,307 44,472 53,410 Other remuneration — — — — — — Total 14,813 10,468 37,075 24,307 44,472 53,410 Catherine LARUE(3) Attendance fees 11,258 8,098 21,256 17,985 33,136 28,122 Other remuneration — — — — — — Total 11,258 8,098 21,256 17,985 33,136 28,122 TOTAL 94,602 74,458 162,539 123,061 318,613 310,123 26. COMPENSATION OF CORPORATE OFFICERS (continued) 2017(4) 2018 2018 IFRS 2 valuation of share warrants granted during the financial year 94,875 — — * After applying a required 21% withholding (1) Jean-François MOUNEY joined the Board of Directors on June 16, 2017 as Chairman. (2) Since the Shareholders' Meeting on June 16, 2017, Charles WOLER is no longer a board member. (3) Anne-Hélène MONSELLATO and Catherine LARUE were appointed to the Board of Directors by the shareholders at the June 16, 2017 Shareholders' Meeting. (4) The remuneration received by Xavier GUILLE DES BUTTES, Frédéric DESDOUITS, Biotech Avenir and Philippe MOONS until June 16, 2017 was in their capacities as members of the Supervisory Board. (5) The attendance fees and other remuneration for Jean-François Mouney above correspond to amounts due for the period from September 16, 2019 to December 31, 2019.

Major Events in the Period - Ad

Major Events in the Period - Additional Information (Details)	Jul. 03, 2019USD ($)	Mar. 29, 2019EUR (€)€ / sharesshares	Mar. 29, 2019USD ($)$ / sharesshares	May 31, 2018	Dec. 31, 2019EUR (€)	Dec. 31, 2019EUR (€)	Dec. 31, 2019USD ($)EUR (€)	Dec. 31, 2018EUR (€)	Dec. 31, 2019EUR (€)	Mar. 26, 2019USD ($)	Dec. 31, 2017EUR (€)
Disclosure Of Major Events In Period [Line Items]
exchange rate					0.89015	0.89015	0.89015	0.87336	0.89015	0.88566	0.83382
Total expenses related to share issuance | €					€ 12,354,000			€ 1,200,000	€ 12,300,000
Upfront payment received | $	$ 35,000,000						$ 35,000,000
Clinical, regulatory and commercial milestone payments | $							$ 193,000,000
Lessee operating lease term of contract						9 years	9 years
Lessee operating lease renewal term				10 years
Construction Costs | €						€ 2,500,000
American Depositary Shares
Disclosure Of Major Events In Period [Line Items]
Public offering price per share | $ / shares			$ 20.32
American Depositary Shares | Global Offering
Disclosure Of Major Events In Period [Line Items]
Number of shares issued		997,500	997,500
Aggregate proceeds before deducting underwriting discounts commissions and offering expenses		€ 137,600,000	$ 155,400,000
American Depositary Shares | Ordinary Shares
Disclosure Of Major Events In Period [Line Items]
Number of shares issued		7,147,500	7,147,500
European Private Placement | Ordinary Shares
Disclosure Of Major Events In Period [Line Items]
Number of shares issued		500,000	500,000
Public offering price per share | € / shares		€ 18

Major Events in the Period - Sc

Major Events in the Period - Schedule of Expenses Incurred and Deducted from Issue Premium by Break Down (Details) - EUR (€) € in Thousands	9 Months Ended	12 Months Ended	24 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019
Disclosure Of Major Events In Period [Abstract]
Registration, filling, listing fees	€ (290)
Underwriting	(9,634)
Legal fees and expenses	(1,225)
Accounting fees and expenses	(1,045)
Printing expenses	(160)
TOTAL	€ (12,354)	€ (1,200)	€ (12,300)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Summary of Applicable Exchange Rates Used to Translate Financial Statements (Details)	12 Months Ended
	Dec. 31, 2019EUR (€)	Dec. 31, 2019EUR (€)USD ($)	Dec. 31, 2018EUR (€)	Dec. 31, 2018EUR (€)USD ($)	Dec. 31, 2017EUR (€)	Dec. 31, 2017EUR (€)USD ($)	Mar. 26, 2019USD ($)
Foreign Exchange Rates [Abstract]
Exchange rate at period end	0.89015	0.89015	0.87336	0.87336	0.83382	0.83382	0.88566
Average exchange rate for the period	0.89341	11,234	0.84758	1,145	0.88704	11,993

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Additional Information (Details) € in Thousands, $ in Millions	Jul. 03, 2019USD ($)	Dec. 31, 2019USD ($)Segment	Jan. 01, 2019EUR (€)	Dec. 31, 2018EUR (€)
Disclosure Of Voluntary Change In Accounting Policy [Line Items]
Non-refundable upfront payment		$ 35
Clinical, regulatory and commercial milestone payments		193
Upfront payment received	$ 35	35
Revenue from upfront upfront payment		34.9
Deferred upfront payment		$ 0.1
Weighted average incremental borrowing rate		1.26%
Right of use assets | €			€ 9,227
Right of use lease liabilities | €			€ 8,947	€ 4,791
Number of segment | Segment		1
Software and License Agreements | Bottom of Range
Disclosure Of Voluntary Change In Accounting Policy [Line Items]
Estimated useful lives of software and license agreements		1 year
Software and License Agreements | Top of Range
Disclosure Of Voluntary Change In Accounting Policy [Line Items]
Estimated useful lives of software and license agreements		8 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2019
Building on Non-Freehold Land
Disclosure Of Intangible Assets With Indefinite Useful Life [Line Items]
Estimated useful lives for property, plant and equipment	10 years
Fittings and Fixtures | Bottom of Range
Disclosure Of Intangible Assets With Indefinite Useful Life [Line Items]
Estimated useful lives for property, plant and equipment	9 years
Fittings and Fixtures | Top of Range
Disclosure Of Intangible Assets With Indefinite Useful Life [Line Items]
Estimated useful lives for property, plant and equipment	25 years
Scientific Equipment | Bottom of Range
Disclosure Of Intangible Assets With Indefinite Useful Life [Line Items]
Estimated useful lives for property, plant and equipment	2 years
Scientific Equipment | Top of Range
Disclosure Of Intangible Assets With Indefinite Useful Life [Line Items]
Estimated useful lives for property, plant and equipment	12 years
Computer Equipment | Bottom of Range
Disclosure Of Intangible Assets With Indefinite Useful Life [Line Items]
Estimated useful lives for property, plant and equipment	2 years
Computer Equipment | Top of Range
Disclosure Of Intangible Assets With Indefinite Useful Life [Line Items]
Estimated useful lives for property, plant and equipment	5 years
Furniture | Bottom of Range
Disclosure Of Intangible Assets With Indefinite Useful Life [Line Items]
Estimated useful lives for property, plant and equipment	4 years
Furniture | Top of Range
Disclosure Of Intangible Assets With Indefinite Useful Life [Line Items]
Estimated useful lives for property, plant and equipment	10 years
Vehicles | Bottom of Range
Disclosure Of Intangible Assets With Indefinite Useful Life [Line Items]
Estimated useful lives for property, plant and equipment	4 years
Vehicles | Top of Range
Disclosure Of Intangible Assets With Indefinite Useful Life [Line Items]
Estimated useful lives for property, plant and equipment	6 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Commitments Related to Operating and Lease Liability Estimated (Details) - EUR (€) € in Thousands	Jan. 01, 2019	Dec. 31, 2018
Disclosure Of Voluntary Change In Accounting Policy [Abstract]
Right of use lease liabilities	€ 8,947	€ 4,791
Differences related to extension options for which the exercise is reasonably certain		5,264
Differences in the amounts retained for the calculation of commitments and lease liability		(396)
Expenses not included in the lease liability but included in the commitments		€ (190)
Undiscounted lease liability estimated under IFRS 16 at 1/1/2019	9,469
Impact of discount	€ (522)

Financial Risks Management - Se

Financial Risks Management - Sensitivity of Group's Cash and Cash Equivalents and Expenses to Variation 10% of US Dollar against Euro (Details)	12 Months Ended
	Dec. 31, 2019EUR (€)	Dec. 31, 2019USD ($)	Dec. 31, 2018EUR (€)		Dec. 31, 2018USD ($)	Dec. 31, 2017EUR (€)		Dec. 31, 2017USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Foreign Exchange Rates [Line Items]
Cash and cash equivalents	€ 276,748,000		€ 207,240,000	[1]		€ 273,820,000	[1]
Euros equivalent to US dollar	0.89341	11,234	0.84758		1,145	0.88704		11,993
10% Increase Decrease in US Dollar vs Euro
Foreign Exchange Rates [Line Items]
Cash and cash equivalents	€ 136,582,000		€ 1,038,000			€ 3,011,000			$ 153,438,000	$ 1,188,000	$ 3,611,000
Expenses	35,922,000	$ 40,355,000	8,396,000		$ 9,613,000	4,997,000		$ 5,993,000
10% Increase of US Dollar vs Euro
Foreign Exchange Rates [Line Items]
Cash and cash equivalents	151,758,000		1,153,000			3,345,000
Expenses	39,914,000		9,328,000			5,552,000
10% Decrease of US Dollar vs Euro
Foreign Exchange Rates [Line Items]
Cash and cash equivalents	124,166,000		944,000			2,737,000
Expenses	€ 32,657,000		€ 7,632,000			€ 4,543,000
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Financial Risks Management - Su

Financial Risks Management - Summary of Cash, Cash Equivalents and Financial Assets (Details) € in Thousands, $ in Thousands	Dec. 31, 2019EUR (€)	Dec. 31, 2019USD ($)	Dec. 31, 2018EUR (€)		Dec. 31, 2018USD ($)	Dec. 31, 2017EUR (€)		Dec. 31, 2017USD ($)
Disclosure Of Cash Cash Equivalents And Financial Assets [Line Items]
Cash and cash equivalents	€ 276,748		€ 207,240	[1]		€ 273,820	[1]
Current and non current financial assets	1,727		1,313			760
Total	278,474		208,553			274,581
Denominated in EUR
Disclosure Of Cash Cash Equivalents And Financial Assets [Line Items]
Cash and cash equivalents	139,863		206,199			270,210
Current and non current financial assets	1,614		1,303			729
Total	€ 141,477		€ 207,502			€ 270,939
Denominated in USD
Disclosure Of Cash Cash Equivalents And Financial Assets [Line Items]
Cash and cash equivalents | $		$ 136,884			$ 1,041			$ 3,611
Current and non current financial assets | $		113			10			31
Total | $		$ 136,997			$ 1,051			$ 3,642
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Financial Risks Management - Ad

Financial Risks Management - Additional Information (Details) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Foreign Exchange Rates [Line Items]
Cash and cash equivalents and other financial assets	€ 278,474	€ 208,553	€ 274,581
Interest Rate Risk
Foreign Exchange Rates [Line Items]
Financial liabilities	€ 183,617	€ 169,593	€ 164,680

Cash and Cash Equivalents - Sum

Cash and Cash Equivalents - Summary of Cash and Cash Equivalents (Details) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017
Cash and cash equivalent [line items]
Short-term deposits	€ 263,147	€ 201,522		€ 244,279
Cash on hand and bank accounts	13,601	5,718		29,541
TOTAL	276,748	207,240	[1]	273,820	[1]
UCITS
Cash and cash equivalent [line items]
Short-term deposits	3,096	29,189		38,052
TERM ACCOUNTS
Cash and cash equivalent [line items]
Short-term deposits	215,018	124,316		138,967
NEGOTIABLE MEDIUM-TERM NOTES
Cash and cash equivalent [line items]
Short-term deposits				4,150
INTEREST-BEARING CURRENT ACCOUNT
Cash and cash equivalent [line items]
Short-term deposits	€ 45,033	€ 48,017		€ 63,110
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Intangible Assets - Schedule of

Intangible Assets - Schedule of Variations in Intangible Assets (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019		Dec. 31, 2018		Dec. 31, 2017
Disclosure Of Intangible Assets [Line Items]
Balance	€ 796	[1]	€ 636	[1]	€ 668
Increase	125		159		(29)
Decrease					(2)
Balance	920		796	[1]	636	[1]
Gross
Disclosure Of Intangible Assets [Line Items]
Balance	2,384		1,921		1,709
Increase	475		529		268
Decrease	(29)		(67)		(56)
Balance	2,830		2,384		1,921
Gross | Software
Disclosure Of Intangible Assets [Line Items]
Balance	2,049		1,900		1,688
Increase	340		216		268
Decrease	(29)		(67)		(56)
Reclassification	378
Balance	2,739		2,049		1,900
Gross | Patents
Disclosure Of Intangible Assets [Line Items]
Balance	21		21		21
Increase	70
Balance	91		21		21
Gross | Other Intangibles
Disclosure Of Intangible Assets [Line Items]
Balance	313
Increase	65		313
Reclassification	(378)
Balance			313
Accumulated Depreciation and Impairment
Disclosure Of Intangible Assets [Line Items]
Balance	(1,588)		(1,285)		(1,042)
Increase	(350)		(370)		(298)
Decrease	29		67		54
Balance	(1,910)		(1,588)		(1,285)
Accumulated Depreciation and Impairment | Software
Disclosure Of Intangible Assets [Line Items]
Balance	(1,567)		(1,264)		(1,020)
Increase	(350)		(370)		(298)
Decrease	29		67		54
Balance	(1,888)		(1,567)		(1,264)
Accumulated Depreciation and Impairment | Patents
Disclosure Of Intangible Assets [Line Items]
Balance	(21)		(21)		(21)
Balance	€ (21)		€ (21)		€ (21)
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Variations in Tangible Assets (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019		Dec. 31, 2018		Dec. 31, 2017
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	€ 7,764	[1]	€ 6,324	[1]	€ 3,010
Increase	10,429		1,459		3,338
Decrease	(1,741)		(18)		(24)
Ending balance	16,453		7,764	[1]	6,324	[1]
Gross
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	15,774		13,123		8,940
Increase	13,339		2,939		4,287
Decrease	(1,875)		(288)		(105)
Ending balance	27,238		15,774		13,123
Gross | Buildings on Non-freehold Land
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	1,458		11
Increase	12,218				11
Reclassification	(1,447)		1,447
Ending balance	12,229		1,458		11
Gross | Scientific Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	10,879		9,576		6,078
Increase	556		1,484		3,546
Decrease	(120)		(235)		(49)
Reclassification	(54)		54
Ending balance	11,260		10,879		9,576
Gross | Fittings and Fixtures
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	1,531		1,126		988
Increase	66		443		138
Decrease			(43)
Reclassification	(5)		5
Ending balance	1,592		1,531		1,126
Gross | Vehicles
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	99		99		82
Increase					61
Decrease					(44)
Ending balance	99		99		99
Gross | Computer Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	1,446		1,954		1,475
Increase	227		200		211
Decrease	(15)		(5)		(12)
Reclassification	11		(702)		281
Ending balance	1,669		1,446		1,954
Gross | Furniture
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	361		357		317
Increase	31		8		40
Decrease	(3)		(4)
Ending balance	389		361		357
Gross | In progress
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	0
Increase	241		805		281
Decrease	(1,737)
Reclassification	1,496		(804)		(281)
Ending balance			0
Accumulated Depreciation and Impairment
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(8,010)		(6,798)		(5,930)
Increase	(2,909)		(1,481)		(949)
Decrease	133		270		81
Ending balance	(10,785)		(8,010)		(6,798)
Accumulated Depreciation and Impairment | Buildings on Non-freehold Land
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(1)
Increase	(1,215)		(1)
Ending balance	(1,216)		(1)
Accumulated Depreciation and Impairment | Scientific Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(5,988)		(5,063)		(4,438)
Increase	(1,303)		(1,142)		(673)
Decrease	119		218		48
Ending balance	(7,172)		(5,988)		(5,063)
Accumulated Depreciation and Impairment | Fittings and Fixtures
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(769)		(722)		(657)
Increase	(105)		(91)		(65)
Decrease			43
Ending balance	(875)		(769)		(722)
Accumulated Depreciation and Impairment | Vehicles
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(45)		(24)		(29)
Increase	(21)		(21)		(17)
Decrease			0		22
Ending balance	(66)		(45)		(24)
Accumulated Depreciation and Impairment | Computer Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(915)		(703)		(530)
Increase	(252)		(216)		(184)
Decrease	12		4		11
Ending balance	(1,155)		(915)		(703)
Accumulated Depreciation and Impairment | Furniture
Disclosure Of Property Plant And Equipment [Line Items]
Beginning balance	(292)		(285)		(276)
Increase	(13)		(11)		(9)
Decrease	3		4
Ending balance	€ (303)		€ (292)		€ (285)
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Details) € in Thousands	12 Months Ended
	Dec. 31, 2019EUR (€)	Dec. 31, 2018EUR (€)		May 31, 2020EUR (€)	Jan. 01, 2019EUR (€)	Dec. 31, 2017EUR (€)		Dec. 31, 2016EUR (€)
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment	€ 16,453	€ 7,764	[1]			€ 6,324	[1]	€ 3,010
Reimbursement of construction cost	2,500
Cost incurred	2,500
Equipment in progress		1,400
Additional cost incurred	1,300
Construction cost incurred	2,500
Leasehold improvements	€ 300
Amortized leasehold improvements	10 years
Right of use assets					€ 9,227
Lease liabilities		€ 4,791			8,947
Major purchases of assets [member]
Disclosure Of Property Plant And Equipment [Line Items]
Right of use assets				€ 2,200
Lease liabilities				€ 2,200
IFRS 16
Disclosure Of Property Plant And Equipment [Line Items]
Right of use assets					7,800
Lease liabilities					€ 7,800
Scientific Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation, right-of-use assets	4,346	2,933
Building on Non-Freehold Land
Disclosure Of Property Plant And Equipment [Line Items]
Depreciation, right-of-use assets	11,974	1,196
Assets Under Finance Lease Contracts | Scientific Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Property, plant and equipment	€ 1,413	€ 1,889				€ 1,895
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Trade and Other Receivables - S

Trade and Other Receivables - Summary of Trade and Other Receivables (Details) - EUR (€) € in Thousands		Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017
Trade And Other Receivables [Abstract]
Trade receivables, net		€ 207	€ 25		€ 61
Research tax credit		9,585	8,785		8,466
Social security costs receivables		5	10		3
VAT receivables		1,814	1,103		994
Grants receivables		3	0		13
Other receivables		420	361		340
TOTAL		12,033	10,284		9,876
Trade receivables, net		207	25		61
Research tax credit		9,585	7,295		6,545
Social security costs receivables		5	10		3
VAT receivables		1,814	1,103		994
Grants receivables		3	(1)		13
Other receivables		420	361		340
TOTAL		€ 12,033	8,794	[1]	7,955	[1]
Research tax credit			1,489		1,921
TOTAL	[1]		€ 1,489		€ 1,921
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Trade and Other Receivables - A

Trade and Other Receivables - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2016	Dec. 31, 2014	Jun. 30, 2019	Dec. 31, 2017
Trade And Other Receivables [Line Items]
Research tax credit	€ 9,585	€ 8,785				€ 8,466
Partial payment of assessment due to ongoing tax audit	(333)
Due amount of research tax credit			€ (447)	€ (1,140)
Litigation settlement amount	432	29
Credit notes from suppliers	408	€ 235				€ 174
French Tax Authorities
Trade And Other Receivables [Line Items]
Research tax credit	€ 8,125
Research Tax Credit
Trade And Other Receivables [Line Items]
Provision for tax liability					€ 1,892
Tax allocation					€ 1,785

Other Financial Assets - Summar

Other Financial Assets - Summary of Other Financial Assets (Details) - EUR (€) € in Thousands		Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017
Disclosure Of Other Financial Assets [Abstract]
Loans		€ 307	€ 259		€ 219
Deposits and guarantees		396	284		274
Liquidity contract		1,023	770		267
Other financial assets		1,727	1,313		760
Loan related security deposit					0
Deposits and guarantees					31
Other current financial assets	[1]				31
Loans		307	259		219
Loan related security deposit		0			0
Deposits and guarantees		396	284		243
Other non-current financial assets		€ 1,727	€ 1,313	[1]	€ 729	[1]
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Other Financial Assets - Additi

Other Financial Assets - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Other Financial Assets [Abstract]
Liquidity account, cash balance	€ 1,023	€ 770	€ 267
Number of shares recorded as deduction from equity	18,132	27,911
Additional contribution to liquidity agreement		€ 1,000

Other Assets - Additional Infor

Other Assets - Additional Information (Details) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Miscellaneous Assets [Abstract]
Other assets	€ 1,968	€ 2,078	€ 1,761

Loans and Borrowings - Addition

Loans and Borrowings - Additional Information (Details)	Oct. 16, 2017EUR (€)DebtInstrument€ / shares	Dec. 31, 2014EUR (€)	Jun. 30, 2010EUR (€)	Dec. 31, 2019EUR (€)	Dec. 31, 2018EUR (€)		Dec. 31, 2017EUR (€)		Dec. 23, 2008EUR (€)
Disclosure Of Detailed Information About Borrowings [Line Items]
Liability				€ 18,165,000	€ 9,104,000		€ 8,812,000
Other non-current loans and borrowings				14,939,000	7,255,000	[1]	6,978,000	[1]
Amount for development agreement with participating feature				66,170,000	67,024,000	[2]	54,189,000	[2]
Convertible Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Convertible bond, yearly interest				6,300,000
Convertible loan nominal amount				€ 180,000,000
Group
Disclosure Of Detailed Information About Borrowings [Line Items]
Repayments of refundable and conditional advances					183,000		166,000
BPI FRANCE - IT-DIAB
Disclosure Of Detailed Information About Borrowings [Line Items]
Discounted rate		5.19%
BPI FRANCE - IT-DIAB | Conditional
Disclosure Of Detailed Information About Borrowings [Line Items]
Advances received									€ 3,229,000
BPI FRANCE - IT-DIAB | Non-repayable
Disclosure Of Detailed Information About Borrowings [Line Items]
Government grants									€ 3,947,000
BPI FRANCE - ADVANCE N°1 - OLNORME II - 1
Disclosure Of Detailed Information About Borrowings [Line Items]
Repayments of refundable and conditional advances							(134,000)
Reimbursed advances					66,000
BPI FRANCE - ADVANCE N°1 - OLNORME II - 1 | Technical and/or Commercial Success
Disclosure Of Detailed Information About Borrowings [Line Items]
Percentage of non-interest bearing advances repayable to nominal amount				100.00%
BPI FRANCE - ADVANCE N°2 - OLNORME II - 2
Disclosure Of Detailed Information About Borrowings [Line Items]
Repayments of refundable and conditional advances							(134,000)
Percentage of non-interest bearing advances repayable to nominal amount				100.00%
Reimbursed advances					66,000
BPI FRANCE - ADVANCE N°3 - OLNORME II - 3
Disclosure Of Detailed Information About Borrowings [Line Items]
Repayments of refundable and conditional advances							(108,000)
Percentage of non-interest bearing advances repayable to nominal amount				100.00%
Reimbursed advances					52,000
BPI France | Development Agreement with Participation Feature
Disclosure Of Detailed Information About Borrowings [Line Items]
Amount for development agreement with participating feature			€ 2,300,000
Period allocated for development agreement with participation feature			7 years
Percentage of interest rate to be paid for development agreement			4.46%
Additional remuneration description				The loan agreement has a provision applicable during the reimbursement period which provides for additional remuneration to BPI France depending on whether the Company had industrial income. This additional remuneration amounts to 0.2294% of sales.
Additional remuneration amounts percentage			0.2294%
Loan repayment maturity				June 2017
BPI France | Development Agreement with Participation Feature | First Two Years
Disclosure Of Detailed Information About Borrowings [Line Items]
Repayment of principal			€ 0
OCEANEs
Disclosure Of Detailed Information About Borrowings [Line Items]
Number of debt instruments issued | DebtInstrument	6,081,081
Nominal unit value per bond	29.60
Aggregate nominal amount	€ 180,000,000						180,000,000
Exchange or conversion premium	30.00%
Reference share price | € / shares	€ 22.77
Interest rate	7.20%
Debt maturity date				October 16, 2022
Trading period	20 days
Redemption prior to maturity terms				Redemption prior to maturity is at the option of the Company from November 6, 2020 if the arithmetic volume-weighted average price of the Company's share price and the then-prevailing conversion ratio (over a 20-day trading period) exceeds 150% of the nominal value of the OCEANEs.
Liability				€ 165,454,000	160,489,000		155,868,000
Liability, current				1,312,000	1,312,000		1,329,000
Other non-current loans and borrowings				€ 164,142,000	€ 159,176,000		€ 154,539,000
Dilutive effect of the convertible bonds expressed as a percentage of share capital				15.60%
OCEANEs | Annual Nominal Interest Rate
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate	3.50%			3.50%
Conditional Advances | BPI FRANCE - IT-DIAB | Additional Payments
Disclosure Of Detailed Information About Borrowings [Line Items]
Maximum amount to be paid if any further amounts to be paid as conditional advance		€ 14,800,000
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.
[2]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method and therefore, the comparative information for 2017 and 2018 has not been restated . The impact of this application is presented in note 4.7

Loans and Borrowings - Summary

Loans and Borrowings - Summary of Other Loans and Borrowings (Details) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017
Disclosure Of Detailed Information About Borrowings [Line Items]
Liability	€ 18,165	€ 9,104		€ 8,812
Other current loans and borrowings	3,226	1,848	[1]	1,834	[1]
Other non-current loans and borrowings	14,939	7,255	[1]	6,978	[1]
Refundable and Conditional advances
Disclosure Of Detailed Information About Borrowings [Line Items]
Liability	3,229	3,229		3,407
Other current loans and borrowings				178
Other non-current loans and borrowings	3,229	3,229		3,229
Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Liability	2,645	3,964		3,488
Other current loans and borrowings	1,105	1,319		1,209
Other non-current loans and borrowings	1,540	2,645		2,279
Obligations Under Leases
Disclosure Of Detailed Information About Borrowings [Line Items]
Liability	12,281	1,900		1,890
Other current loans and borrowings	2,112	520		420
Other non-current loans and borrowings	10,169	1,381		1,469
Accrued Interests
Disclosure Of Detailed Information About Borrowings [Line Items]
Liability	1	3		3
Other current loans and borrowings	1	3		3
Other Financial Loans and Borrowings
Disclosure Of Detailed Information About Borrowings [Line Items]
Liability	7	7		24
Other current loans and borrowings	€ 7	€ 7		€ 24
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Loans and Borrowings - Summar_2

Loans and Borrowings - Summary of Refundable and Conditional Advances (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Detailed Information About Borrowings [Line Items]
Refundable and conditional advances, Net book value	€ 3,229	€ 3,229	€ 3,407
BPI FRANCE - IT-DIAB
Disclosure Of Detailed Information About Borrowings [Line Items]
Refundable and conditional advances, Grant date	Dec. 23, 2008	Dec. 23, 2008	Dec. 23, 2008
Refundable and conditional advances, Total amount allocated	€ 3,229	€ 3,229	€ 3,229
Refundable and conditional advances, Receipts	3,229	3,229	3,229
Refundable and conditional advances, Net book value	€ 3,229	€ 3,229	€ 3,229
BPI FRANCE - ADVANCE N°1 - OLNORME II - 1
Disclosure Of Detailed Information About Borrowings [Line Items]
Refundable and conditional advances, Grant date			Nov. 24, 2010
Refundable and conditional advances, Total amount allocated			€ 250
Refundable and conditional advances, Receipts			200
Refundable and conditional advances, Repayments			(134)
Refundable and conditional advances, Effects of discounting			(2)
Refundable and conditional advances, Net book value			€ 64
BPI FRANCE - ADVANCE N°2 - OLNORME II - 2
Disclosure Of Detailed Information About Borrowings [Line Items]
Refundable and conditional advances, Grant date			Nov. 24, 2010
Refundable and conditional advances, Total amount allocated			€ 250
Refundable and conditional advances, Receipts			200
Refundable and conditional advances, Repayments			(134)
Refundable and conditional advances, Effects of discounting			(2)
Refundable and conditional advances, Net book value			€ 64
BPI FRANCE - ADVANCE N°3 - OLNORME II - 3
Disclosure Of Detailed Information About Borrowings [Line Items]
Refundable and conditional advances, Grant date			Nov. 24, 2010
Refundable and conditional advances, Total amount allocated			€ 200
Refundable and conditional advances, Receipts			160
Refundable and conditional advances, Repayments			(108)
Refundable and conditional advances, Effects of discounting			(2)
Refundable and conditional advances, Net book value			€ 51

Loans and Borrowings - Summar_3

Loans and Borrowings - Summary of Bank Loans (Details) € in Thousands	12 Months Ended
	Dec. 31, 2019EUR (€)Facility Size	Dec. 31, 2018EUR (€)Facility Size	Dec. 31, 2017EUR (€)Facility Size
Disclosure Of Detailed Information About Borrowings [Line Items]
Liability	€ 18,165	€ 9,104	€ 8,812
Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Liability	2,645	3,964	3,488
Bank Loan Outstanding	€ 2,645	€ 3,964
Bank Loans | Research and Laboratory Equipment
Disclosure Of Detailed Information About Borrowings [Line Items]
Bank Loan Outstanding			€ 3,488
CDN 4 | Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date	June 2017	June 2017
Facility Size | Facility Size	600	600
Interest rate	0.36%	0.36%
Liability	€ 0	€ 0
Installments	48 monthly	48 monthly
Bank Loan Outstanding	€ 226	€ 376
CDN 4 | Bank Loans | Research and Laboratory Equipment
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date			June 2017
Facility Size | Facility Size			600
Interest rate			0.36%
Installments			48 monthly
Bank Loan Outstanding			€ 525
CDN 3 | Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date	April 2016	April 2016
Facility Size | Facility Size	500	500
Interest rate	0.72%	0.72%
Installments	60 monthly	60 monthly
Bank Loan Outstanding	€ 135	€ 236
CDN 3 | Bank Loans | Research and Laboratory Equipment
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date			April 2016
Facility Size | Facility Size			500
Interest rate			0.72%
Installments			60 monthly
Bank Loan Outstanding			€ 335
CIC 5 | Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date	July 2017	July 2017
Facility Size | Facility Size	1,000	1,000
Interest rate	0.69%	0.69%
Liability	€ 0	€ 0
Installments	60 monthly	60 monthly
Bank Loan Outstanding	€ 554	€ 753
CIC 5 | Bank Loans | Research and Laboratory Equipment
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date			July 2017
Facility Size | Facility Size			1,000
Interest rate			0.69%
Liability			€ 500
Installments			60 monthly
Bank Loan Outstanding			€ 451
CIC 4 | Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date	December 2016	December 2016
Facility Size | Facility Size	265	265
Interest rate	0.69%	0.69%
Installments	60 monthly	60 monthly
Bank Loan Outstanding	€ 111	€ 164
CIC 4 | Bank Loans | Research and Laboratory Equipment
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date			December 2016
Interest rate			0.69%
Installments			60 monthly
Bank Loan Outstanding			€ 217
CIC 3 | Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date	March 2015	March 2015
Facility Size | Facility Size	500	500
Interest rate	0.85%	0.85%
Liability	€ 0	€ 0
Installments	16 quarterly	16 quarterly
Bank Loan Outstanding	€ 0	€ 32
CIC 3 | Bank Loans | Research and Laboratory Equipment
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date			March 2015
Facility Size | Facility Size			500
Interest rate			0.85%
Installments			16 quarterly
Bank Loan Outstanding			€ 158
BNP 3 | Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date	October 2016	October 2016
Facility Size | Facility Size	1,050	1,050
Interest rate	0.80%	0.80%
Liability	€ 0	€ 0
Installments	20 quarterly	20 quarterly
Bank Loan Outstanding	€ 525	€ 735
BNP 3 | Bank Loans | Research and Laboratory Equipment
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date			October 2016
Facility Size | Facility Size			1,050
Interest rate			0.80%
Installments			20 quarterly
Bank Loan Outstanding			€ 945
Other | Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Bank Loan Outstanding	€ 14	€ 19
Other | Bank Loans | Research and Laboratory Equipment
Disclosure Of Detailed Information About Borrowings [Line Items]
Bank Loan Outstanding			€ 23
BNP 2 | Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date	June 2016	June 2016
Facility Size | Facility Size	500	500
Interest rate	0.80%	0.80%
Liability	€ 0	€ 0
Installments	20 quarterly	20 quarterly
Bank Loan Outstanding	€ 177	€ 277
BNP 2 | Bank Loans | Research and Laboratory Equipment
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date			June 2016
Facility Size | Facility Size			500
Interest rate			0.80%
Installments			20 quarterly
Bank Loan Outstanding			€ 377
BNP | Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date	December 2014	December 2014
Facility Size | Facility Size	500	500
Interest rate	2.00%	2.00%
Liability	€ 0	€ 0
Installments	20 quarterly	20 quarterly
Bank Loan Outstanding	€ 0	€ 103
BNP | Bank Loans | Research and Laboratory Equipment
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date			December 2014
Facility Size | Facility Size			500
Interest rate			2.00%
Installments			20 quarterly
Bank Loan Outstanding			€ 205
BNP 4 | Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date	April 2017	April 2017
Facility Size | Facility Size	800	800
Interest rate	0.87%	0.87%
Liability	€ 0	€ 0
Installments	60 monthly	60 monthly
Bank Loan Outstanding	€ 537	€ 695
BNP 4 | Bank Loans | Research and Laboratory Equipment
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date			April 2017
Facility Size | Facility Size			800
Interest rate			0.87%
Liability			€ 800
Installments			60 monthly
NEUFLIZE 2 | Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date	June 2016
Facility Size | Facility Size	500
Interest rate	1.10%
Liability	€ 0
Installments	12 quarterly
Bank Loan Outstanding	€ 0
NEUFLIZE 2 | Bank Loans | Research and Laboratory Equipment
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date			June 2016
Facility Size | Facility Size			500
Interest rate			1.10%
Installments			12 quarterly
Bank Loan Outstanding			€ 252
CDN 5 | Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date	November 2018	November 2018
Facility Size | Facility Size	500	500
Interest rate	0.46%	0.46%
Installments	48 monthly	48 monthly
Bank Loan Outstanding	€ 365	€ 490
NEUFLIZE | Bank Loans
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt maturity date		June 2016
Facility Size | Facility Size		500
Interest rate		1.10%
Liability		€ 0
Installments		12 quarterly
Bank Loan Outstanding		€ 84

Loans And Borrowings - Summar_4

Loans And Borrowings - Summary of Maturities of Financial Liabilities (Details) € in Thousands	Dec. 31, 2019EUR (€)
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Refundable and conditional advances	€ 3,229
TOTAL - Other loans and borrowings	180,390
TOTAL	183,619
Lease
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	12,281
Convertible Loans
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	165,454
Bank Loans
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	2,645
Accrued Interests
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	1
Other Financial Loans and Borrowings
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	7
BPI FRANCE - IT-DIAB
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Refundable and conditional advances	3,229
Within 1 Year
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	4,539
TOTAL	4,539
Within 1 Year | Lease
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	2,112
Within 1 Year | Convertible Loans
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	1,312
Within 1 Year | Bank Loans
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	1,105
Within 1 Year | Accrued Interests
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	1
Within 1 Year | Other Financial Loans and Borrowings
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	7
Later than one year and not later than two years [member]
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	3,060
TOTAL	3,060
Later than one year and not later than two years [member] | Lease
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	2,118
Later than one year and not later than two years [member] | Bank Loans
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	942
Later than two years and not later than three years [member]
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	166,260
TOTAL	166,260
Later than two years and not later than three years [member] | Lease
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	1,575
Later than two years and not later than three years [member] | Convertible Loans
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	164,142
Later than two years and not later than three years [member] | Bank Loans
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	544
Later than three years and not later than four years [member]
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	1,205
TOTAL	1,205
Later than three years and not later than four years [member] | Lease
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	1,151
Later than three years and not later than four years [member] | Bank Loans
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	54
Later than four years and not later than five years [member]
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	1,103
TOTAL	1,103
Later than four years and not later than five years [member] | Lease
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	1,103
Later than five years [member]
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Refundable and conditional advances	3,229
TOTAL - Other loans and borrowings	4,223
TOTAL	7,452
Later than five years [member] | Lease
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Other loans and borrowings	4,223
Later than five years [member] | BPI FRANCE - IT-DIAB
Disclosure Of Maturity Analysis For Derivative Financial Liabilities [Line Items]
TOTAL - Refundable and conditional advances	€ 3,229

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Financial Assets And Liabilities Carrying Values By Category And Fair Values (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Detailed Information About Borrowings [Line Items]
Carrying value as per statement of financial position	€ 1,727	€ 1,313	€ 760
Level 1 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	276,748	207,240	273,820
Level 2 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	911	568	555
Fair value	213,669	199,084	180,359
Level 3 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	3,229	3,229	3,407
Gross
Disclosure Of Detailed Information About Borrowings [Line Items]
Carrying value as per statement of financial position	277,658	207,808	274,375
Carrying value of Assets at fair value through profit and loss	276,748	207,240	273,820
Carrying value loans and receivables	911	568	555
Financial liabilities	216,898	202,313	183,766
Aggregate nominal amount	216,898	202,313	183,766
Loans | Level 2 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	307	259	219
Loans | Gross
Disclosure Of Detailed Information About Borrowings [Line Items]
Carrying value as per statement of financial position	307	259	219
Carrying value loans and receivables	307	259	219
Deposits and guarantees | Level 2 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	396	284	274
Deposits and guarantees | Gross
Disclosure Of Detailed Information About Borrowings [Line Items]
Carrying value as per statement of financial position	396	284	274
Carrying value loans and receivables	396	284	274
Trade receivables | Level 2 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	207	25	61
Trade receivables | Gross
Disclosure Of Detailed Information About Borrowings [Line Items]
Carrying value as per statement of financial position	207	25	61
Carrying value loans and receivables	207	25	61
Cash and cash equivalents | Level 1 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	276,748	207,240	273,820
Cash and cash equivalents | Gross
Disclosure Of Detailed Information About Borrowings [Line Items]
Carrying value as per statement of financial position	276,748	207,240	273,820
Carrying value of Assets at fair value through profit and loss	276,748	207,240	273,820
Conditional Advances | Level 3 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	3,229	3,229	3,407
Conditional Advances | Gross
Disclosure Of Detailed Information About Borrowings [Line Items]
Financial liabilities	3,229	3,229	3,407
Aggregate nominal amount	3,229	3,229	3,407
Convertible Loans | Level 2 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	165,454	160,489	155,868
Convertible Loans | Gross
Disclosure Of Detailed Information About Borrowings [Line Items]
Financial liabilities	165,454	160,489	155,868
Aggregate nominal amount	165,454	160,489	155,868
Bank Loans | Level 2 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	2,645	3,964	3,488
Bank Loans | Gross
Disclosure Of Detailed Information About Borrowings [Line Items]
Financial liabilities	2,645	3,964	3,488
Aggregate nominal amount	2,645	3,964	3,488
Obligations under finance leases | Level 2 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	12,281	1,900	1,890
Obligations under finance leases | Gross
Disclosure Of Detailed Information About Borrowings [Line Items]
Financial liabilities	12,281	1,900	1,890
Aggregate nominal amount	12,281	1,900	1,890
Accrued Interests | Level 2 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	1	3	3
Accrued Interests | Gross
Disclosure Of Detailed Information About Borrowings [Line Items]
Financial liabilities	1	3	3
Aggregate nominal amount	1	3	3
Other Financial Loans and Borrowings | Level 2 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	7	7	24
Other Financial Loans and Borrowings | Gross
Disclosure Of Detailed Information About Borrowings [Line Items]
Financial liabilities	7	7	24
Aggregate nominal amount	7	7	24
Trade payables | Level 2 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	32,753	32,649	19,053
Trade payables | Gross
Disclosure Of Detailed Information About Borrowings [Line Items]
Financial liabilities	32,753	32,649	19,053
Aggregate nominal amount	32,753	32,649	19,053
Other payables | Level 2 | Fair value
Disclosure Of Detailed Information About Borrowings [Line Items]
Fair value	527	71	34
Other payables | Gross
Disclosure Of Detailed Information About Borrowings [Line Items]
Financial liabilities	527	71	34
Aggregate nominal amount	€ 527	€ 71	€ 34

Trade and Other Payables - Sche

Trade and Other Payables - Schedule of Trade and Other Payables (Details) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017
Trade and other payables - Total
Trade payables	€ 32,753	€ 32,649		€ 19,053
Social security costs payables	3,581	2,949		4,217
Employee profit sharing	17	17		17
VAT payables	2	1		19
Taxes payables	487	286		241
Other payables	527	71		34
TOTAL	37,368	35,974		23,580
Trade and other payables - Current
Trade payables	32,753	32,649		19,053
Social security costs payables	3,581	2,949		4,217
Employee profit sharing	17	17		17
VAT payables	2	1		19
Taxes payables	487	286		241
Other payables	76	71		34
TOTAL	36,917	€ 35,974	[1]	€ 23,580	[1]
Trade and other payables - Non current
Other payables	450
TOTAL	€ 450
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Provisions - Additional Informa

Provisions - Additional Information (Details) - EUR (€) € in Thousands	Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017
Provisions [Abstract]
Current provisions	€ 2,061	€ 112	[1]	€ 361	[1]
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Employee Benefits - Additional

Employee Benefits - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017
Disclosure Of Information About Defined Benefit Plans [Abstract]
Defined contribution plan expense	€ 927	€ 765		€ 543
Pension provisions	€ 1,408	€ 1,085	[1]	€ 936	[1]
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Employee Benefits - Summary of

Employee Benefits - Summary of Assumptions Used for Employees for the Measurement of Retirement Indemnity to Employees (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Defined Benefit Plans [Line Items]
Population	Permanent staff
Retirement age	65 years
Terms of retirement	Initiated by the employee
Life expectancy	On the basis of the INSEE table
Probability of continued presence in the company at retirement age	On the basis of the DARES table
Discount rate	0.75%	1.53%	1.50%
Within 1 Year
Disclosure Of Defined Benefit Plans [Line Items]
Salary growth rate	5.80%	5.80%	5.80%
Beyond
Disclosure Of Defined Benefit Plans [Line Items]
Salary growth rate	3.00%	3.00%	3.00%

Employee Benefits - Summary o_2

Employee Benefits - Summary of Changes in Present Value of Defined Benefit Obligation (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Information About Defined Benefit Plans [Abstract]
Defined benefit obligation, beginning balance	€ 1,085	€ 936	€ 849
Current service cost	138	104	76
Interest cost on benefit obligation	17	14	13
Actuarial losses / (gains) on obligation	168	31	210
Past service costs			(211)
Defined benefit obligation, ending balance	€ 1,408	€ 1,085	€ 936

Employee Benefits - Summary o_3

Employee Benefits - Summary of Sensitivity of the Retirement and Post-Employment Benefits to a Variation of the Discount Rate (Details) € in Thousands	Dec. 31, 2019EUR (€)
Disclosure Of Information About Defined Benefit Plans [Abstract]
Changes in assumptions/discount rate	0.25%
Impact/present value of the undertaking	€ (51)
Changes in assumptions/discount rate	(0.25%)
Impact/present value of the undertaking	€ 53

Equity - Additional Information

Equity - Additional Information (Details) - EUR (€) € in Thousands	Dec. 27, 2018	Dec. 31, 2019	Dec. 31, 2018	[1]	Dec. 31, 2017		Oct. 16, 2017
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares in entity held to entitle double voting rights		2,311,439
Percentage of double voting rights		5.95%
Deferred tax liabilities		€ 1,193	€ 1,773		€ 2,165	[1]
Number of shares issued upon performance condition change on compensation	17,484
Total number of shares comprising the share capital		38,858,617
AGA S 2016-2
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares vested		7,796
AGA S 2017-1
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares vested		19,400
Initial Public Offering
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of new shares		7,647,500
Gross amount received from issuance of shares		€ 137,600
OCEANEs
Disclosure Of Classes Of Share Capital [Line Items]
Debt maturity date		October 16, 2022
Nominal amount					180,000		€ 180,000
Deferred tax liabilities					€ 14,312
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Other Income - Schedule of Othe

Other Income - Schedule of Other Income (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Other Income [Line Items]
Other income	€ 10,122	€ 7,425	€ 6,737
CIR Tax Credit
Disclosure Of Other Income [Line Items]
Other income	8,125	7,295	6,545
CICE Tax Credit
Disclosure Of Other Income [Line Items]
Other income	1,992	€ 130	171
Government Grants and Subsidies
Disclosure Of Other Income [Line Items]
Other income	€ 5		€ 21

Other Income - Additional Infor

Other Income - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017
Disclosure Of Other Income [Line Items]
Exchange gains on trade receivables	€ 1,985
Other operating income recognized as financial income		€ 38
Other income	€ 10,122	€ 7,425	[1]	€ 6,737	[1]
Percentage of employment tax credit		6.00%		7.00%
Maximum percentage of employment tax credit to French minimum wage.		250.00%		250.00%
CICE Employment Tax Credit
Disclosure Of Other Income [Line Items]
Other income		€ 122		€ 170
[1]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method and therefore, the comparative information for 2017 and 2018 has not been restated . The impact of this application is presented in note 4.7

Operating Expense - Summary of

Operating Expense - Summary of Operating Expenses and Other Operating Income (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017
Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]
Research and development expenses	€ (66,170)	€ (67,024)	[1]	€ (54,189)	[1]
General and administrative expenses	(17,265)	(9,076)	[1]	(9,421)	[1]
Marketing and market access expenses	(13,708)	(717)	[1]
Other operating income (expenses)	(1,649)	(162)	[1]	60	[1]
TOTAL	(98,793)	(76,979)		(63,550)
Raw materials & consumables used
Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]
Research and development expenses	(2,017)	(1,724)		(2,117)
General and administrative expenses	(177)	(126)		(112)
Marketing and market access expenses	(8)	(4)
TOTAL	(2,202)	(1,855)		(2,229)
Contracted research & development activities conducted by third parties
Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]
Research and development expenses	(41,509)	(47,659)		(35,088)
General and administrative expenses	(59)	(2)		(7)
Marketing and market access expenses	0
TOTAL	(41,568)	(47,662)		(35,095)
Employee expenses
Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]
Research and development expenses	(11,740)	(9,431)		(7,915)
General and administrative expenses	(7,598)	(3,778)		(5,491)
Marketing and market access expenses	(1,645)	(416)
TOTAL	(20,984)	(13,625)		(13,406)
Other expenses (maintenance, fees, travel, taxes)
Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]
Research and development expenses	(6,188)	(6,502)		(7,973)
General and administrative expenses	(8,972)	(5,451)		(3,374)
Marketing and market access expenses	(11,979)	(287)
Other operating income (expenses)	(1,668)	(164)		68
TOTAL	(28,807)	(12,403)		(11,280)
Depreciation, amortization & impairment charges
Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]
Research and development expenses	(4,716)	(1,707)		(1,095)
General and administrative expenses	(458)	283		(437)
Marketing and market access expenses	(76)	(11)
TOTAL	(5,251)	(1,435)		(1,532)
Gain / (loss) on disposal of property, plant & equipment
Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]
Other operating income (expenses)	19	2		(8)
TOTAL	€ 19	€ 2		€ (8)
[1]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method and therefore, the comparative information for 2017 and 2018 has not been restated . The impact of this application is presented in note 4.7

Operating Expense - Additional

Operating Expense - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017
Disclosure Of Operating Expense [Line Items]
Reduction in the amount recognized for invoices not received	€ 6,994
Research and development expenses	(66,170)	€ (67,024)	[1]	€ (54,189)	[1]
General and administrative expenses	€ (17,265)	(9,076)	[1]	(9,421)	[1]
NASH Education Program
Disclosure Of Operating Expense [Line Items]
Research and development expenses				€ (1,808)
General and administrative expenses		€ (959)
[1]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method and therefore, the comparative information for 2017 and 2018 has not been restated . The impact of this application is presented in note 4.7

Operating Expense - Summary o_2

Operating Expense - Summary of Employee Expenses and Number of Employees (Details) € in Thousands	12 Months Ended
	Dec. 31, 2019EUR (€)Employee	Dec. 31, 2018EUR (€)Employee	Dec. 31, 2017EUR (€)Employee
Disclosure Of Operating Expense [Line Items]
Wages and salaries | €	€ (14,018)	€ (9,012)	€ (9,267)
Social security costs | €	(5,171)	(3,722)	(3,996)
Changes in pension provision | €	(138)	(104)	135
Share-based compensation | €	(1,657)	(787)	(278)
TOTAL | €	€ (20,984)	€ (13,625)	€ (13,406)
Average number of employees	175	135	123
Average age of employees	37 years 1 month	38 years 11 months	38 years 4 months
Number of employees	194	148	125
Research and Development
Disclosure Of Operating Expense [Line Items]
Number of employees	108	84	77
Services Related to Research and Development
Disclosure Of Operating Expense [Line Items]
Number of employees	19	16	15
Administration and Management
Disclosure Of Operating Expense [Line Items]
Number of employees	60	48	33
Marketing and Commercial
Disclosure Of Operating Expense [Line Items]
Number of employees	7
Senior Staff
Disclosure Of Operating Expense [Line Items]
Number of employees	144	115	92
Staff
Disclosure Of Operating Expense [Line Items]
Number of employees	45	30	29
Apprentices
Disclosure Of Operating Expense [Line Items]
Number of employees	5	3	4
Male
Disclosure Of Operating Expense [Line Items]
Number of employees	78	57	45
Female
Disclosure Of Operating Expense [Line Items]
Number of employees	116	91	80

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of years of successive plan	4 years
Existing turnover rate	15.00%
Revised turnover rate	0.00%
Share Price Period To Determine Volatility Assumptions Prior to Grant Date	3 years
IFRS 2
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Expenses recognized	€ 1,645	€ 787	€ 278

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Share-based Compensation Under Each Plan According to Change in Estimate (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	€ 1,645	€ 787	€ 278
Share-based compensation annual expense calculated	7,787
Share-based compensation annual expense remaining	2,004
BSA 2014-A
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	945
BSA 2014-A | Non-executive officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	365
BSA 2014-A | Consultants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	581
BSA 2014-B
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	1,045
BSA 2014-B | Non-executive officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	365
BSA 2014-B | Consultants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	680
BSAAR 2014-A
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	43
BSAAR 2014-A | Non-executive officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	9
BSAAR 2014-A | Consultants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	34
BSAAR 2014-B
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	191
Share-based compensation annual expense remaining	0
BSAAR 2014-B | Non-executive officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	35
Share-based compensation annual expense remaining	0
BSAAR 2014-B | Consultants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	156
BSAAR 2014-C
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	189
Share-based compensation annual expense remaining	0
BSAAR 2014-C | Non-executive officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	35
BSAAR 2014-C | Consultants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	154
Share-based compensation annual expense remaining	€ 0

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Share-Based Compensation Based on Program (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	€ 1,645	€ 787	€ 278
Share-based compensation annual expense calculated	7,787
Share-based compensation annual expense remaining	2,004
BSA 2015-A
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	335
BSA 2015-A | Non-executive officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	178
BSA 2015-A | Consultants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	157
BSA 2015-B
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	315
BSA 2015-B | Non-executive officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	178
BSA 2015-B | Consultants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense calculated	138
AGA D 2016-1
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense		127	38
Share-based compensation annual expense calculated	166
Share-based compensation annual expense remaining	0
AGA D 2016-1 | Executive Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense		25	7
Share-based compensation annual expense calculated	32
Share-based compensation annual expense remaining	0
AGA D 2016-1 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense		101	31
Share-based compensation annual expense calculated	133
Share-based compensation annual expense remaining	0
AGA D 2016-2
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	39	17	17
Share-based compensation annual expense calculated	74
AGA D 2016-2 | Executive Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	8	3	3
Share-based compensation annual expense calculated	14
AGA D 2016-2 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	31	14	14
Share-based compensation annual expense calculated	59
AGA S 2016-1
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense		151	44
Share-based compensation annual expense calculated	197
AGA S 2016-1 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense		151	44
Share-based compensation annual expense calculated	197
AGA S 2016-2
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	44	22	22
Share-based compensation annual expense calculated	88
AGA S 2016-2 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	44	22	22
Share-based compensation annual expense calculated	88
SO 2016-1
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	213	83	83
Share-based compensation annual expense calculated	383
SO 2016-1 | Executive Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	36	13	13
Share-based compensation annual expense calculated	63
SO 2016-1 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	176	70	70
Share-based compensation annual expense calculated	319
SO 2016-2
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	93	38	38
Share-based compensation annual expense calculated	170
SO 2016-2 | Executive Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	16	6	6
Share-based compensation annual expense calculated	28
SO 2016-2 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	77	32	32
Share-based compensation annual expense calculated	142
SO US 2016-1
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	(24)	12	12
SO US 2016-1 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	(24)	12	12
SO US 2016-2
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	(11)	5	5
SO US 2016-2 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	(11)	5	5
BSA 2017-A
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	6	63
Share-based compensation annual expense calculated	69
BSA 2017-A | Non-executive officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	4	43
Share-based compensation annual expense calculated	47
BSA 2017-A | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	2	20
Share-based compensation annual expense calculated	22
BSA 2017-B
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	3	66
Share-based compensation annual expense calculated	70
Share-based compensation annual expense remaining	0
BSA 2017-B | Non-executive officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	2	46
Share-based compensation annual expense calculated	48
Share-based compensation annual expense remaining	0
BSA 2017-B | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	1	21
Share-based compensation annual expense calculated	22
Share-based compensation annual expense remaining	0
AGA D 2017-1
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	1	17	199
Share-based compensation annual expense calculated	217
AGA D 2017-1 | Executive Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	0	2	28
Share-based compensation annual expense calculated	30
AGA D 2017-1 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	1	15	171
Share-based compensation annual expense calculated	187
AGA D 2017-2
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	2	29	56
Share-based compensation annual expense calculated	131
Share-based compensation annual expense remaining	44
AGA D 2017-2 | Executive Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	0	3	8
Share-based compensation annual expense calculated	18
Share-based compensation annual expense remaining	6
AGA D 2017-2 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	2	26	48
Share-based compensation annual expense calculated	113
Share-based compensation annual expense remaining	37
AGA S 2017-1
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense			209
Share-based compensation annual expense calculated	209
AGA S 2017-1 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense			209
Share-based compensation annual expense calculated	209
AGA S 2017-2
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	2	24	45
Share-based compensation annual expense calculated	104
Share-based compensation annual expense remaining	34
AGA S 2017-2 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	2	24	45
Share-based compensation annual expense calculated	104
Share-based compensation annual expense remaining	34
SO 2017-1
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	2	28	27
Share-based compensation annual expense calculated	61
Share-based compensation annual expense remaining	4
SO 2017-1 | Executive Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	0	5	5
Share-based compensation annual expense calculated	11
Share-based compensation annual expense remaining	1
SO 2017-1 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	2	23	22
Share-based compensation annual expense calculated	50
Share-based compensation annual expense remaining	4
SO 2017-2
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	3	48	2
Share-based compensation annual expense calculated	81
Share-based compensation annual expense remaining	28
SO 2017-2 | Executive Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	1	8	0
Share-based compensation annual expense calculated	15
Share-based compensation annual expense remaining	5
SO 2017-2 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	3	39	2
Share-based compensation annual expense calculated	66
Share-based compensation annual expense remaining	23
SO US 2017-1
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	0	3	(4)
Share-based compensation annual expense remaining	0
SO US 2017-1 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	0	3	(4)
Share-based compensation annual expense remaining	0
SO US 2017-2
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	0	5	(6)
Share-based compensation annual expense remaining	0
SO US 2017-2 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	0	5	€ (6)
Share-based compensation annual expense remaining	0
AGA D 2018
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	135	10
Share-based compensation annual expense calculated	277
Share-based compensation annual expense remaining	132
AGA D 2018 | Executive Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	21	2
Share-based compensation annual expense calculated	43
Share-based compensation annual expense remaining	21
AGA D 2018 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	114	9
Share-based compensation annual expense calculated	234
Share-based compensation annual expense remaining	111
AGA S 2018
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	148	12
Share-based compensation annual expense calculated	305
Share-based compensation annual expense remaining	145
AGA S 2018 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	148	12
Share-based compensation annual expense calculated	305
Share-based compensation annual expense remaining	145
SO 2018
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	285	24
Share-based compensation annual expense calculated	849
Share-based compensation annual expense remaining	539
SO 2018 | Executive Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	40	3
Share-based compensation annual expense calculated	118
Share-based compensation annual expense remaining	75
SO 2018 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	245	21
Share-based compensation annual expense calculated	730
Share-based compensation annual expense remaining	464
SO US 2018
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	25	3
Share-based compensation annual expense calculated	76
Share-based compensation annual expense remaining	48
SO US 2018 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	25	€ 3
Share-based compensation annual expense calculated	76
Share-based compensation annual expense remaining	48
BSA 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	7
Share-based compensation annual expense calculated	26
Share-based compensation annual expense remaining	20
BSA 2019 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	7
Share-based compensation annual expense calculated	26
Share-based compensation annual expense remaining	20
AGA A D 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	35
Share-based compensation annual expense calculated	242
Share-based compensation annual expense remaining	207
AGA A D 2019 | Executive Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	5
Share-based compensation annual expense calculated	38
Share-based compensation annual expense remaining	33
AGA A D 2019 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	29
Share-based compensation annual expense calculated	204
Share-based compensation annual expense remaining	175
AGA S 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	41
Share-based compensation annual expense calculated	288
Share-based compensation annual expense remaining	246
AGA S 2019 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	41
Share-based compensation annual expense calculated	288
Share-based compensation annual expense remaining	246
SO 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	86
Share-based compensation annual expense calculated	599
Share-based compensation annual expense remaining	513
SO 2019 | Executive Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	10
Share-based compensation annual expense calculated	68
Share-based compensation annual expense remaining	58
SO 2019 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	76
Share-based compensation annual expense calculated	531
Share-based compensation annual expense remaining	455
SO US 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	1
Share-based compensation annual expense calculated	43
Share-based compensation annual expense remaining	42
SO US 2019 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation annual expense	1
Share-based compensation annual expense calculated	43
Share-based compensation annual expense remaining	€ 42

Share-Based Compensation - Su_3

Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Share Warrants (Details)	12 Months Ended
	Dec. 31, 2019shares€ / shares	Dec. 31, 2017shares€ / shares	Dec. 31, 2015shares€ / shares	Dec. 31, 2014shares€ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting	Jun. 15, 2018
Date of the decision and delegation of the Board of Directors to the CEO	Oct. 18, 2019
Date of the CEO decision	Oct. 31, 2019
Beneficiaries	Consultants
Total number of BSAAR subscribed	35,070
Total number of BSAAR voided	0
Total number of BSAAR remaining	35,070
Issue Price | € / shares	€ 1.23
Excercise price | € / shares	12.32
Estimated fair value - according to IFRS 2 | € / shares	€ 0.75
End of exercise period	05/31/2024
Valuation method used	Black & Scholes
Expected dividends	0.00%
Expected volatility	40.00%
Risk-free interest rate	0.00%
Expected life	8 months 12 days
BSA 2017-A
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting		Jun. 16, 2017
Date of the decision and delegation of the Board of Directors to the CEO		Nov. 21, 2017
Date of the CEO decision		Dec. 6, 2017
Beneficiaries		Consultants and officers
Total number of BSAAR subscribed		18,345
Total number of BSAAR voided		0
Total number of BSAAR remaining		18,345
Issue Price | € / shares		€ 2
Excercise price | € / shares		19.97
Estimated fair value - according to IFRS 2 | € / shares		€ 3.78
End of exercise period		06/30/2022
Valuation method used		Black & Scholes
Expected dividends		0.00%
Expected volatility		36.40%
Risk-free interest rate		0.00%
Expected life		6 years
BSA 2017-B
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting		Jun. 16, 2017
Date of the decision and delegation of the Board of Directors to the CEO		Nov. 21, 2017
Date of the CEO decision		Dec. 6, 2017
Beneficiaries		Consultants and officers
Total number of BSAAR subscribed		18,345
Total number of BSAAR voided		0
Total number of BSAAR remaining		18,345
Issue Price | € / shares		€ 2
Excercise price | € / shares		19.97
Estimated fair value - according to IFRS 2 | € / shares		€ 3.81
End of exercise period		07/15/2022
Valuation method used		Black & Scholes
Expected dividends		0.00%
Expected volatility		35.70%
Risk-free interest rate		0.00%
Expected life		6 years
BSA 2015-A
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting			Apr. 2, 2014
Date of the Management Board meeting			Jan. 9, 2015
Beneficiaries			Consultants and officers
Total number of BSAAR subscribed			12,860
Total number of BSAAR voided			12,860
Total number of BSAAR remaining			0
Issue Price | € / shares			€ 0.01
Excercise price | € / shares			€ 35.95
End of exercise period			05/31/2019
Valuation method used			Black & Scholes
Expected dividends			0.00%
Expected volatility			74.90%
Risk-free interest rate			0.40%
Expected life			4 years
BSA 2015-B
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting			Apr. 2, 2014
Date of the Management Board meeting			Jan. 9, 2015
Beneficiaries			Consultants and officers
Total number of BSAAR subscribed			12,860
Total number of BSAAR voided			12,860
Total number of BSAAR remaining			0
Issue Price | € / shares			€ 0.01
Excercise price | € / shares			€ 35.95
End of exercise period			11/30/2019
Valuation method used			Black & Scholes
Expected dividends			0.00%
Expected volatility			74.90%
Risk-free interest rate			0.40%
Expected life			4 years
BSA 2014-A
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting				Apr. 2, 2014
Date of the Management Board meeting				Jul. 24, 2014
Beneficiaries				Consultants and officers
Total number of BSAAR subscribed				46,765
Total number of BSAAR voided				46,765
Total number of BSAAR remaining				0
Issue Price | € / shares				€ 0.01
Excercise price | € / shares				€ 23.50
End of exercise period				09/30/2018
Valuation method used				Black & Scholes
Expected dividends				0.00%
Expected volatility				74.90%
Risk-free interest rate				0.40%
Expected life				4 years
BSA 2014-B
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting				Apr. 2, 2014
Date of the Management Board meeting				Jul. 24, 2014
Beneficiaries				Consultants and officers
Total number of BSAAR subscribed				46,765
Total number of BSAAR voided				46,765
Total number of BSAAR remaining				0
Issue Price | € / shares				€ 0.01
Excercise price | € / shares				€ 23.50
End of exercise period				02/28/2019
Valuation method used				Black & Scholes
Expected dividends				0.00%
Expected volatility				74.90%
Risk-free interest rate				0.40%
Expected life				4 years

Share-Based Compensation - Su_4

Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Redeemable Warrants (Details)	12 Months Ended
	Dec. 31, 2019shares€ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting	Jun. 15, 2018
Date of the decision and delegation of the Board of Directors to the CEO	Oct. 18, 2019
Date of the CEO decision	Oct. 31, 2019
Total number of BSAAR voided	0
Total number of BSAAR remaining	35,070
Issue Price | € / shares	€ 1.23
Exercise period	05/31/2024
Valuation method used	Black & Scholes
Expected dividends	0.00%
Expected volatility	40.00%
Risk-free interest rate	0.00%
Expected life	8 months 12 days
BSAAR 2014-A - B and C | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting	Feb. 24, 2015
Date of the Management Board meeting	Jul. 22, 2016
Total number of BSAAR subscribed	10,800
Total number of BSAAR voided	0
Total number of BSAAR exercised	0
Total number of BSAAR remaining	10,800
Issue Price | € / shares	€ 23.5
Exercise period	From 01/01/2018 to 27/07/2020
Estimated fair value—valued by expert opinion | € / shares	€ 4.60
Valuation method used	Black & Scholes
Expected dividends	0.00%
Expected volatility	75.40%
Risk-free interest rate	0.00%
Expected life	4 years
BSAAR 2014-A - B and C | Employees and Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting	Apr. 2, 2014
Date of the Management Board meeting	Sep. 16, 2014
Total number of BSAAR subscribed	62,717
Total number of BSAAR voided	61,484
Total number of BSAAR exercised	1,233
Total number of BSAAR remaining	0
Issue Price | € / shares	€ 23.5
Exercise period	voided on 09.2018 - 05.2019 and 07.2019
Valuation method used	Black & Scholes
Expected dividends	0.00%
Expected volatility	75.40%
Risk-free interest rate	0.40%
Expected life	4 years
BSAAR 2014-A - B and C | Employees and Officers | Bottom of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Estimated fair value—valued by expert opinion | € / shares	€ 8.44
BSAAR 2014-A - B and C | Employees and Officers | Top of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Estimated fair value—valued by expert opinion | € / shares	€ 11.29

Share-Based Compensation - Su_5

Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Free Shares (Details)	12 Months Ended
	Dec. 31, 2019shares€ / shares	Dec. 31, 2018shares€ / shares	Dec. 31, 2017shares€ / shares	Dec. 31, 2016shares€ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting	Jun. 15, 2018
Date of the decision and delegation of the Board of Directors to the CEO	Oct. 18, 2019
Total number of AGA voided	0
Total number of AGA remaining	35,070
Valuation method used	Black & Scholes
Expected dividends	0.00%
Expected volatility	40.00%
Risk-free interest rate	0.00%
AGA D | Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting	Jun. 15, 2018
Date of the decision and delegation of the Board of Directors to the CEO	Jul. 18, 2019
Date of the Executive Board Meeting	Jul. 18, 2019
Total number of AGA subscribed	3,000
Total number of AGA voided	0
Total number of AGA definitively vested	0
Total number of AGA remaining	3,000
Acquisition period	From 07/18/2019 to 09/16/2022
Valuation method used	Monte Carlo
Price of the share at the time of allocation | € / shares	€ 17.06
Expected dividends	0.00%
Expected volatility	40.16%
Risk-free interest rate	0.00%
Turnover rate	0.00%
AGA D | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting	Jun. 15, 2018
Date of the decision and delegation of the Board of Directors to the CEO	Jul. 18, 2019
Date of the Executive Board Meeting	Jul. 18, 2019
Total number of AGA subscribed	16,070
Total number of AGA voided	450
Total number of AGA definitively vested	0
Total number of AGA remaining	15,620
Acquisition period	From 07/18/2019 to 09/16/2022
Valuation method used	Monte Carlo
Price of the share at the time of allocation | € / shares	€ 17.06
Expected dividends	0.00%
Expected volatility	40.16%
Risk-free interest rate	0.00%
Turnover rate	0.00%
AGA S | Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting	Jun. 15, 2018
Date of the decision and delegation of the Board of Directors to the CEO	Jul. 18, 2019
Date of the Executive Board Meeting	Jul. 18, 2019
Total number of AGA subscribed	0
Total number of AGA voided	0
Total number of AGA definitively vested	0
Total number of AGA remaining	0
Acquisition period	From 07/18/2019 to 09/16/2022
Valuation method used	Monte Carlo
Price of the share at the time of allocation | € / shares	€ 17.06
Expected dividends	0.00%
Expected volatility	40.16%
Risk-free interest rate	0.00%
Turnover rate	0.00%
AGA S | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting	Jun. 15, 2018
Date of the decision and delegation of the Board of Directors to the CEO	Jul. 18, 2019
Date of the Executive Board Meeting	Jul. 18, 2019
Total number of AGA subscribed	17,556
Total number of AGA voided	702
Total number of AGA definitively vested	0
Total number of AGA remaining	16,854
Acquisition period	From 07/18/2019 to 09/16/2022
Valuation method used	Monte Carlo
Price of the share at the time of allocation | € / shares	€ 17.06
Expected dividends	0.00%
Expected volatility	40.16%
Risk-free interest rate	0.00%
Turnover rate	0.00%
AGA D and S
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting		Jun. 15, 2018
Date of the decision and delegation of the Board of Directors to the CEO		Nov. 7, 2018
Date of the Executive Board Meeting		Nov. 22, 2018
Total number of AGA subscribed		35,800
Total number of AGA voided		1,872
Total number of AGA definitively vested		0
Total number of AGA remaining		33,928
Acquisition period		From 11/22/2018 to 12/31/2020
Valuation method used		Monte Carlo
Price of the share at the time of allocation | € / shares		€ 20.02
Expected dividends		0.00%
Expected volatility		38.00%
Risk-free interest rate		0.00%
Turnover rate		15.00%
AGA D and S 2017-1 and 2017-2
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting			Jun. 16, 2017
Date of the decision and delegation of the Board of Directors to the CEO			Nov. 22, 2017
Date of the Executive Board Meeting			Dec. 6, 2017
Total number of AGA subscribed			41,196
Total number of AGA voided			9,846
Total number of AGA definitively vested			19,403
Total number of AGA remaining			11,947
Acquisition period			From 12/06/2017 to 12/31/2020
Valuation method used			Monte Carlo
Price of the share at the time of allocation | € / shares			€ 21.95
Expected dividends			0.00%
Expected volatility			53.70%
Risk-free interest rate			0.00%
Turnover rate			15.00%
AGA D and S 2016-1 and 2016-2
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting				Jun. 21, 2016
Date of the Management Board meeting				Dec. 15, 2016
Total number of AGA subscribed				30,709
Total number of AGA voided				5,429
Total number of AGA definitively vested				25,280
Total number of AGA remaining				0
Acquisition period				From 12/15/2016 to 12/15/2019
Valuation method used				Monte Carlo
Price of the share at the time of allocation | € / shares				€ 20.78
Expected dividends				0.00%
Expected volatility				63.00%
Risk-free interest rate				0.00%
Turnover rate				15.00%

Share-Based Compensation - Su_6

Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Stock Options (Details)	12 Months Ended
	Dec. 31, 2019shares€ / shares	Dec. 31, 2018shares€ / shares	Dec. 31, 2017shares€ / shares	Dec. 31, 2016shares€ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting	Jun. 15, 2018
Date of the decision and delegation of the Board of Directors to the CEO	Oct. 18, 2019
Date of the CEO decision	Oct. 31, 2019
Excercise price | € / shares	€ 12.32
Valuation method used	Black & Scholes
Expected dividends	0.00%
Expected volatility	40.00%
Risk-free interest rate	0.00%
SO | Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting	Jun. 15, 2018
Date of the decision and delegation of the Board of Directors to the CEO	Jul. 18, 2019
Date of the CEO decision	Jul. 18, 2019
Total number of SO subscribed	15,130
Total number of SO voided	0
Total number of SO definitively vested	0
Total number of SO remaining	15,130
Excercise price | € / shares	€ 13.99
Vesting period	From 07/18/2019 to 09/16/2022
Exercise period	From 09/17/2022 to 09/17/2029
Fair value | € / shares	€ 4.59
Valuation method used	Monte Carlo
Price of the share at the time of allocation | € / shares	€ 17.06
Expected dividends	0.00%
Expected volatility	40.16%
Risk-free interest rate	0.00%
Turnover rate	0.00%
SO | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting	Jun. 15, 2018
Date of the decision and delegation of the Board of Directors to the CEO	Jul. 18, 2019
Date of the CEO decision	Jul. 18, 2019
Total number of SO subscribed	92,750
Total number of SO voided	1,780
Total number of SO definitively vested	0
Total number of SO remaining	90,970
Excercise price | € / shares	€ 13.99
Vesting period	From 07/18/2019 to 09/16/2022
Exercise period	From 09/17/2022 to 09/17/2029
Fair value | € / shares	€ 4.59
Valuation method used	Monte Carlo
Price of the share at the time of allocation | € / shares	€ 17.06
Expected dividends	0.00%
Expected volatility	40.16%
Risk-free interest rate	0.00%
Turnover rate	0.00%
SO 1 et 2 2017 | Employees and Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting			Jun. 16, 2017
Date of the decision and delegation of the Board of Directors to the CEO			Nov. 21, 2017
Date of the CEO decision			Dec. 6, 2017
Total number of SO subscribed			96,250
Total number of SO voided			21,577
Total number of SO definitively vested			0
Total number of SO remaining			74,673
Excercise price | € / shares			€ 17.91
Vesting period			From 12/06/2017 to 12/31/2020
Exercise period			From 01/01/2021to 12/31/2027
Fair value | € / shares			€ 9.32
Valuation method used			Monte Carlo
Price of the share at the time of allocation | € / shares			€ 21.95
Expected dividends			0.00%
Expected volatility			53.70%
Risk-free interest rate			0.00%
Turnover rate			15.00%
SO US 2017 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting			Jun. 16, 2017
Date of the decision and delegation of the Board of Directors to the CEO			Nov. 21, 2017
Date of the CEO decision			Dec. 6, 2017
Total number of SO subscribed			13,000
Total number of SO voided			13,000
Total number of SO definitively vested			0
Total number of SO remaining			0
Excercise price | € / shares			€ 22.54
Vesting period			From 12/06/2017 to 12/31/2020
Exercise period			From 01/01/2021to 12/31/2027
Fair value | € / shares			€ 9.32
Valuation method used			Monte Carlo
Price of the share at the time of allocation | € / shares			€ 21.95
Expected dividends			0.00%
Expected volatility			53.70%
Risk-free interest rate			0.00%
Turnover rate			15.00%
SO US 1 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting	Jun. 15, 2018
Date of the decision and delegation of the Board of Directors to the CEO	Jul. 18, 2019
Date of the CEO decision	Jul. 18, 2019
Total number of SO subscribed	30,620
Total number of SO voided	0
Total number of SO definitively vested	0
Total number of SO remaining	30,620
Excercise price | € / shares	€ 16.9
Vesting period	From 07/18/2019 to 09/16/2022
Exercise period	From 09/17/2022 to 09/17/2029
Fair value | € / shares	€ 3.67
Valuation method used	Monte Carlo
Price of the share at the time of allocation | € / shares	€ 17.06
Expected dividends	0.00%
Expected volatility	40.16%
Risk-free interest rate	0.00%
Turnover rate	0.00%
SO US 2016 | Employees and Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting				Jun. 21, 2016
Date of the Management Board meeting				Dec. 15, 2016
Total number of SO subscribed				62,875
Total number of SO voided				13,169
Total number of SO definitively vested				49,706
Total number of SO remaining				0
Excercise price | € / shares				€ 15.79
Vesting period				From 12/15/2016 to 12/15/2019
Exercise period				From 12/16/2019 to 12/16/2026
Fair value | € / shares				€ 10.3
Valuation method used				Monte Carlo
Price of the share at the time of allocation | € / shares				€ 20.79
Expected dividends				0.00%
Expected volatility				63.00%
Risk-free interest rate				0.00%
Turnover rate				15.00%
SO US 2 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting	Nov. 27, 2019
Date of the decision and delegation of the Board of Directors to the CEO	Nov. 27, 2019
Date of the CEO decision	Nov. 27, 2019
Total number of SO subscribed	13,350
Total number of SO voided	0
Total number of SO definitively vested	0
Total number of SO remaining	13,350
Excercise price | € / shares	€ 14.31
Vesting period	From 11/27/2019 to 01/16/2023
Exercise period	From 01/17/2023 to 01/17/2030
Fair value | € / shares	€ 3.23
Valuation method used	Monte Carlo
Price of the share at the time of allocation | € / shares	€ 14.5
Expected dividends	0.00%
Expected volatility	40.00%
Risk-free interest rate	0.00%
Turnover rate	0.00%
SO US 2016 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting				Jun. 21, 2016
Date of the Management Board meeting				Dec. 15, 2016
Total number of SO subscribed				10,500
Total number of SO voided				10,500
Total number of SO definitively vested				0
Total number of SO remaining				0
Excercise price | € / shares				€ 21.12
Vesting period				From 12/15/2016 to 12/15/2019
Exercise period				From 12/16/2019 to 12/16/2026
Fair value | € / shares				€ 8.52
Valuation method used				Monte Carlo
Price of the share at the time of allocation | € / shares				€ 20.79
Expected dividends				0.00%
Expected volatility				63.00%
Risk-free interest rate				0.00%
Turnover rate				15.00%
SO 2018 | Employees and Officers
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting		Jun. 15, 2018
Date of the decision and delegation of the Board of Directors to the CEO		Nov. 7, 2018
Date of the CEO decision		Nov. 7, 2018
Total number of SO subscribed		122,000
Total number of SO voided		2,000
Total number of SO definitively vested		0
Total number of SO remaining		120,000
Excercise price | € / shares		€ 16
Vesting period		From 11/07/2018 to 12/31/2021
Exercise period		From 01/01/2022 to 12/31/2028
Fair value | € / shares		€ 9.32
Valuation method used		Monte Carlo
Price of the share at the time of allocation | € / shares		€ 22.12
Expected dividends		0.00%
Expected volatility		44.07%
Risk-free interest rate		0.00%
Turnover rate		15.00%
SO US 2018 | Employees
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Date of the Shareholders meeting		Jun. 15, 2018
Date of the decision and delegation of the Board of Directors to the CEO		Nov. 7, 2018
Date of the CEO decision		Nov. 7, 2018
Total number of SO subscribed		17,500
Total number of SO voided		3,000
Total number of SO definitively vested		0
Total number of SO remaining		14,500
Excercise price | € / shares		€ 21.65
Vesting period		From 11/07/2018 to 12/31/2021
Exercise period		From 01/01/2022 to 12/31/2028
Fair value | € / shares		€ 6.9
Valuation method used		Monte Carlo
Price of the share at the time of allocation | € / shares		€ 22.12
Expected dividends		0.00%
Expected volatility		44.07%
Risk-free interest rate		0.00%
Turnover rate		15.00%

Share-Based Compensation - Su_7

Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Performance Conditions (Details)	12 Months Ended
	Dec. 31, 2019
SO 2019 SOUS2019 AGA2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Evaluation date for performance conditions	07/31/2022
Nature of internal conditions	66 2/3% of the instruments will be exercisable or definitively vested, and 100% of the free shares for the AGA S 2019 will be vested, regardless of the variation of the stock market price of the Company’s shares, if at least one of the three following conditions is fulfilled: (i) if a marketing authorization is granted or an application for marketing authorization is examined:  by the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA) for elafibranor for NASH; or:  by the U.S. Food and Drug Administration (FDA)/the competent European authorities in the field of IVD for NIS4 for NASH; or: (ii) if at least two of the four clinical trial among the following trials have delivered their principal results or are ongoing:  Phase III clinical trials for elafibranor for PBC; or  clinical trial evaluating elafibranor’s efficacy in NASH pediatric patients; or  Phase IIb clinical trial or clinical trial aimed at registration for NTZ in fibrosis; or  Clinical trial evaluating elafibranor or NTZ in combination therapy for NASH or for hepatic fibrosis; or: (iii) if at least a new licensing agreement, on one or another of Genfit’s products in one or several territories, is entered into by the Company.
Nature of external conditions	33 1/3 % of the instruments will be exercisable or definitively vested, in proportion to the variation of the Company’s stock market price as per the following breakdown: (i) if the Final Price is strictly lower than the Initial Price, the number of the Stock Options exercisable is equal to 0; (ii) if the Final Price is between (i) a value equal to or higher than the Initial Price and (ii) a value lower than the Ceiling Price, the number of Stock Options exercisable is equal to: [(Final Price / Initial Price)-1]/2 x 1/3 of number of Stock Options; (iii) if the Final Price is equal to or higher than the Ceiling Price, the number of Stock Options exercisable is equal to the entire one-third of the Stock Options allocated
AGA S 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Evaluation date for performance conditions	07/31/2022
Nature of internal conditions	The free shares will definitively vest upon the same internal performance conditions as the SO 2019, SO US 2019 and AGA D 2019 plans
SO US 2019-2
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Nature of internal conditions	66 2/3 % of the instruments will be exercisable if at least if at least one of the three following conditions is fulfilled: (i) if elafibranor has been granted marketing authorization by the European Medicines Agency (EMA) or the U.S. Food and Drug Administration (FDA) in NASH or PBC or NIS4 has been authorized by FDA or received CE marking from the EMA; (ii) a licensing agreement pertaining to elafibranor or NTZ has been signed for the U.S. market and/or for at least two of the five major European markets (Germany, France, Italy, United Kingdom, Spain) and/or Japan; (iii) at least two clinical trials for drug registration are underway. Nature of external conditions
Nature of external conditions	33 1/3 % of the instruments will be exercisable, in proportion to the variation of the Company’s stock market price as per the following breakdown: (i) if the Final Price is strictly lower than the Initial Price, the number of the Stock Options exercisable is equal to 0; (ii) if the Final Price is between (i) a value equal to or higher than the Initial Price and (ii) a value lower than the Ceiling Price, the number of Stock Options exercisable is equal to: [(Final Price / Initial Price)-1]/2 x 1/3 of number of Stock Options; (iii) if the Final Price is equal to or higher than the Ceiling Price, the number of Stock Options exercisable is equal to the entire one-third of the Stock Options allocated.

Share-Based Compensation - Su_8

Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Performance Conditions (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2019
SO 2019 SOUS2019 AGA2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Percentage of exercisable or definitively allocated instruments regardless of stock market price variation	66.67%
Percentage of exercisable or definitively allocated instruments proportion to stock market price evolution	33.33%
SO US 2019-2
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Percentage of exercisable or definitively allocated instruments regardless of stock market price variation	66.67%
Percentage of exercisable or definitively allocated instruments proportion to stock market price evolution	33.33%

Financial Income and Expenses -

Financial Income and Expenses - Summary of Financial Income and Expenses (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	[1]	Dec. 31, 2017	[1]
Financial Income And Expenses [Abstract]
Interest income	€ 2,626	€ 202		€ 389
Foreign exchange gain	2,272	101		59
Other financial income	324	425		195
TOTAL - Financial income	5,221	728	[2]	642	[2]
Interest expenses	(11,289)	(10,955)		(2,309)
Interest expenses for leases	(148)	(21)		(10)
Foreign exchange losses	(1,657)	(127)		(764)
Other financial expenses	(17)	(14)		(13)
TOTAL - Financial expenses	(13,110)	(11,118)	[2]	(3,096)	[2]
Financial profit (loss)	€ (7,889)	€ (10,391)	[2]	€ (2,453)	[2]
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.
[2]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method and therefore, the comparative information for 2017 and 2018 has not been restated . The impact of this application is presented in note 4.7

Financial Income and Expenses_2

Financial Income and Expenses - Additional Information (Details) - OCEANEs	Dec. 31, 2019	Oct. 16, 2017
Disclosure Of Financial Income And Expenses [Line Items]
Interest rate		7.20%
Discounting of bond debt, effective interest rate	7.20%
Fixed Interest Rate
Disclosure Of Financial Income And Expenses [Line Items]
Interest rate	3.50%	3.50%

Income Tax - Additional Informa

Income Tax - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Tax loss carry forwards	€ 384,471	€ 305,530		€ 226,708
Taxable profit limit	€ 1,000
Percentage of profit exceeding limit offsetting taxable profit	50.00%
Post-employment benefit expense, defined benefit plans impact on deferred tax assets		304		262
Deferred tax liabilities	€ 3,182
Deferred tax assets	1,988
Deferred tax liabilities	1,193	1,773	[1]	2,165	[1]
Temporary Difference From Postemployments
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Temporary differences		1,085		936
Deferred tax liabilities	352
Deferred tax assets	352
OCEANEs
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Temporary differences		€ 1,773		2,165
Deferred tax liabilities				€ 14,312
OCEANEs | Temporary Differences
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Line Items]
Deferred tax liabilities	3,182
Deferred tax assets	1,989
Deferred tax liabilities	€ 1,193
[1]	The Group applied IFRS 16 “Leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of this application is presented in note 4.7.2 Application of the new IFRS 16 standard.

Earnings (Loss) Per Share - Sum

Earnings (Loss) Per Share - Summary of Earnings (Loss) Per Share (Details) - EUR (€) € / shares in Units, € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018		Dec. 31, 2017
Earnings Per Share [Abstract]
Profit (loss) for the period (in € thousands)	€ (65,144)	€ (79,521)	[1],[2]	€ (55,728)	[1],[2]
Weighted average number of ordinary shares for the period	36,987,982	31,167,203		31,166,437
Profit (loss) per share (in €)	€ (1.76)	€ (2.55)		€ (1.79)
Weighted average number of ordinary shares used in the above calculation	36,987,982	31,167,203		31,166,437
[1]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method and therefore, the comparative information for 2017 and 2018 has not been restated . The impact of this application is presented in note 4.7
[2]	The Group applied IFRS16 ”leases” from January 1, 2019 using the modified retrospective method, and therefore, the comparative information for 2017 and 2018 has not been restated. The impact of the application is presented in note 4.7

Litigation and Contingent Lia_2

Litigation and Contingent Liabilities - Additional Information (Details) - EUR (€) € in Thousands	Sep. 11, 2018	Dec. 31, 2019	Jun. 30, 2019
Research Tax Credit
Disclosure Of Contingent Liabilities [Line Items]
Research tax credit repaid	€ 432
Provision for tax liability			€ 1,892
Research Tax Credit Receivable For Two Thousand Fourteen
Disclosure Of Contingent Liabilities [Line Items]
Provision for tax liability		€ 1,892

Related Parties - Additional In

Related Parties - Additional Information (Details) € in Millions	12 Months Ended
	Dec. 31, 2019EUR (€)EmployeeCo-founder
Biotech Avenir SAS
Disclosure Of Transactions Between Related Parties [Line Items]
Number of co-founders hold share capital of related party | Co-founder	4
Number of employees hold share capital of related party | Employee	13
Percentage of share capital held by related party	4.86%
PCAS Group
Disclosure Of Transactions Between Related Parties [Line Items]
Amounts paid to related party transactions | €	€ 1.7

Compensation of Corporate Off_3

Compensation of Corporate Officers - Summary of Compensation Paid to Officers (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Chairman and Chief Executive Officer
Disclosure Of Compensation Of Corporate Officers [Line Items]
Short-term employee benefits (gross + employer's social contributions, paid)	€ 1,338	€ 1,569	€ 1,476
Post-employment pension & medical benefits			199
Share-based payment transactions	109	104	51
Director fees Genfit Corp (net)	22	30	37
TOTAL	1,469	€ 1,703	€ 1,763
Chief Executive Officer
Disclosure Of Compensation Of Corporate Officers [Line Items]
Short-term employee benefits (gross + employer's social contributions, paid)	140
TOTAL	€ 140

Compensation of Corporate Off_4

Compensation of Corporate Officers - Additional Information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Mar. 31, 2019	May 31, 2020	Dec. 31, 2018
Disclosure Of Compensation Of Corporate Officers [Line Items]
CEO corporate contract non-compete indemnity compensation upon termination description	twelve (12) months of fixed compensation, calculated on the basis of the gross amounts due for the past twelve months ended
CEO Corporate Contract Non-Compete Indemnity Compensation Eligibility Period	12 months
CEO corporate contract non-compete indemnity compensation upon termination description	increased, where applicable, by the amount of the annual variable compensation due for the previous year. This compensation is intended to compensate the prohibition made to the Chief Executive Officer, for a period of 12 months following the termination of his functions, for whatever reason, to work in any way whatsoever with certain companies carrying out a directly competitive activity of the Company.
CEO gross negligence severance pay description	twelve (12) months of fixed compensation, calculated on the basis of the gross amounts due for the twelve past completed months
CEO gross negligence severance pay eligibility period	12 months
CEO gross negligence severance pay description	increased, where applicable, by the amount of annual variable compensation due for the previous year. This compensation will be paid one month after his effective termination of activity within the Group. The compensation will not be paid if, on his initiative, the Chief Executive Officer leaves the Company to exercise new functions or changes functions within the Group, or even if he has the possibility of asserting in the short term his retirement rights. It is also specified that any sum paid under the non-competition clause will be deducted from the sums due under the severance pay and vice versa.
Maximum commitment amount	€ 341
Chairman and Chief Executive Officer
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts payable, related party transactions	€ 187,631			€ 562,893
Insurance premium to be paid		€ 3,146
Chairman and Chief Executive Officer | Scenario Forecast
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts forgo, related party transactions			€ 187,631

Compensation of Corporate Off_5

Compensation of Corporate Officers - Schedule of Director's Fees and Other Compensation Due and Paid to Non Executive Directors (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due	€ 318,613	€ 162,539	€ 94,602
Amounts paid	310,123	123,061	74,458
IFRS 2 valuation of share warrants granted during the financial year			94,875
Jean Francois Mouney
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due	103,665
Amounts paid	89,507
Jean Francois Mouney | Attendance Fees
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due	14,791
Amounts paid	633
Jean Francois Mouney | Other Remuneration
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due	88,874
Amounts paid	88,874
Xavier GUILLE DES BUTTES
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due	68,016	53,330	30,218
Amounts paid	67,580	41,311	24,688
Xavier GUILLE DES BUTTES | Attendance Fees
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due	68,016	53,330	30,218
Amounts paid	67,580	41,311	24,688
Charles WOLER
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due			5,925
Amounts paid			5,925
Charles WOLER | Attendance Fees
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due			5,925
Amounts paid			5,925
Frederic DESDOUITS
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due	33,136	21,174	13,627
Amounts paid	30,302	17,113	11,258
Frederic DESDOUITS | Attendance Fees
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due	33,136	21,174	13,627
Amounts paid	30,302	17,113	11,258
Philippe MOONS
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due	36,188	29,704	18,763
Amounts paid	41,202	22,345	14,023
Philippe MOONS | Attendance Fees
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due	36,188	29,704	18,763
Amounts paid	41,202	22,345	14,023
Anne-Helene MONSELLATO
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due	44,472	37,075	14,813
Amounts paid	53,410	24,307	10,468
Anne-Helene MONSELLATO | Attendance Fees
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due	44,472	37,075	14,813
Amounts paid	53,410	24,307	10,468
Catherine LARUE
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due	33,136	21,256	11,258
Amounts paid	28,122	17,985	8,098
Catherine LARUE | Attendance Fees
Disclosure Of Compensation Of Corporate Officers [Line Items]
Amounts due	33,136	21,256	11,258
Amounts paid	€ 28,122	€ 17,985	€ 8,098

Compensation of Corporate Off_6

Compensation of Corporate Officers - Schedule of Director's Fees and Other Compensation Due and Paid to Non Executive Directors (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Disclosure Of Compensation Of Corporate Officers [Abstract]
Directors remuneration withholding percentage	21.00%	21.00%	21.00%

Commitments - Additional Inform

Commitments - Additional Information (Details) € in Thousands, $ in Thousands	Jul. 01, 2016USD ($)	Dec. 31, 2019EUR (€)	Dec. 31, 2018EUR (€)	Dec. 31, 2017EUR (€)
Disclosure Of Commitments [Line Items]
Amount of transfer penalties		€ 1,360
Rental payment obligation under the lease agreement		542	€ 455	€ 455
NASH Education Program
Disclosure Of Commitments [Line Items]
Endowment fund		€ 45	€ 959	€ 1,808
Top of Range | Pinnacle Clinical Research
Disclosure Of Commitments [Line Items]
Donation paid | $	$ 1,582